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Platelet activation and subsequent thrombus formation are important for 
preventing excessive blood loss at sites of vascular injury, a process termed 
haemostasis.  However, excessive platelet activation at sites of 
atherosclerotic plaque rupture can lead to thrombus formation, which may 
occlude the vessel and cause heart attack or stroke.  The platelet collagen 
receptor GPVI is essential for thrombus formation, but is largely dispensable 
for haemostasis. 
Tetraspanins are transmembrane proteins which compartmentalise the 
membrane through formation of dynamic tetraspanin-enriched microdomains.  
Due to regulation of a wide range of partner proteins, tetraspanins have been 
implicated in many cellular processes, including platelet activation, though 
most platelet tetraspanins have not been characterised. 
The aim of this thesis was to investigate the novel platelet tetraspanin 
Tspan18, using the Tspan18 knockout mouse.  Tspan18 was shown to have a 
role in platelet activation and platelet Ca2+ signalling specifically downstream 
of GPVI.  Tspan18 also appeared to have a role in haemostasis, as Tspan18 
deficient mice displayed a severe bleeding phenotype.  The bleeding was 
shown to be driven by non-haematopoietic cells and is therefore unlikely to be 
platelet-driven.  Additionally, Tspan18-induced Ca2+ mobilisation was shown 
to be dependant on functioning Orai1 Ca2+ channels and a novel interaction 
between Tspan18 and the Orai family was identified.  Together, these findings 
suggest a role for Tspan18 in platelet activation and regulation of Ca2+ 
mobilisation, potentially via interaction with Orai proteins. 
 
ACKNOWLEDGEMENTS 
Firstly, I would like to say thank you to all members of the Tomlinson lab, past 
and present, who have offered me support, friendship and advice over the 
past four years.  Mike, you have been a fantastic mentor; your 
encouragement and unwavering optimism made even the toughest problems 
approachable.  I would like to say thank you for your guidance and patience, 
and for always being genuinely enthusiastic about my project.  Jing, your 
brilliance in the lab was truly amazing – I hope at least a little bit of it rubbed 
off on me at some point.  Thank you for your kindness and for looking after all 
of us.  Lizzie and Jas, Thank you for being there when I needed to talk 
through my data and complain about science.  The past four years wouldn’t 
have been half as funny without you, so thank you for making the office and 
the lab such a great place to work.  Pete, thank you for your advice and help 
with the Tspan18 project, especially with the paper.   
Prof Steve Watson and all the members of his group have given me countless 
help and advice throughout my PhD.  Thank you to all of you for sharing your 
expertise and equipment and for always making me feel welcome in your lab.   
Thank you to the many people from across Biosciences and the IBR who 
have offered help, equipment and guidance when I needed it.  Thank you to 
Steve Publicover and Frank Michellangeli for taking the time to help and 
advise me on my project and for offering use of your lab equipment.  Thank 
you to everyone who contributed to discussions in Friday lab meeting for your 
help and advice on my data.  Also thank you to all members of the Rappoport 
lab who have been fantastic office mates and good friends.  Thank you to Roy 
Bicknell and Victoria Heath for letting me dabble in endothelial biology and for 
help during the early stages of my PhD.  I would also like to express my 
gratitude to the very hardworking staff at the BMSU who looked after my 
animals.  I really appreciate all the work you have done behind the scenes 
which has enabled me to generate this data. 
Massive thanks also go to Gareth Lewis for all of your brilliant advice, for 
continuing to be a wonderful friend and for being the first person to encourage 
me to do a PhD. 
I would also like to thank my family for their support in everything I do.  Mum 
and Dad, you taught me to be strong and determined and your 
encouragement has always empowered me to believe in myself.  Thank you 
for your enduring confidence in me, for always offering your reassurance and 
understanding, and for always being ready with a large glass of wine! 
Finally, and most importantly, thank you to my husband Alex.  When I have 
felt like everything else is against me, I could always rely on you to be on my 
side.  You are always willing to listen to my problems, even when you are 
stressed about your own.  Thank you for believing in me and for supporting 
me unconditionally through everything. 
 
 
TABLE OF CONTENTS 
 
CHAPTER 1: GENERAL INTRODUCTION……………………………........ 1 
   
1.1 PLATELETS…………………………….................................................. 2 
1.1.1 Haemostasis……………………………............................................ 2 
1.1.2 Thrombus formation ……………………………................................ 4 
1.1.3 Platelets in health and disease……………………………................ 6 
1.1.4 Multiple signalling pathways balance inhibitory and activating 
stimuli in platelets……………………………………………….……... 
 
10 




   
1.2 STORE OPERATED Ca2+ ENTRY……………………………………….. 23 
1.2.1 Overview of Orai and STIM as key regulators of SOCE…………... 23 
1.2.2 Different isoforms of STIM1 and Orai1……………………………… 26 
1.2.3 The molecular mechanism of STIM1 activation……………………. 28 
1.2.4 The molecular mechanism of Orai1 activation……………………… 29 
1.2.5 SOCE is vital for GPVI signalling…………………………………..... 32 
   
1.3 TETRASPANINS…………………………………………………………… 38 
1.3.1 Tetraspanin structure………………………………………………..... 39 
1.3.2 Tetraspanin interactions………………………………………………. 42 
1.3.3 Tetraspanin function…………………………………………………… 44 
1.3.4 Platelet tetraspanins…………………………………………………… 48 
1.3.5 Tspan18………………………………………………………………… 52 
   
1.4 PROJECT OBJECTIVES…………………………………………………. 57 
   
   
CHAPTER 2: MATERIALS AND METHODS……………………………...... 58 
   
2.1 MICE, REAGENTS AND CELL CULTURE……………………………... 59 
2.1.1 Mice……………………………………………………………………... 59 
2.1.2 Plasmids………………………………………………………………… 59 
2.1.3 Antibodies………………………………………………………………. 60 
2.1.4 Cell culture……………………………………………………………… 61 
   
2.2 TRANSFECTION…………………………………………………………… 62 
2.2.1 Transfection by electroporation………………………………………. 62 
2.2.2 Transfection by polyethylenimine (PEI)……………………………... 62 
   
2.3 PLATELET PREPARATION……………………………………………… 64 
2.3.1 Mouse platelet preparation …………………………………………… 64 
2.3.2 Human platelet preparation…………………………………………… 65 
   
2.4 PLATELET FUNCTION ASSAYS………………………………………... 66 
2.4.1 Assessment of mouse blood cell counts……………………………. 66 
2.4.2 Assessment of cell surface expression of platelet receptors……… 66 
2.4.3 Light transmission aggregometry…………………………………..... 67 
 
2.4.4 Measurement of platelet secretion…………………………………… 67 
2.4.5 Platelet spreading……………………………………………………… 68 
2.4.6 Aggregate formation under flow……………………………………… 69 
2.4.7 Platelet Ca2+ signalling measurements……………………………… 69 
2.4.8 Platelet phosphotyrosine blotting…………………………………..... 70 
   
2.5 IN VIVO ASSAYS………………………………………………………….. 72 
2.5.1 Tail bleeding……………………………………………………………. 72 
2.5.2 Thrombus formation following chemical injury……………………… 72 
2.5.3 Thrombus formation following mechanical injury…………………... 73 
2.5.4 Generating chimeric mice…………………………………………….. 73 
   
2.6 NFAT/AP-1 LUCIFERASE REPORTER ASSAY………………………. 75 
2.6.1 Measurement of luciferase signalling……………………………….. 75 




   
2.7 BIOCHEMICAL ASSAYS…………………………………………………. 77 
2.7.1 Western blotting……………………………………………………….. 77 
2.7.2 Immunoprecipitation in HEK293 T cells……………………………... 77 
2.7.3 Immunoprecipitation in human platelets…………………………...... 78 
2.7.4 Biotinylation…………………………………………………………...... 79 
2.7.5 Cell surface cross-linking……………………………………………... 79 
2.7.6 Enzyme linked immunosorbant assay (ELISA)…………………….. 80 
   
2.8 PCR………………………………………………………………………….. 81 
2.8.1 Genotyping mouse tissue…………………………………………….. 81 
2.8.2 Genotyping from mouse blood……………………………………...... 81 
2.8.3 Real-time quantitative PCR…………………………………………… 82 
   
2.9 ENDOTHELIAL FUNCTION ASSAYS…………………………………... 85 
2.9.1 siRNA transfection of HUVEC………………………………………... 85 
2.9.2 Scratch wound assay………………………………………………….. 86 
2.9.3 Co-culture tube formation assay……………………………………... 86 
   
   
CHAPTER 3: TSPAN18 REGULATES GPVI INDUCED PLATELET 
ACTIVATION AND PLATELET Ca2+ SIGNALLING……………………….. 
 
88 
   
3.1 INTRODUCTION…………………………………………………………… 89 
3.1.1 Tspan18 is a platelet tetraspanin…………………………………….. 89 
   
3.2 AIMS…………………………………………………………………………. 91 
   
3.3 RESULTS…………………………………………………………………… 92 
3.3.1 Normal blood cell numbers and expression of platelet surface 
receptors in Tspan18 deficient mice…………………………………. 
 
92 
   
3.3.2 Tspan18 deficient platelets display disrupted aggregation  




3.3.3 Tspan18 deficient platelets display disrupted spreading 
downstream of GPVI…………………………………………………... 
 
106 
3.3.4 Protein tyrosine phosphorylation induced by GPVI is normal in 
Tspan18 deficient platelets…………………………………………… 
 
108 
3.3.5 Tspan18 deficient platelets have reduced SOCE and  
reduced global Ca2+ signalling……………………………………….. 
 
111 








3.3.8 Haemostasis is disrupted in Tspan18 deficient mice………………. 124 
   
3.4 DISCUSSION……………………………………………………………..... 126 
   
   
CHAPTER 4: TSPAN18 ACTIVATES Ca2+ SIGNALLING VIA 





   
4.1 INTRODUCTION…………………………………………………………… 133 
4.1.1 Store operated Ca2+ entry…………………………………………..... 133 
4.1.2 The NFAT/AP-1 luciferase reporter assay………………………….. 134 
4.1.3 Tspan18 in NFAT activation and Ca2+ signalling…………………… 135 
   
4.2 AIMS…………………………………………………………………………. 137 
   
4.3 RESULTS…………………………………………………………………… 138 
4.3.1 Importance of the Tspan18 variable region in Tspan18 induced 
activation of a Ca2+ sensitive reporter in DT40 B cells…………..... 
 
138 




4.3.3 Tspan18 interacts with the Orai family of Ca2+ channels………..... 146 
4.3.4 Tspan18 forms a robust interaction with Orai1……………………... 149 
4.3.5 Tspan18 preferentially interacts with de-glycosylated Orai1……… 155 
   
4.4 DISCUSSION……………………………………………………………..... 158 
   
   
CHAPTER 5: THE HAEMOSTASIS DEFECT IN TSPAN18 KNOCKOUT 





   
5.1 INTRODUCTION…………………………………………………………… 164 
5.1.1 Tspan18 is an endothelial tetraspanin………………………………. 164 
5.1.2 The role of non-haematopoietic cells in haemostasis……………… 164 




   
5.2 AIMS…………………………………………………………………………. 168 
   
 
5.3 RESULTS…………………………………………………………………… 169 
5.3.1 Non-haematopoietic cells drive the disruption to haemostasis  
in Tspan18 deficient mice…………………………………………….. 
 
169 
5.3.2 Plasma levels of endothelial derived clotting factors vWF and 
FVIII are normal in Tspan18 deficient mice…………………………. 
 
173 




   
5.4 DISCUSSION……………………………………………………………..... 179 
   
   
CHAPTER 6: GENERAL DISCUSSION…………………………………….. 185 
   
6.1 Summary of key findings……………………………………………… 186 
6.2 The interaction between Tspan18 and Orai1……………………..... 187 
6.3 The mechanism of Tspan18 action………………………………….. 189 
6.4 The role of Tspan18 on non-haematopoietic cells…………………. 195 
6.5 Future directions……………………………………………………..... 198 
   
APPENDICES…………………………………………………………………… 201 
1 Tspan18 knockout mice have normal body weight and  
normal heart weight……………………………………………………. 
 
202 
2 Optimisation of siRNA knockdown of Tspan18 in HUVEC.............. 204 
3 Characterising Orai1 antibodies……………………………………… 206 
4 Published papers………………………………………………………. 210 
   
   
REFERENCES………………………………………………………………...... 211 
   
   
 
 
LIST OF FIGURES AND TABLES 
 
CHAPTER 1  
  
Figure 1.1 Thrombus formation prevents excessive blood loss at sites 
of vascular injury……………………………………………….. 
 
6 




Figure 1.3 The GPVI signalling pathway………………………………… 22 
Figure 1.4 The role of STIM and Orai in SOCE…………………………. 25 
Figure 1.5 The conformational changes required for STIM1 activation 
and Orai1 channel formation……………………................... 
 
32 
Figure 1.6 The tetraspanin family of proteins…………………………… 38 
Figure 1.7 The conserved structure of tetraspanin proteins…………… 42 
Figure 1.8 Tetraspanin associated proteins in platelets………………... 51 
Figure 1.9 Targeting strategy involved in generating the Tspan18 
knockout mouse by homologous recombination…………… 
 
56 
   
   
CHAPTER 2  
   
Table 2.1 Details of all antibodies used in western blotting, flow 
cytometry, and immunoprecipitation experiments………….. 
 
60 




Table 2.3 An outline of primer sequences of the primers used in  
PCR for genotyping of mouse tissue………………………… 
 
82 




   
   
CHAPTER 3  
   




Figure 3.2 Platelets from Tspan18 deficient mice express normal  
levels of the major platelet surface receptors………………. 
 
94 
Figure 3.3 Washed Tspan18 deficient platelets display reduced  
aggregation downstream of GPVI……………………………. 
 
99 
Figure 3.4 Washed Tspan18 deficient platelets display normal  
aggregation to thrombin, CLEC-2 mAb and collagen……… 
 
101 
Figure 3.5 Washed Tspan18 deficient platelets display reduced  
secretion downstream of GPVI………………………………. 
 
102 
Figure 3.6 Tspan18 deficient platelets in platelet rich plasma display 
defective aggregation downstream of GPVI activation……. 
 
103 
Figure 3.7 Tspan18 deficient platelets in platelet rich plasma display  
normal aggregation to PAR4 peptide and ADP, but mildly  




Figure 3.8 Washed Tspan18 deficient platelets display reduced  




Figure 3.9 Protein tyrosine phosphorylation induced by GPVI is  
normal in Tspan18 deficient platelets……………………….. 
 
110 
Figure 3.10 Global Ca2+ signalling is reduced in Tspan18 deficient  
platelets downstream of GPVI………………………………... 
 
114 
Figure 3.11 Release of Ca2+ from intracellular stores is reduced in 
Tspan18 deficient platelets within Ca2+ free media………… 
 
115 




Figure 3.13 Aggregate formation under arterial shear conditions in the 
Tspan18 knockout platelets is normal…………………......... 
 
118 
Figure 3.14 Aggregate formation under venous shear conditions in the 
Tspan18 knockout platelets is normal…………………......... 
 
119 
Figure 3.15 Thrombus formation in vivo is normal in Tspan18 deficient 
mice following mechanical injury…………………………….. 
 
122 
Figure 3.16 Thrombus formation in vivo is normal in Tspan18 deficient 
mice following chemical injury……………………................. 
 
123 
Figure 3.17 Impaired haemostasis in the tail bleeding assay in 
Tspan18 deficient mice……………………………………….. 
 
125 
   
   
CHAPTER 4  
   
Figure 4.1 Model of NFAT/AP-1 reporter activation…………………….. 135 
Figure 4.2 Tspan18 activates  a Ca2+ responsive NFAT luciferase 
reporter in DT40 B cells........................................................ 
 
141 
Figure 4.3 The variable region of Tspan18 is sufficient to activate 
NFAT, in the context of an intact tetraspanin....................... 
 
142 




Figure 4.5 Tspan18 interacts with the Orai family of Ca2+ channels..... 148 
Figure 4.6 Tspan18 interacts with Orai1................................................ 152 




Figure 4.8 A comparison of the Tspan18-Orai1 interaction under 
weak and stringent lysis conditions...................................... 
 
154 
Figure 4.9 Tspan18 interacts with the de-glycosylated form of Orai1... 157 
   
   
CHAPTER 5  
   
Figure 5.1 Normal haemostasis in the tail bleeding assay in  
C57BL/6 chimeric mice, but impaired haemostasis in 




Figure 5.2 Validation of Tspan18 chimeric mice by genotyping………. 172 
Figure 5.3 Tspan18 deficient mice have normal levels of plasma  
vWF and FVIII…………………………………………………..   
 
175 
Figure 5.4 Tspan18 knockdown disrupts endothelial function in a 
scratch wound assay………..………………………………… 
 
177 





CHAPTER 6  
   
Figure 6.1 Potential mechanisms of Tspan18 regulation of Orai1……. 195 
   
   
APPENDICES  
   
Figure 1a Bodyweight of the Tspan18-deficient mice is normal……… 203 
Figure 1b Tspan18 deficient mice have normal heart weight………… 203 




Figure 3a Characterising Orai1 antibodies for use in western  
blotting…………………………………………………………...  
208 
Figure 3b Characterising Orai1 antibodies for immunoprecipitation….   209 





ACD  Acid citrate dextrose 
ADAM10 A disintegrin and metalloprotease domain-containing protein 10 
ADP  Adenosine diphosphate 
AMP  Adenosine monophosphate 
ANOVA Analysis of variance 
AP-1  Activator protein 1 
ATP  Adenosine triphosphate 
BSA  Bovine serum albumin 
CAD  CRAC activation domain 
cAMP  Cyclic adenosine monophosphate 
CCG  Cysteine-cysteine-glycine motif 
CD19  Cluster of differentiation 19 
cGMP  Cyclic guanylyl monophosphate 
CLEC-2 C-type lectin like receptor 2 
CRAC  Ca2+ release activated Ca2+ current 
CRP  Collagen related peptide 
Ct  Cycle threshold 
DAG  Diaceyl-glycerol 
DNA  Deoxyribonucleic acid 
DTSSP 3, 3’-dithiobis [sulfosuccinimidylpropionate] 
EGTA  Ethylene glycol tetraacetic acid 
ELISA  Enzyme-linked immunosorbant assay 
EMT  Epithelial mesenchymal transition 
EP3  Prostaglandin E receptor 3 
ER  Endoplasmic reticulum 
EWI-2  Immunoglobulin super family member 8 
FACS  Fluorescence activated cell sorting 
FBS  Foetal bovine serum 
FEVR  Familial exudative vitreoretinopathy 
FITC  Fluorescein isothiocyanate 
FVa  Factor Va 
FVIIa  Factor VIIa 
FXa  Factor Xa 
FXIIa  Factor XIIa 
GC  Guanylyl cyclase 
GDP  Guanosine diphosphate 
GFP  Green fluorescent protein  
GPCR  G-protein coupled receptor 
GPO  Glycine-proline-hydroxyproline 
GPVI  Glycoprotein VI 
GTP  Guanosine triphosphate 
HCV  Hepatitis C virus 
HMEC Human microvascular endothelial cells 
HUVEC Human umbilical vein endothelial cells 
ICAM-1 Intercellular adhesion molecule 1 
Ig  Immunoglobulin 
IP3  Inositol triphosphate 
ITAM  Immunoreceptor tyrosine based activation motif 
 
LacZ  Lactose operon 
LAT  Linker for activation of T-cells 
LTA  Light transmission aggregometry 
MAPK  Mitogen-activating protein kinase 
mRNA Messenger ribonucleic acid 
NFAT  Nuclear factor of activated T-cells 
NO  Nitric oxide 
PAGE  Polyacrylamide gel electrophoresis 
Panx-1 Pannexin-1 
PAR  Protease activated receptor 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PDE  Phosphodiesterase 
PEI  Polyethylenimine 
PGI2  Prostaglandin I2 
PIP2  Phosphatidyl inositol 4, 5-bisphosphate 
PKA  Protein kinase A 
PKC  Protein kinase C 
PKD2  Protein kinase D2 
PKG1  Protein kinase G 1 
PLCβ  Phospholipase C β 
PLCγ  Phospholipase C γ 
PMA  Phorbol 12-myristate 13-acetate 
PSGL-1 P selectin glycoprotein ligand 1 
RhoA  Ras homologue gene family member A 
SAM  Sterile α motif 
SCID  Severe combined immunodeficiency 
SDS  Sodium dodecyl sulphate 
SERCA Sarco/endoplasmic reticulum Ca2+-ATPase 
SH2  Src homology 2 
SH3  Src homology 3 
siRNA  Short interfering ribonucleic acid  
SNP  Single nucleotide polymorphism 
SOAR  STIM1 Orai1 activating region 
SOCE  Store operated Ca2+ entry 
SPCA2 Secretory pathway Ca2+-ATPase 
SR  Sarcoplasmic reticulum 
STIM  Stromal interaction molecule 
STIM-C STIM1 C-terminal 
STIM-N STIM1 N-terminal 
TM  Transmembrane domain 
TP  Thromboxane receptor 
TRPC  Transient receptor potential cation channel 
TxA2  Thromboxane A2 
UP  Uroplakin 
VASP  Vasodilator-stimulated phosphoprotein 
VCAM-1 Vascular cell adhesion protein 1 
VEGF  Vascular endothelial growth factor 
vWF  Von Willebrand factor  
Xgal  5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside










 - 2 - 
1.1 PLATELETS 
Platelets are small, anuclear blood cells which have roles in many biological 
processes, though the best characterised is their role in haemostasis and 
prevention of blood loss.  Platelets are formed from mature megakaryocyte 
progenitors in the bone marrow, which extend cytoplasmic processes, called 
proplatelets, into the circulation where budding and fragmentation results in 
platelet formation (J. E. Italiano, 2013).  Once in the bloodstream, platelets 
are maintained at the edges of the flow and are therefore in close proximity to 
the endothelial lined vessel wall.  Abnormalities in platelet production can 
cause thrombocytopenia (low platelet count) which is associated with an 
increased risk of bleeding (J. E. Italiano, 2013). 
 
1.1.1 Haemostasis 
At sites of vascular injury, the body prevents excessive blood loss via a 
process called haemostasis.  Damage to a blood vessel induces an 
immediate reaction from surrounding smooth muscle cells, endothelial cells 
and platelets.  This is a highly regulated process, involving several key stages 
which act to reduce blood loss and to initiate the wound healing response. 
Firstly, vasoconstriction occurs via contraction of smooth muscle cells, which 
form the muscular wall of the vessel, causing narrowing of the lumen to 
reduce blood flow (van Hinsbergh, 2012).  One example of the multiple stimuli 
which can induce smooth muscle cell contraction is thromboxane A2 (TxA2), 
which is released by platelets at sites of vascular injury.  This vasoconstrictor 
activates a G-protein coupled receptor, stimulating Gq protein responses, 
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leading to activation of myosin-light chain kinase and induction of muscle cell 
contraction (Wilson, Susnjar, Kiss, Sutherland, & Walsh, 2005). 
Following vasoconstriction, primary haemostasis occurs, which involves 
activation of platelets.  Platelets are maintained in the circulation in an inactive 
state, but at sites of vascular injury they become activated and aggregate 
together to form a platelet plug and therefore stem the loss of blood.  
Formation of this platelet plug, or thrombus, involves activation of multiple 
signalling receptors on the platelet surface, to induce platelet activation, 
shape change, adhesion and aggregation (Broos, Feys, De Meyer, 
Vanhoorelbeke, & Deckmyn, 2011).  These signalling mechanisms are 
discussed in more detail in sections 1.1.2 and 1.1.4. 
The final stage of haemostasis, secondary haemostasis, involves activation of 
the coagulation cascade and formation of a fibrin clot.  Initiation of the 
coagulation cascade is marked by complex formation between plasma 
protease factor VIIa (FVIIa) and tissue factor, which promotes thrombin 
generation (Chou et al., 2004; B Nieswandt, Pleines, & Bender, 2011).  
Thrombin acts not only to promote platelet activation, but also induces fibrin 
formation from fibrinogen.  Finally, cross-linking of fibrin produces a fibrin 
mesh which acts to reinforce the thrombus.  A process called clot retraction 
also occurs, during which actin stress fibres within the platelets contract to 
reduce the size of the clot and to protect the clot from disruption by the blood 
flow (Stegner & Nieswandt, 2011).   
Together, these immediate responses at sites of vascular damage can 
prevent excessive blood loss.  The role that platelets play within this system 
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and the ability to activate quickly is vital for successful haemostasis.  
However, regulation of platelet activation is important to prevent thrombus 
formation and disruption to blood flow at sites away from vascular damage. 
 
1.1.2 Thrombus formation  
The mechanisms underlying thrombus formation are well characterised and 
the impact that platelet activation and thrombus formation has during 
haemostasis is depicted in figure 1.1.  Within an undamaged vessel, the 
endothelium inhibits platelet activation in order to prevent unwanted thrombus 
formation.  For example, endothelial secretion of both prostaglandin I2 (PGI2) 
and nitric oxide (NO) reduce platelet activation (figure 1.1, A).  PGI2 is 
produced in endothelial cells by PGI2 synthase from the precursor 
prostaglandin H2.  PGI2 reduces platelet activation through G-protein coupled 
receptor (GPCR) activation and subsequent G-protein mediated increases in 
cytosolic cyclic adenosine monophosphate (cAMP), which leads to reduced 
intracellular Ca2+ concentration (Mitchell, Ali, Bailey, Moreno, & Harrington, 
2008; Schwarz, Walter, & Eigenthaler, 2001).  NO, also synthesised by 
endothelial cells, inhibits adhesion and platelet aggregation through activation 
of guanylyl cyclase and thus increased cyclic guanylyl monophosphate 
(cGMP), which also reduces intracellular Ca2+ (Mitchell et al., 2008; S 
Moncada & Higgs, 2006).  Additionally, endothelial cells express the ecto-
nucleotidase CD39, which hydrolyses platelet-secreted adenosine 
diphosphate (ADP) into adenosine monophosphate (AMP), thus reducing 
ADP-induced platelet activation (Marcus et al., 1997; van Hinsbergh, 2012).   
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However, following injury to the vessel wall and exposure to the sub-
endothelial matrix, platelets become activated.  An initial interaction between 
exposed collagen and the platelet occurs via the glycoprotein von Willebrand 
factor (vWF), which allows for initial tethering of the platelet to collagen fibres 
within the high shear environment of the vessel (Stegner & Nieswandt, 2011) 
(figure 1.1, B).  This tethering process then allows for an interaction to form 
between the platelet collagen receptor glycoprotein VI (GPVI) and collagen 
(Stegner & Nieswandt, 2011).  Activation of GPVI by collagen binding initiates 
a phosphorylation signalling cascade resulting in platelet activation (Stegner & 
Nieswandt, 2011).  Activated platelets undergo a period of shape change, 
during which rearrangement of the actin cytoskeleton mediates platelet 
adhesion, clot retraction and secretion of secondary mediators.  Positive 
feedback mediators such as ADP and TxA2, which are secreted from platelet 
dense granules, act to potentiate platelet activation and recruit more platelets 
from the blood flow to the site of injury (Stegner & Nieswandt, 2011) (figure 
1.1, C).  Finally, thrombus formation is stabilised via activation of platelet 
surface integrins such as αIIbβ3, which mediates platelet-platelet interactions, 
and α2β1, α5β1 and α6β1 which bind collagen, fibronectin and laminin 
respectively (Stegner & Nieswandt, 2011).  In addition, the platelet plug is 
supported by a mesh of fibrin, which is formed via the cleavage of fibrinogen 
by thrombin, a process driven by the coagulation cascade and secondary 
haemostasis (figure 1.1, D).  The precise mechanisms behind this complex 
process and the interplay which balances inhibitory and activatory signals in 
platelets are discussed in more detail in section 1.1.4. 
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Figure 1.1 – Thrombus formation prevents excessive blood loss at sites of vascular 
injury.  In a quiescent, uninjured vessel, the endothelium releases anti-thrombotic agents such 
as PGI2 and NO to inhibit platelet activation (A).  Following injury to the endothelium, 
components of the basal membrane such as collagen are exposed, and blood cells and plasma 
leak out of the damaged vessel.  Platelets react to the exposed collagen and tether to collagen 
fibres via vWF. Black arrows represent deceleration of the platelets from the flow of blood 
due to this initial tethering stage (outline in more detail in section1.1.4) (B).  The initial 
tethering process slows the platelet and allows an interaction between collagen and GPVI to 
form, which induces platelet activation, shape change and secretion of secondary mediators, 
such as ADP and TxA2 (C).  Integrin activation induces aggregation, and fibrin drives 
formation of the haemostatic plug (D). 
 
1.1.3 Platelets in health and disease 
Although platelet activation has an important role during haemostasis, recent 
research has implicated platelets in several other biological processes and 
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platelet activation and thrombus formation has also been implicated in several 
disease processes.  For example, interaction between platelets and lymphatic 
endothelial cells has been shown to be important for normal development and 
function of the lymphatic system, especially in preventing backflow of blood 
into the lymphatic vessels at lymphovenous junctions.  Podoplanin, expressed 
on the lymphatic endothelium, activates the platelet receptor C-type lectin like 
receptor 2 (CLEC-2), which leads to platelet aggregation and prevents 
leakage of blood components into the lymphatic system (Bertozzi et al., 2010; 
Finney et al., 2012; Hess et al., 2014; Suzuki-Inoue et al., 2010; Uhrin et al., 
2010).  Additionally, at lymphovenous junctions which display impaired valve 
function, thrombus formation within the lymphatic environment can be 
protective against blood-lymphatic mixing (Hess et al., 2014).  CLEC-2 is also 
important in development and maintenance of lymph nodes and in mice with 
platelets deficient in CLEC-2, blood filled lymph nodes and fibrosis was 
observed due to reduced lymph node integrity (Bénézech & Nayar, 2014).  
Platelet CLEC-2 and GPVI mediated signalling has also been implicated in 
maintaining vascular integrity during inflammation, when lymphocytes 
transmigrate through the vessel wall (Boulaftali et al., 2013).  This is 
particularly important in high endothelial venules, through which lymphocytes 
transmigrate to reach the lymph nodes.  Podoplanin-induced CLEC-2 
signalling and platelet activation is important to maintain integrity of these 
vessels (Herzog et al., 2013).  Finally, platelets have also been shown to play 
an important role in facilitating the closure of the ductus arteriosus; a vessel 
between the aorta and the pulmonary artery which must be closed after birth 
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to prevent post natal mortality.  Platelets support remodelling and contribute to 
the thrombotic sealing of this area (Echtler et al., 2010).   
Platelets have also been implicated in poor cancer prognosis, as they can 
coat the surface of tumour cells in the blood stream and are able to facilitate 
adhesion to the vessel wall, tumour growth and metastasis (Lowe, Navarro-
Nunez, & Watson, 2012).  One mechanism which has been widely studied is 
the interaction between platelet CLEC-2 and tumour cell podoplanin.  
Podoplanin is highly expressed on cancer cells and several studies have 
linked podoplanin to increased metastasis and malignant tumour progression 
(Mishima et al., 2006; P. Yuan et al., 2006).  Investigation into activation of 
platelet CLEC-2 by tumour cell podoplanin, implicated a role for CLEC-2 
induced platelet aggregation in tumour growth and metastasis (Suzuki-Inoue 
et al., 2007, 2010).  Interestingly, if podoplanin-induced platelet activation is 
suppressed, then a significant reduction in pulmonary metastasis is observed 
(Miyata et al., 2014), which highlights the potential for therapeutic targeting of 
platelets to combat cancer metastasis.  Platelets also play additional roles in 
cancer progression, for example activation of protease activated receptor 
(PAR) pathways can lead to release of angiogenic factors such as vascular 
endothelial growth factor (VEGF), which promote vessel growth and therefore 
mediates tumour growth (J. E. I. Italiano et al., 2008; Lowe et al., 2012). 
In addition to being necessary during haemostasis, thrombus formation is also 
heavily implicated in both heart attack and stroke, as arterial thrombus 
formation at sites of atherosclerotic plaque rupture can lead to occlusion of 
the vessel.  Formation of atherosclerotic plaques occurs as a result of severe 
inflammation of the endothelium caused by deposits of cholesterol and 
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accumulation of macrophages (Palomo, Toro, & Alarcón, 2008; Sakakura et 
al., 2013).  Progression of plaque formation eventually leads to narrowing of 
the vessel and potential disruption to blood flow.  Rupture of an unstable 
plaque induces thrombus formation, as the surrounding platelets are exposed 
to damaged endothelium and components of the sub-endothelium matrix, all 
of which induce platelet activation and aggregation.  The coagulation cascade 
has also been implicated in atherothrombosis, as coagulation factors such as 
FXI regulates thrombus formation at sites of acutely ruptured plaques (van 
Montfoort et al., 2014), FVIIa contributes to activation of initial thrombus 
formation, and factor XIIa (FXIIa) has been shown to stabilise the thrombus 
during pathological atherothrombosis (Kuijpers et al., 2014).  Culmination of 
thrombosis and the coagulation cascade at sites of plaque rupture can 
produce blood clots which completely occlude the vessel, preventing blood 
flow within the artery and causing heart attack or stoke.  New roles for 
platelets in the early stages of plaque formation are also being investigated.  It 
appears that activated platelets can interact with and activate the endothelium 
at sites prior to plaque formation.  Therefore platelets could potentially be 
promoting inflammation and thus initiating plaque formation (Rondina, 
Weyrich, & Zimmerman, 2013). 
A better understanding of the mechanisms behind platelet activation could 
provide potential future targets for anti-thrombotic therapies for heart attack, 
which is currently one of the principle causes of mortality worldwide (Mendis, 
Puska, & Norrving, 2011). 
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1.1.4 Multiple signalling pathways balance inhibitory and activating 
stimuli in platelets  
Inappropriate platelet activation at sites distant from vascular damage needs 
to be avoided in order to prevent unwanted thrombus formation, therefore 
inhibitory signals to maintain platelets in a ‘resting’ state are vitally important.  
However, it is also crucial that platelet activatory signals are robust enough to 
overcome inhibition of platelet activation when required.  The fine balance of 
these positive and negative signals, which was briefly outlined in section 
1.1.2, involves a multitude of signalling receptors and signal transduction 
pathways. 
One important physiological platelet inhibitor is NO, which is secreted by 
endothelial cells to keep the platelets in a ‘resting’ state within a healthy 
vessel.  Inhibition of platelet activation by endothelial-secreted NO occurs 
predominantly via the cGMP-PKG signalling pathway.  NO diffuses across the 
platelet membrane and activates the NO-sensitive enzyme guanylyl cyclase 
(GC), thus increasing the production of cGMP (Smolenski, 2012).  Increased 
levels of cGMP in the platelet lead to activation of protein kinase G 1 (PKG1), 
which then acts on a range of different substrates; inducing phosphorylation 
and ultimately inhibiting platelet activation.  The importance of PKG1 within 
the inhibitory NO-cGMP pathway was demonstrated by the prothrombic 
phenotype observed in PKG1 knockout mice; mice lacking PKG1 showed an 
increase in platelet adhesion and platelet activation in the presence of NO 
(Massberg et al., 1999).  One example of a PKG1 substrate is vasodilator-
stimulated phosphoprotein (VASP), which has an important role in the 
regulation of actin cytoskeleton dynamics.  Mice lacking VASP show 
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increased adhesion and defective inhibition via the NO-cGMP pathway, 
suggesting that phosphorylation of VASP by PKG1 has an important role in 
platelet inhibition (Massberg et al., 2004).   
PGI2 which is also released by the endothelium is another important inhibitor 
of platelet activation, though it acts through a different mechanism to NO.  
PGI2 binds to a GPCR on the platelet surface and triggers a signalling 
pathway through activation of the associated G-proteins.  Specifically, binding 
of PGI2 leads to activation of the Gs G-protein through promotion of the GTP-
bound active form of the protein (Smolenski, 2012).  Active GTP-bound Gs 
then goes on to activate adenylate cyclase (AC) which stimulates synthesis of 
cAMP.  In a similar mechanism as described for cGMP, cAMP utilises a 
kinase to continue the signalling cascade, specifically activating protein kinase 
A (PKA); upon cAMP binding to the regulatory subunits of PKA, the catalytic 
domains dissociate and go on to phosphorylate its substrates.  Substrates of 
PKA include VASP and also the intracellular Ca2+ store channel protein IP3 
receptors (Smolenski, 2012).  Both PKA and PKG1 act on many different 
substrates and phosphorylation of these substrates ultimately leads to 
modulation of the actin cytoskeleton to prevent platelet shape change and 
regulation of Ca2+ release from intracellular stores to prevent platelet 
activation (Smolenski, 2012).  Despite the need for these inhibitory signals in 
platelets, mechanisms exist to reduce cAMP and cGMP levels in the platelet, 
as balancing these cyclic nucleotides is vital for balancing platelet inhibition 
and activation.  Regulation of cAMP and cGMP occurs mainly through 
degredation via the phosphodiesterase (PDE) family of proteins.  In platelets, 
PDE2 and PDE3 specifically degrade cAMP and PDE5 specifically degrades 
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cGMP (Smolenski, 2012).  Activation of the PDE proteins occurs via a 
negative feedback loop, which helps to keep the cytosolic levels of cAMP and 
cGMP in check.  However, to ultimately be able to induce platelet activation 
when required at sites of vascular damage, strong activatory signals need to 
be produced to overcome these inhibitory effects. 
The process of platelet activation at sites of vascular damage involves 
multiple cell surface receptors.  Investigation into their signalling has 
demonstrated that platelet surface receptors rely on two key downstream 
signalling pathways.  Receptors such as GPVI/FcRγ and CLEC-2 rely on 
tyrosine phosphorylation signalling cascades downstream of immunoreceptor 
tyrosine based activation motif (ITAM) and hemITAM motif activation 
respectively.  Other platelet receptors such as PAR, thromboxane receptors 
(TP) and P2Y receptors are GPCRs which rely on G-protein activated 
signalling pathways (Bernhard Nieswandt & Watson, 2003; Stegner & 
Nieswandt, 2011).  Ultimately, these pathways converge to reduce cAMP and 
increase intracellular Ca2+ which amplifies platelet activation and stabilises 
platelet adhesion through integrin activation, as demonstrated by the diagram 
in figure 1.2.   
Exposure of collagen fibres at sites of vascular damage acts as the initial 
signal to stimulate platelet activation.  However, in arterial shear conditions, 
the platelets must undergo a process of tethering, to decelerate the platelet, 
before direct interaction with collagen and platelet activation can occur.  This 
process is reliant on the adhesive glycoprotein GPIb-V-IX complex, which 
interacts with vWF multimers which become immobilised on exposed collagen 
fibres (M Moroi et al., 1997).  Without this initial stage of platelet tethering, 
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platelet activation is impaired, as demonstrated by the bleeding disorder 
Bernard-Soulier syndrome, which is caused by the lack or dysfunction of the 
GPIb-V-IX complex (Berndt & Andrews, 2011).  Interaction of GPIb-V-IX with 
vWF not only facilitates tethering of the platelet at the site of injury, but also 
induces weak activation of the integrin αIIbβ3, and can induce intracellular 
Ca2+ mobilisation (Stegner & Nieswandt, 2011).  
Although the capture of platelets from the blood flow is reliant on the GPIb-
vWF interaction, this is not sufficient to provide firm adhesion of the platelet to 
the exposed collagen fibre.  In order to achieve this, strong activation signals 
are required.  The platelet collagen receptor GPVI is able to produce the 
activatory signals required, following capture of the platelet.  GPVI is a 
transmembrane Ig super family receptor, which interacts with collagen fibres 
via glycine-proline-hydroxyproline (GPO) repeats, which induces cross-linking 
of the receptor (Watson, Auger, McCarty, & Pearce, 2005).  Following cross-
linking, GPVI signals via the ITAM motif found in the intracellular tail of the 
associated FcRγ chain, which eventually leads to activation of phospholipase 
Cγ (PLCγ), causing increased cytosolic Ca2+ concentration via release from 
intracellular stores, and influx from the extracellular environment (Bernhard 
Nieswandt & Watson, 2003; Y. a Senis, Mazharian, & Mori, 2014).  The 
complex signalling cascade of this important platelet collagen receptor is 
described in more detail in section 1.1.5 and is represented in figure 1.3.  
Interestingly, mice lacking GPVI/FcRγ do not display vastly prolonged 
bleeding times, which suggests that although this receptor has an important 
role in platelet activation, some level of redundancy with other receptors on 
the platelet surface might occur (B Nieswandt, Schulte, et al., 2001).  
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However, mice lacking GPVI/FcRγ are protected against arterial thrombosis in 
the transient middle cerebral artery occlusion model of stroke and display 
reduced damage to brain tissue due to a reduction in thromboinflammation 
(Kleinschnitz et al., 2007).  This presents GPVI as an attractive target for 
treatment of ischemic coronary disease, as there is the potential to reduce 
artherothrombosis without increasing the risk of bleeding or brain injury after 
reperfusion (Kleinschnitz et al., 2007).  Additionally, GPVI has been implicated 
in inflammation models other than those following pathological vascular 
events such as stroke.  Both GPVI and CLEC-2 have a role in maintenance of 
vascular integrity during inflammation (Boulaftali et al., 2013) and GPVI has 
also been implicated in promotion of inflammation in rheumatoid arthritis 
(Boilard et al., 2010). 
The role of GPVI is not limited to platelet activation through increasing 
cytosolic Ca2+ concentration.  This receptor also has an important role in 
activation of platelet integrins through an ‘inside-out’ mechanism, which 
converts them from inactive to an active state (Y. a Senis et al., 2014).  
Integrins are adhesion receptors, which exist as heterodimeric 
transmembrane proteins made from α and β subunits.  Integrins play a vital 
role in mediating cell adhesion and specifically in platelets, this is important 
during platelet activation and thrombus formation (B Nieswandt et al., 2011; 
Stegner & Nieswandt, 2011).  In a resting platelet, integrins are held in an 
inactive state and have low affinity for their ligands; this is important to prevent 
platelet adhesion away from sites of vascular damage and prevent 
inappropriate platelet adhesion.  Upon activation of platelet surface receptors, 
integrins shift to an active state with high binding affinity for their ligands.  This 
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shift is triggered by inside-out signalling from platelet surface receptors such 
as GPVI, and others including GPCRs and ITAM mechanisms (B Nieswandt 
et al., 2011; Stegner & Nieswandt, 2011).  In addition to the role in adhesion 
that these integrins play on the platelet surface, outside-in signalling 
mechanisms are triggered following binding of integrins to their ligands.  A 
broad variety of cytosolic integrin-binding proteins play a role in promoting 
platelet spreading and clot retraction follwing integrin activation. 
Three different β1 integrins have been identified in platelets; α2β1, α5β1 and 
α6β1.  Activation of α2β1 facilitates firm adhesion of the platelet to exposed 
collagen fibres (Inoue, Suzuki-Inoue, Dean, Frampton, & Watson, 2003).  
Additionally, α5β1 and α6β1 help to further stabilise adhesion of the platelet 
through interactions with fibronectin and laminin respectively (Stegner & 
Nieswandt, 2011).  However, the β1 integrins are suggested to play more of a 
supportive role and are considered not to be essential for firm platelet 
adhesion (B Nieswandt et al., 2011; Stegner & Nieswandt, 2011).  This is 
demonstrated by the lack of severe disruption to thrombus formation following 
loss of α2β1, suggesting that loss of the β1 integrins can be compensated by 
other platelet surface protein which contribute to adhesion (B Nieswandt, 
Brakebusch, et al., 2001).  In addition to the β1 integrins, the platelet surface 
is also populated with two β3 integrins; αIIbβ3 and αVβ3.  The αVβ3 integrin 
is expressed at very low levels on the platelet surface and is poorly 
understood however αIIbβ3 is the most abundant integrin on the platelet 
surface and has been widely studied due to the vital role it plays in thrombus 
formation (B Nieswandt et al., 2011).  Loss of the integrin αIIbβ3 on the 
platelet surface results in increased bleeding and lack of thrombus formation 
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in mice (Hodivala-dilke et al., 1999; Tronik-Le Roux et al., 2000), and 
mutations leading to lack or dysfunction of αIIbβ3 in humans causes the 
bleeding disorder Glanzmann’s thrombasthenia (Sebastiano, Bromberg, 
Breen, & Hurford, 2010).  This demonstrates that loss of this particular integrin 
cannot be compensated through alternative interactions and confirms the 
importance of the role it plays in platelet aggregation.  This particular integrin 
is vital in forming platelet-platelet interactions through association with 
fibrinogen, which forms a bridge with αIIbβ3 integrins on opposing platelet 
surfaces, therefore allowing platelet aggregation and thrombus growth 
(Watson et al., 2005).  It has also been suggested that vWF is another ligand 
for this integrin and that this interaction is important for platelet-platelet 
interactions to occur within high shear environments (Ruggeri, Dent, & 
Saldívar, 1999). 
In addition to the initial activatory signals from GPVI, other platelet surface 
proteins are also important in potentiating platelet activation and driving 
thrombus formation, including G-protein coupled receptors such as the PAR 
receptors, TPα/TPβ receptors and the P2Y1/P2Y12 receptors.  The PAR 
receptors are activated by the prothrombotic agent thrombin, which is 
produced locally at sites of vascular damage through the coagulation 
cascade.  Gq-coupled responses from PAR activation lead to downstream 
phospholipase Cβ (PLCβ) activation and ultimately increased Ca2+ 
concentration through release from intracellular stores (De Candia, 2012).  
G12/13-coupled responses from PAR activation leads to downstream 
activation of Ras homologue gene family member A (RhoA), from its inactive 
guanosine diphosphate (GDP)-bound form into its active guanosine 
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triphosphate (GTP)-bound form (De Candia, 2012).  Once active, this small 
GTPase can trigger phosphorylation events which lead to myosin light chain 
phosphorylation, which has been shown to drive platelet shape change.  The 
process of shape change within the platelet is driven by dynamic changes to 
the cytoskeleton and allows for the normally discoid platelet to spread and 
adhere strongly to exposed collagen fibres.  Changes to the cytoskeleton can 
also drive secretion of secondary mediators, such as ADP and  TxA2, through 
trafficking of platelet dense granules to the plasma membrane (Broos et al., 
2011; Stegner & Nieswandt, 2011). 
Platelet-secreted ADP activates P2Y1 and P2Y12 receptors on the platelet 
cell surface which activate downstream Gq and Gi signalling respectively.  As 
described above, activation of Gq-proteins induces increased Ca2+ 
concentrations through activation of PLCβ.  Activation of Gi-coupled signalling 
inhibits adenylyl cyclase, which normally converts adenosine triphosphate 
(ATP) into cAMP, thus Gi signalling reduces cAMP activity (Jin, Daniel, & 
Kunapuli, 1998).  The action of cAMP inhibits many platelet activatory 
processes such as degranulation leading to secretion, rearrangement of the 
cytoskeleton and increasing intracellular Ca2+ (Schwarz et al., 2001; Stegner 
& Nieswandt, 2011).  Therefore Gi-protein induced inhibition of andenylyl 
cyclase promotes secretion, shape change and platelet activation through 
reduction of cAMP. 
Platelet secreted TxA2 activates TPα/TPβ receptors, which also activate Gq-
proteins.  Therefore activation of TP receptors drives increasing Ca2+ 
concentration and inhibition of cAMP production, as outlined above (Stegner 
& Nieswandt, 2011). 
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P2X1 adenosine triphosphate (ATP)-gated cation channels also contribute to 
platelet activation, through direct flux of Ca2+ into the cell.  Following binding 
of ATP, P2X1 allows flux of Ca2+ and other cations into the platelet.  The Ca2+ 
signal provided by P2X1 receptors is important for platelet shape change, and 
promotion of dense granule secretion (Mahaut-Smith, Jones, & Evans, 2011).  
The activation of P2X1 has also been shown to amplify platelet activation via 
synergy with other platelet receptors and can increase signalling responses to 
low doses of platelet agonists such as thrombin and collagen (Mahaut-Smith 
et al., 2011). 
These platelet receptors, which are shown in figure 1.2, demonstrate some of 
the signalling pathways involved in platelet activation.  Further signalling 
receptors also contribute to platelet activation; CLEC-2 signals in a very 
similar mechanism to GPVI, with the intracellular tail utilising a hemITAM motif 
to initiate tyrosine phosphorylation signalling cascade (May et al., 2009; Y. a 
Senis et al., 2014).  Receptors such as adrenergic receptors, prostaglandin E 
receptor 3 (EP3) and 5-hydroxytimamine 2A receptors signal through G-
protein coupled mechanisms (Broos et al., 2011; Stegner & Nieswandt, 2011).  
Additional receptors which contribute to platelet activation as well as new 
levels of regulation of currently known platelet receptors are still being 
identified.  For example, the selective anion channel pannexin-1 (Panx-1) has 
recently been shown to facilitate Ca2+ mobilisation and platelet aggregation, 
potentially through secondary activation of the P2X1 receptors on the platelet 
surface (Taylor, Wright, Vial, Evans, & Mahaut-Smith, 2014). 
Culmination of signalling from all of these different receptors allows for 
maximal platelet activation, and also promotes regulation of this vital process. 

































Figure 1.2 – Multiple surface receptors contribute to platelet activation and aggregation.  
The primary wave of platelet activation is mediated by adhesion to exposed extracellular 
matrix at sites of injury.  Tethering of the GPIb-IX-V complex to collagen via vWF slows the 
platelet from the blood flow and allows interaction between GPVI and collagen to form.  
Once bound to collagen, GPVI signals via an ITAM motif within the FcRγ chain which 
initiates a phosphorylation cascade resulting in increased cytosolic Ca
2+
, secretion of 
secondary mediators such as ADP and TxA2, platelet activation and activation of integrin 
α2β1 to stabilise adhesion to collagen.  ADP activates the P2Y1 and P2Y12 receptors, 
coupled to Gq and Gi proteins respectively.  TxA2 activates TPα and TPβ receptors, coupled 
to Gq proteins.  Thrombin is generated at sites of vascular injury and as well as contributing 
to fibrin generation, activates the PAR receptors, coupled to Gq and G12/13 proteins.  These 
secondary wave agonists amplify and sustain platelet activation through increasing cytosolic 
Ca
2+
, decreasing cAMP activity and inducing shape change.  Ca
2+
 influx via ATP-gated P2X1 
channels amplifies platelet activation.  Ultimately, this leads to activation of integrin αIIbβ3, 
which mediates platelet-platelet interaction, thus driving aggregation. 
 
1.1.5 Downstream signalling from the platelet collagen receptor GPVI 
The platelet collagen receptor GPVI has two extracellular immunoglobulin (Ig) 
domains and a proline-rich Src homology 3 (SH3)-binding domain within the 
short intracellular tail, to allow for interaction of kinase proteins (Masaaki 
Moroi & Jung, 2004).  The functional receptor is associated with the FcRγ 
chain, which contains an ITAM motif within the intracellular tail, which is 
defined by two YxxL/I motifs separated by 6-12 residues (Horii, Kahn, & Herr, 
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2006; Masaaki Moroi & Jung, 2004).  GPVI itself does not possess intrinsic 
kinase activity, therefore transfer of the signal to induce platelet activation is 
reliant on Src family kinases to complete a complex tyrosine phosphorylation 
cascade (Y. a Senis et al., 2014).  This signalling cascade is outlined in figure 
1.3 and is discussed in more detail below. 
Following cross-linking of GPVI induced by binding collagen, activation of the 
downstream phosphorylation cascade begins with the Src family kinases Lyn 
or Fyn phosphorylating two tyrosine residues within the ITAM motif in the 
cytosolic tails of the associated FcRγ chain (Dütting, Bender, & Nieswandt, 
2012; Stegner, Haining, & Nieswandt, 2014; Zahid et al., 2012).  
Phosphorylation of the ITAM recruits Syk, via 2 Src homology 2 (SH2) 
domains, which enables phosphorylation of Syk by Lyn.  Syk can then go on 
to phosphorylate the linker for activation of T-cells (LAT) and enable formation 
and activation of the LAT signalosome; a scaffold of adaptor proteins which 
recruits PLCγ2 close to the plasma membrane (Dütting et al., 2012; Stegner 
et al., 2014; Zahid et al., 2012).  These adapters include SLP-76 and also 
Gads, which aid in linking LAT to SLP-76 (Hughes et al., 2008).  Completion 
of the LAT signalosome promotes activation of PLCγ2, which in turn produces 
diaceylglycerol (DAG) and inositol trisphosphate (IP3) from hydrolysis of 
phosphatidyl inositol 4, 5 bisphosphate (PIP2).  IP3 can then stimulate flux of 
Ca2+ from the intracellular Ca2+ store, into the cytosol, via IP3 receptors.  In 
turn, depletion of Ca2+ from the intracellular store induces influx of Ca2+ from 
the extracellular environment in a process called store operated Ca2+ entry 
(SOCE) (Smyth et al., 2010; Stegner et al., 2014), which is discussed in more 
detail in section 1.2.  The overall increase in cytosolic Ca2+ induces platelet 
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activation, shape change and secretion via several key Ca2+ activated 
proteins.  For example, the protein kinase C (PKC) isoform PKCα has been 
shown to be important in platelet secretion downstream of increases in Ca2+ 
concentration (Konopatskaya et al., 2009).  PKCα regulates secretion via 
activation of protein kinase D 2 (PKD2) and mutation or loss of either PKCα or 
PKD2 in platelets leads to reduced secretion of dense granules, decreased 
aggregation and decreased thrombus formation (Konopatskaya et al., 2009, 
2011).  The GPVI signalling pathway is vitally important to initiate strong 
activatory signals to promote platelet aggregation through integrin activation, 
shape change and secretion of secondary mediators.  This signalling cascade 
is reliant on Ca2+ signalling to produce platelet activation. 


















































Figure 1.3 – The GPVI signalling pathway.  Following GPVI activation by collagen, 
phosphorylation of the ITAM motif in the intracellular tails of the FcRγ chain via Fyn and 
Lyn occurs.  This leads to recruitment of Syk and a downstream phosphorylation cascade 
which induces formation of the LAT signalosome and recruitment of PLCγ2 to the 
membrane.  Active PLCγ2 induces production of IP3, which stimulates flux of Ca
2+
 from the 
intracellular Ca
2+
 store into the cytosol via IP3 receptors.  Depletion of Ca
2+
 from the 
intracellular store induces flux from the extra cellular environment via Orai channels during 
store operated Ca
2+
 entry.  Increased intracellular Ca
2+
 induces secretion of secondary 
mediators, alterations to the actin cytoskeleton to induce shape change, and aggregation.  
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1.2 STORE OPERATED Ca2+ ENTRY 
The process of SOCE facilitates flux of Ca2+ into the cell following depletion of 
intracellular Ca2+ stores and as such is vitally important for sustaining high 
levels of intracellular Ca2+ during signalling events.  The influx of Ca2+ from 
the extracellular environment also enables replenishment of the depleted 
intracellular Ca2+ stores, therefore enabling the cell to undergo future 
signalling events (Smyth et al., 2010).  As Ca2+ acts as a signal transducer in 
many different signalling pathways across multiple cell types, regulation of the 
mechanism of Ca2+ entry is vital, to prevent unwanted signalling activation 
and to ensure enough Ca2+ is available to the cell when required. 
 
1.2.1 Overview of Orai and STIM as key regulators of SOCE 
Many different signalling pathways utilise Ca2+ as a secondary signalling 
mechanism to activate specific responses in the cell.  Following stimulation of 
cell surface receptors, activation of PLC leads to hydrolysis of PIP2, which 
releases IP3 as a soluble messenger.  IP3 can then diffuse through the 
cytoplasm where it binds to the IP3 receptor; a conformational change in the 
receptor occurs, which induces opening of the channel to allow flux of Ca2+ 
into the cytosol (Lewis, 2007; Smyth et al., 2010).  In most cell types, IP3 
receptors are located on the membrane of the endoplasmic reticulum (ER), 
which acts as the intracellular Ca2+ store (Lewis, 2007; Smyth et al., 2010).   
Following depletion of Ca2+ from the ER, subsequent influx of Ca2+ from the 
extracellular environment occurs via a pathway called the Ca2+ release 
activated Ca2+ (CRAC) current, which is reliant on two key proteins: the Ca2+ 
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sensory molecule stromal interaction molecule  (STIM1 and 2) and the CRAC 
channel protein family (Orai1, 2 and 3) (Soboloff et al., 2006). 
In a resting state, STIM proteins are found within the membrane of the ER 
where they bind Ca2+ via the EF hand motif, which holds the protein in a 
folded conformation (for more detail on STIM structure, refer to section 1.2.2).  
Dissociation of Ca2+ from STIM, driven by store depletion, induces a 
conformational change and oligomerization of STIM.  STIM proteins then 
translocate to areas of the ER which are adjacent to the plasma membrane 
and form puncta, which are able to interact with Orai within the plasma 
membrane (Soboloff, Rothberg, Madesh, & Gill, 2012).  Interaction of STIM 
with Orai proteins induces clustering and enables formation of functional pore-
forming channels.  The formation of functional Orai channels is believed to 
require either 4 or 6 subunits, though the exact structure is still debated 
(discussed in more detail in section 1.2.3).  Following formation of the 
functional channel, Ca2+ is able to flux into the cell (Soboloff et al., 2006, 
2012).  Orai channels are highly selective for Ca2+ ions, utilising a selectivity 
filter mechanism which requires important residues both within the pore and 
outside of the pore on the extracellular side of the channel (Hou, Pedi, Diver, 
& Long, 2012). 
Orai channels are not the only Ca2+ channels found on the cell surface, and 
channels of the transient receptor potential cation channel (TRPC) family 
have also been considered as potential CRAC channels (Smyth et al., 2010).  
TRPC channels can associate with STIM proteins and they are sometimes 
activated downstream of PLC stimulation and depletion of intracellular stores.  
However, channels formed by TRPC proteins are less selective for Ca2+ than 
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those formed by Orai1 (Smyth et al., 2010).  The consequence of interaction 
between TRPC with STIM and Orai proteins and the level of coordination 
between them is not fully understood.  However, it is widely accepted that 
when TRPC channels are activated downstream of store depletion, the non-
selective channels which are formed are distinct from CRAC channels (Smyth 
et al., 2010).  The widely accepted mechanism of SOCE is depicted in figure 












Figure 1.4 – The role of STIM and Orai in SOCE.  When Ca
2+
 within the ER lumen binds 
STIM, the protein is held in an inactive conformation.  Activation of IP3 receptors 
downstream of cell surface receptor signalling enables flux of Ca
2+
 out of the ER and into the 
cytosol (A).  Ca
2+
 becomes depleted and dissociates from STIM, inducing a conformational 
change, oligomerization and relocation to areas of the ER close to the plasma membrane (B).  
STIM form puncta close to the plasma membrane and interact with Orai proteins, to induce 
clustering and activation of the channels, to allow flux of extracellular Ca
2+
 into the cell (C). 
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1.2.2 Different isoforms of STIM and Orai 
The STIM family consists of STIM1 and STIM2 and although these two 
isoforms are both widely expressed, STIM1 is localised within the ER 
membrane and the plasma membrane, whereas STIM2 is found only in the 
ER (Smyth et al., 2010).  STIM1 and STIM2 share approximately 65% 
sequence homology and have similar domain structure (Stathopulos, Zheng, 
& Ikura, 2009).  However, oligomerization and activation of STIM2 occurs 
more slowly than STIM1 (Stathopulos, Zheng, Li, Plevin, & Ikura, 2008) which 
is thought to be due to differences in the kinetics of the Ca2+ binding domain 
at the N-terminus of STIM (see section 1.2.3 for more detail on STIM 
structural domains) (Stathopulos et al., 2009).  Additionally, differences in the 
C-terminal domain of STIM1 and STIM2, which are involved in binding Orai1, 
demonstrate the isolated mechanisms of these two isoforms.  The 
phenylalanine residue at position 394 within the C-terminal domain of STIM1 
has been shown to be important for interaction with and activation of Orai1, as 
mutation of this residue to a histidine leads to ineffective association and 
gating of Orai1 (X. Wang et al., 2014).  The equivalent residue within the C-
terminal of STIM2, leucine 394, generates partial interaction and activation of 
Orai1, but not to the full capacity observed for STIM1 (X. Wang et al., 2014).  
Interestingly, a role for STIM2 in replenishing intracellular stores following low 
levels of store depletion has been suggested (Thiel, Lis, & Penner, 2013).  
Whereas STIM1 was activated in response to strong signals (complete store 
depletion), STIM2 was activated in response to weaker stimuli, which 
suggests a potential mode of regulation of SOCE, depending on the level of 
store depletion (Thiel et al., 2013).  Overall, it seems likely that STIM1 is the 
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main regulator of SOCE in the cell, whereas STIM2 has a role in regulating 
basal cytosolic and intracellular store Ca2+ levels. (Baba, Matsumoto, & 
Kurosaki, 2014; Smyth et al., 2010). 
Within the Orai family of transmembrane proteins, there are 3 different 
isoforms; Orai1, Orai2 and Orai3.  All three proteins have similar sequence, 
including conserved residues such as glutamate at position 106, which is 
important for ion selectivity.  All three are also able to reconstitute functional 
channels which are stimulated by store depletion and which are highly 
selective for Ca2+ ions (Gwack et al., 2007).  However, Orai1 is often the more 
highly expressed of the three and has been the most widely studied (Hoth & 
Niemeyer, 2013).  It is not yet clear whether Orai proteins are able to 
heteromultimerise in order to form functional channels, though Orai1 has been 
immunoprecipitated with Orai2 and Orai3, suggesting an interaction, and in 
some cases, loss of Orai1 results in compensation by Orai2 and Orai3 
(Gwack et al., 2007).  However, the extent of cooperation between the 
different isoforms is most probably cell-specific, as Orai2 and Orai3 do not 
always reconstitute channel function in the absence of Orai1.  It is therefore 
difficult to assess the exact roles of the different isoforms in general terms 
(Hoth & Niemeyer, 2013).  Some studies have suggested that Orai3 displays 
structural differences to Orai1, particularly within the intracellular termini 
domains, though the functional effects of these differences and the 
physiological implications have not yet been elucidated (Shuttleworth, 2012). 
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 1.2.3 The molecular mechanism of STIM1 activation  
STIM1 is a single transmembrane protein, with the N-terminal (STIM1-N) 
located within the lumen of the ER acting as a Ca2+ sensor, and the C-
terminal (STIM1-C) located in the cytosol, acting to interact with and stimulate 
Orai channel proteins (X. Yang, Jin, Cai, Li, & Shen, 2012).  STIM1-N 
contains tandem EF-hand motifs which bind Ca2+ in the ER lumen alongside a 
sterile α motif (SAM) (Stathopulos et al., 2009, 2008).  STIM1-C contains the 
STIM1 Orai1 activating region (SOAR), which has been recognised as 
essential for oligomerization and activation of Orai1.  SOAR is comprised of 
two coiled-coil domains, which have been shown to form a STIM1-C 
homodimer which is held in a v-shaped folded conformation by an inhibitory 
helix within the CC1 domain, as shown in figure 1.5 (X. Yang et al., 2012). 
Upon Ca2+ depletion in the ER lumen, dissociation of Ca2+ from the EF hand 
motif exposes hydrophobic regions within the EF-SAM domain, driving 
dimerisation of STIM1-N, which drives the conformational changes required to 
induce ‘unfolding’ of STIM1-C and allow interaction with Orai1, as shown in 
figure 1.5 (Stathopulos et al., 2009, 2008).  It is believed that this occurs 
through dimerisation of the inhibitory helices, which releases the SOAR dimer 
into an unfolded conformation, which is able to span the distance between the 
ER membrane and the plasma membrane (Zhou et al., 2013).  
Oligomerization of STIM1 occurs and interaction with Orai1 induces channel 
formation and Ca2+ influx.  Recently, a positively charged region at the tip of 
the SOAR domain was identified to be vitally important for interaction with and 
activation of Orai1 (X. Wang et al., 2014; X. Yang et al., 2012). 
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1.2.4 The molecular mechanism of Orai1 activation 
The basic structure of Orai1 is relatively well defined, though the mechanisms 
and 3D structure required for clustering and in functional pore formation are 
highly debated.  Orai1 has 4 transmembrane domains (TM1-4) with 
intracellular termini, 2 extracellular regions, and a glycosylation site within the 
second extracellular region at Asparagine 223 (Smyth et al., 2010; Srikanth & 
Gwack, 2012).  The N and C terminals are regarded as important sites for 
associating proteins to interact with Orai1, including interaction of STIM1 
(Srikanth & Gwack, 2012).  The coiled-coil domain within the C terminus of 
STIM1 is particularly important for re-arrangement and co-localisation of Orai1 
subunits with STIM1.  It is widely accepted that TM1 of each Orai1 subunit 
lines the pore of the channel and mutation of arginine 91 within TM1 leads to 
non-functional channels and severe combined immunodeficiency (SCID) in 
humans due to the detrimental effects of reduced Ca2+ signalling on cells of 
the immune system (Feske et al., 2006).  The mutation which occurs (arginine 
91 to tryptophan 91) increases the hydrophobicity between the TM1 and N-
terminal regions, thus causing loss of pore function, without disrupting 
interaction with STIM1 (Feske et al., 2006; Smyth et al., 2010).  Several 
residues are important in ion selectivity of the channel including glutamate 
106, which is found on the extracellular side of the protein and is conserved 
across the family, and which if mutated to aspartate induces a reduction in 
channel selectivity (Smyth et al., 2010).  An additional 3 residues found within 
the extracellular region between TM1 and TM2 are also involved in forming 
the selectivity filter for the channel, though they are not conserved across the 
family (Smyth et al., 2010).   
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The dynamics of multimer formation and the state of resting Orai1 subunits 
within the membrane is widely debated.  For example, some groups have 
demonstrated that functional Orai1 channels are formed from tetramers, as 
outlined in figure 1.5, and that these tetramers may be formed through 
dimerisation of resting Orai1 dimers (Penna et al., 2008).  However, there is 
not a consensus of opinion on the resting state of Orai1 subunits, as some 
groups argue that the multimeric channel could be pre-formed as 
homotetramer in the membrane ready for activation (Madl et al., 2010). 
Similarly, there is also debate over the exact composition of the functional 
Orai1 channels.  Several different experimental techniques, including use of 
preassembled Orai1 multimers (Mignen, Thompson, & Shuttleworth, 2008), 
single-molecule photo-bleaching (Ji et al., 2008) and high resolution 
microscopy (Maruyama et al., 2009), have demonstrated that functional 
channels exist as tetramers, as depicted in figure 1.5.  However more 
recently, another group using crystallography demonstrated that functional 
Orai1 channels exist as hexamers (Hou et al., 2012).  In this study, a detailed 
3D analysis of a functional channel formed from drosophila Orai1, which has 
73% sequence identity to human within the TM domains, was completed.  The 
six TM1 helices formed the lining of the pore and TM2 and TM3 helices were 
packed in closely around this inner ring.  TM4 helices were excluded to an 
outer ring and the TM4 cytoplasmic extensions of neighbouring subunits were 
packed together in pairs via an antiparallel coiled-coil helix arrangement.  This 
was held in place through interaction of hydrophobic residues, isoleucine 316 
and leucine 319, within these regions, believed to provide stability to the 
whole structure (Hou et al., 2012).  However, recent functional analysis of the 
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hexamer structure has raised questions to its true functional relevance 
(Thompson & Shuttleworth, 2013).  These functional studies highlighted that 
the hexamer channels were not selective for Ca2+ ions, as they were 
permeable to both Na+ and Cs+ monovalent ions (Thompson & Shuttleworth, 
2013), which is in sharp contrast to the highly Ca2+-selective nature of Orai 
channels normally.  The hexamer structure which had been proposed was 
confirmed using cross-linking and size exclusion chromatography (Hou et al., 
2012), but further analysis is required to convince the field that this isn’t simply 
a non-selective channel which fails to mimic the true fingerprint of a normal 
CRAC channel.  In summary, although the transmembrane helices 
arrangement and interaction of STIM1 via the TM4 C-terminal extensions is 
widely accepted, the number of Orai subunits required and the resting state of 
the channel is widely disputed.  











Figure 1.5 – The conformational changes required for STIM1 activation and Orai1 
channel formation.  As shown by the upper panel, Orai1 channels are formed through 
multimerisation of Orai1 units in either tetramer or hexamer complexes.  The TM1 (blue) of 
each subunit lines the pore of the channel and TM4 (yellow) creates the outer ring of the 
structure.  TM4 extensions (yellow) extend into the cytoplasm. As shown by the lower panel, 
STIM1 is held in an inactive, folded conformation when Ca
2+
 is bound to the EF-hand motif 
in the ER lumen, this conformation is stabilised by the inhibitory CC1 domain (A).  When 
activated through dissociation of Ca
2+
 STIM1 dimerises via the EF-SAM domain and STIM1 
extends towards the plasma membrane and oligomerises.  The interaction between STIM1 
SOAR and the TM4 extensions and TM1 membrane-proximal regions of Orai1 promotes 
Orai1 multimerisation and opening of the channel to allow flux of Ca
2+
 into the cell.  Lysine 
rich regions in the C-terminal of STIM1 interact close to the plasma membrane (B). 
 
1.2.5 SOCE is vital for GPVI signalling 
As discussed throughout section 1.1, thrombus formation is heavily reliant on 
Ca2+ signalling, as increases in cytosolic Ca2+ in platelets leads to 
downstream secretion, shape change and aggregation.  Typically, the 
concentration of Ca2+ found in a resting platelet, as with many non-excitable 
cells, is within the region of 100 nM, however this can increase by 10-100 fold 
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during platelet activation (Rink & Sage, 1990).  This large increase in 
intracellular Ca2+ concentration provides the driving force behind many of the 
platelet activatory responses which lead to aggregation, and is made possible 
through the process of SOCE.  Once SOCE channels at the membrane are 
activated, the influx of Ca2+ into the platelet is driven by the large 
concentration gradient of Ca2+ in the blood in comparison to intracellular 
levels.  Typically, circulating free Ca2+ concentrations are within the range of 
1.0 – 1.3 mM and total blood Ca2+ concentration, including bound Ca2+ which 
forms a complex with serum proteins such as albumin, is normally within the 
range of 2.2 – 2.6 mM.  This large difference in extracellular and intracellular 
Ca2+ concentration allows for rapid influx of Ca2+ into the platelet via open 
SOCE channels, and therefore rapid signal transduction and platelet 
activation. 
Influx of Ca2+ from the extracellular environment specifically via SOCE is vital 
in platelets, as demonstrated by the finding that both STIM1 and Orai1 are 
important for normal platelet activation and thrombus formation (Bergmeier et 
al., 2009; Braun et al., 2009; David Varga-Szabo, Braun, et al., 2008).  
Interestingly, it seems that SOCE is especially important in facilitating 
signalling downstream of GPVI, more so than downstream of other platelet 
activatory pathways. 
In platelets, Ca2+ is stored within the dense tubular system, or sarcoplasmic 
reticulum (SR), as well as within lysosome-related organelles (D Varga-
Szabo, Braun, & Nieswandt, 2009).  Although the precise mechanism of store 
release in platelets is not clear, STIM1 has been identified on platelets 
(Grosse et al., 2007; David Varga-Szabo, Braun, et al., 2008) and both STIM1 
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and STIM2 have been shown to be localised to the acidic lysosome-related 
organelles (Zbidi et al., 2011).  STIM1 has been recognised as the primary 
Ca2+ sensor, as platelets deficient in STIM2 did not display marked 
differences in Ca2+ mobilisation, platelet activation or thrombus formation 
(Gilio et al., 2010).  In contrast, platelets deficient in STIM1 had reduced 
release of Ca2+ from the intracellular stores after stimulation with thapsigargin, 
which indicates a reduced Ca2+ store content, and also showed reduced influx 
of Ca2+ via SOCE (David Varga-Szabo, Braun, et al., 2008).  Ca2+ entry in 
response to a range of platelet agonists was also reduced, though 
aggregation of the platelets was only impaired downstream of GPVI 
activation.  The defects observed within GPVI-ITAM reliant processes, and 
normal activation of the platelets through G-protein coupled pathways, 
suggest that STIM1 and SOCE are vitally important downstream of GPVI, but 
might not be vital in activation of platelets through other signalling pathways 
(David Varga-Szabo, Braun, et al., 2008).  During in vivo analysis, mice with 
STIM1 deficient platelets displayed reduced thrombus formation in two 
different models and were also protected from cerebral ischemia in a model of 
stroke (David Varga-Szabo, Braun, et al., 2008) 
Orai1 is also expressed in human and mouse platelets, and Orai1 is more 
highly expressed than either Orai2 or Orai3 (Braun et al., 2009).  To date 
there have been two different mouse models used to study the role of Orai1 in 
platelets; knock out mice lacking expression of Orai1 (Orai1-/-) (Braun et al., 
2009) and knock in mice expressing a loss of function mutant of Orai1 
(Orai1R93W) (Bergmeier et al., 2009). Similarly to STIM1 depletion, loss of 
Orai1 in Orai1-/- mice resulted in reduced SOCE, and reduced Ca2+ 
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mobilisation across a range of platelet agonists, though release of Ca2+ from 
the intracellular stores appeared normal (Braun et al., 2009).  Despite 
defective Ca2+ mobilisation across a range of agonists, Orai1 deficient 
platelets displayed reduced aggregation only downstream of GPVI activation 
(Braun et al., 2009), again suggesting that SOCE is important for platelet 
activation downstream of ITAM-induced signalling but not G-protein coupled 
signalling.  During in vivo analysis, mice with Orai1 deficient platelets were 
protected form arterial thrombus formation, similarly to mice with STIM1 
deficient platelets (Braun et al., 2009).  These findings demonstrating loss of 
Ca2+ mobilisation and aggregation defects suggests that Orai1 is the primary 
SOCE channel in platelets, as Orai2 and Orai3 were not able to compensate 
for the loss of Orai1.  Additionally, the potential role for the Ca2+ channel 
TRPC1 in platelet SOCE has been dismissed, as mice deficient in TRPC1 
show no defect in SOCE, platelet activation or in vivo thrombus formation 
(David Varga-Szabo, Authi, et al., 2008).  Some similarities were observed in 
assessment of the Orai1R93W mice, as Ca2+ mobilisation following stimulation 
by multiple agonists was reduced and SOCE following stimulation with 
thapsigargin was also reduced (Bergmeier et al., 2009).  In results similar to 
those seen with Orai1-/- mice, Orai1R93W mice had normal release of Ca2+ from 
the intracellular stores, but reduced flux of Ca2+ from the extracellular 
environment (Bergmeier et al., 2009; Braun et al., 2009).  However, Orai1R93W 
mice displayed normal aggregation responses across a range of platelet 
agonists, and normal aggregate formation on collagen under flow (Bergmeier 
et al., 2009).  The authors suggested that the release of Ca2+ from the 
intracellular stores would have been sufficient to allow aggregation to occur 
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normally, which is in conflict of the findings with the Orai1-/- mice, which 
displayed defective aggregation downstream of GPVI activation (Bergmeier et 
al., 2009; Braun et al., 2009).  Despite the differences between these two 
models, platelets responses from the Orai1R93W mice such as integrin 
activation, P-selectin exposure and phosphatidyl serine exposure were all 
impaired, which suggests that impairment of Orai1 in platelets and resulting 
reductions in intracellular Ca2+ concentrations does have an impact on normal 
platelet function (Bergmeier et al., 2009).  The differences observed across 
the two models may be a result of the variation in experimental design, or 
could be due to the different methods of mouse model generation.  
Importantly, both studies agree that Orai1 is a major component of SOCE in 
platelets and that without Orai1, platelet Ca2+ signalling is greatly reduced. 
The GPVI-specific defects observed in both STIM1 and Orai1 deficient 
platelets suggest that SOCE is important downstream of ITAM-induced 
signalling, but not G-protein induced signalling.  Platelet aggregation was 
normal downstream of agonists such as thrombin and ADP, which activate G-
protein coupled pathways, despite Ca2+ signalling being reduced in response 
to these agonists.  This could suggest that these pathways rely not only on 
Ca2+ signals during platelet activation, but that another activatory signal could 
be sufficient for aggregation downstream of G-protein signalling in platelets.  
Alternatively, non-GPVI pathways may not require such a large increase in 
Ca2+ concentration in order to activate downstream platelet activation and 
therefore may rely on non-SOCE mechanisms, such as TRPC.  TRPC1 and 
TRPC6 have been shown to have no role in SOCE in platelets, but instead it 
has been suggested they could be activated downstream of other pathways 
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such as DAG (Ramanathan et al., 2012).  Other TRPC channels are known to 
be activated downstream of G-protein mechanisms (Lang, Münzer, Gawaz, & 
Borst, 2013).  Therefore activation of STIM1 and Orai1 deficient platelets by 
non-GPVI agonists may be possible through utilisation of other Ca2+ entry 
mechanisms.  This is an area which needs further clarification, as TRPC 
channels have been shown to form complexes with Orai and STIM proteins, 
therefore these processes are likely to be linked (Jardin, Gómez, Salido, & 
Rosado, 2009; Jardin, Lopez, Salido, & Rosado, 2008; Lang et al., 2013). 
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1.3 TETRASPANINS 
Tetraspanins are a large family of small transmembrane proteins that are 
highly conserved throughout evolution and of which there are 33 members in 
human, displayed in figure 1.6.  These proteins are expressed throughout the 
body and have been implicated in multiple biological processes through 
regulation of specific partner proteins.  In addition to forming interactions with 
partner proteins, tetraspanins interact with each other to form tetraspanin 
enriched microdomains, which act as platforms for optimal signalling, 
adhesion and proteolysis (Stéphanie Charrin, Jouannet, Boucheix, & 




































Figure 1.6 – The tetraspanin family of identified proteins.  The sequence alignment tool, 
Cluster Omega, was used to compare the amino acid sequence alignment of the 33 human 
tetraspanins.  The data is displayed in the form of a dendogram to show how closely the 
different members of the family are related.  Adapted from Haining et al, 2011. 
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1.3.1 Tetraspanin structure 
As their name suggests, tetraspanin proteins are characterised by four 
transmembrane domains, short intracellular tails and two extracellular loops of 
unequal size, as demonstrated by the diagram in figure 1.7.  The most highly 
conserved area within the tetraspanin family is the cysteine-cysteine-glycine 
(CCG) motif within the large extracellular loop which, along with the 2-6 other 
cysteine residues within this region, form disulphide bonds which maintain the 
structure of the large extracellular loop (Kitadokoro et al., 2001).  Tetraspanins 
also undergo post-translational modifications including palmitoylation at 
cysteine residues within the intracellular loop and cytoplasmic tails at 
membrane proximal regions, N-linked glycosylation within the large 
extracellular loop (up to 3 predicted sites), and ubiquitination of the 
cytoplasmic tails (Stéphanie Charrin et al., 2009). 
Determining the exact 3D structure of tetraspanins has proven to be a difficult 
task and no full atomic resolution structure of a whole tetraspanin exists, 
though a few key studies have attempted to elucidate the structure of these 
proteins.  The cryo-electron microscopy structure of the tetraspanin uroplakins 
(UP) UPIa and UPIb complex has been revealed, which showed that these 
proteins form a compact, rod-like structure which protrudes approximately 3.5-
5 nm above the plasma membrane (Min, Wang, Sun, & Kong, 2006).  The 
rod-like structure was believed to be driven by the tightly bound bundle 
formed by the transmembrane helices.  Additionally, the extracellular region of 
the protein formed a ‘mushroom-like’ structure (Min et al., 2006).  Using 
crystallography, the structure of the large extracellular region of CD81 has 
also been resolved (Kitadokoro et al., 2001), and following this, computational 
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modelling  methods were used to predict the rest of the structure (Michel 
Seigneuret, 2006).  Additionally, structural studies of the importance of the 
large extracellular region of CD81 in ligand interactions has provided further 
information on the functional basis of tetraspanin structure (Rajesh et al., 
2012).  These studies have outlined a tightly packed transmembrane region 
made of left-handed coiled coil helices.  The small extracellular loop emerges 
from transmembrane 1, into transmembrane 2 and is comprised of a β-strand 
which contains a hydrophobic region (figure 1.7).  The large extracellular loop 
connects transmembrane regions 3 and 4 and contains 5 α-helices, which 
form a ‘mushroom-like’ structure (figure 1.7).  The large extracellular loop is 
divided into 2 regions; helices A, B and E make up the membrane proximal 
region, which associates closely with the hydrophobic region of the small 
extracellular loop via a hydrophobic groove, which holds the two extracellular 
regions closely together.  The two smaller helices, C and D, make up the 
variable region of the large extracellular loop, alongside the conserved CCG 
motif.  The disulphide bonds formed between the CCG motif and the 2 
additional cysteine residues in this region holds the variable domain in the 
correct conformation, which is held on the opposite side of the protein to the 
small extracellular loop (figure 1.7).  Although CD81 and UPIa/UPIb share 
only 12-13% sequence identity, these studies suggest a very similar structure, 
which suggests these defining features could be ubiquitous across the 
tetraspanin family.   
Despite these characteristics which are shared across the tetraspanin family, 
the variable region within the large extracellular loop of tetraspanin proteins is 
known to differ greatly.  The variable region of the large extracellular loop, 
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containing helices C and D, has been shown through sequence alignment and 
subsequent structure prediction to be highly variable in both size and the 
number of cysteine residues present (M Seigneuret, Delaguillaumie, 
Lagaudrière-Gesbert, & Conjeaud, 2001).  This suggests that the variable 
region will differ in 3D structure across the tetraspanin family.  This is 
potentially due to a role for this region in regulating tetraspanin-partner protein 
interactions (María Yáñez-Mó, Barreiro, Gordon-Alonso, Sala-Valdés, & 
Sánchez-Madrid, 2009); the different structures potentially offer specificity to 
each separate tetraspanin.  This is discussed in more detail in section 1.3.2. 


















Figure 1.7 – The conserved structure of tetraspanin proteins.  Proteins from across the 
tetraspanin family are characterised by several conserved structural features.  They have four 
transmembrane regions, labelled 1-4, which are tightly packed to form a rod-like structure.  
They also have intracellular tails, marked in blue, which contain cysteine residues, marked in 
yellow, which are often sites for palmitoylation close to the plasma membrane.  They also 
have a small extracellular loop which links TM1 and TM2, marked in red, and a large 
extracellular loop, marked in green, which contains the variable region believed to be 
important in partner protein binding.  The extracellular loops often contain sites for N-linked 
glycosylation, as marked in purple.  Additionally, all tetraspanins contain a conserved CCG 
motif within the large extracellular loop which, along with other conserved residues, forms 
between 2 and four disulphide bonds, which help to stabilise the structure. 
 
1.3.2 Tetraspanin interactions 
Investigation into tetraspanin function revealed a role for these proteins in 
organisation of membrane proteins into tetraspanin enriched microdomains, 
thus promoting compartmentalisation of the membrane (Stéphanie Charrin, 
Manié, Billard, et al., 2003; Hemler, 2005; Rubinstein, 2011).  Formation of 
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these domains is a complex process, but is believed to occur via two distinct 
levels of interaction. 
The primary tetraspanin interaction occurs between the tetraspanin and its 
specific partner protein.  This is a relatively strong interaction which can 
withstand stringent detergent conditions, such as Triton X-100 (Yauch, 
Berditchevski, Harler, Reichner, & Hemler, 1998) and digitonin (Serru et al., 
1999).  Studies utilising chimeric proteins have helped to highlight which 
tetraspanin domains are important in tetraspanin-partner protein interaction, 
specifically highlighting the role of the variable region within the extracellular 
domain (see section 1.3.1 for more information on tetraspanin structure).  For 
example, the high affinity interaction of the tetraspanin CD81 with the E2 
envelope protein of hepatitis C virus (HCV) requires the variable region 
(Drummer, Wilson, & Poumbourios, 2002; Higginbottom et al., 2000), and the 
variable region within the large extracellular loop of the tetraspanin CD9 is 
important for normal adhesive function of intercellular adhesion molecule 1 
(ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on endothelial 
cells during leukocyte extravasation (Barreiro, Ovalle, Higginbottom, & Monk, 
2005).  Additionally, transmembrane regions have been implicated as 
important for some tetraspanin-partner protein interactions.  The interaction 
between the tetraspanin uroplakins and their partners relies on 
transmembrane region 3 (Min et al., 2006) and the interaction between the 
tetraspanin CD81 and immunoglobulin super family member 8 (EWI-2) is 
reliant on transmembrane regions 3 and 4 (Montpellier et al., 2011). 
The secondary level of interaction involves clustering of primary tetraspanin-
partner protein complexes together via tetraspanin-tetraspanin interaction.  
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These small complexes are thought to be supported by interactions with lipids 
within the plasma membrane.  Palmitoylation of the intracellular regions of 
tetraspanins enables interaction with the lipid bilayer and reinforces 
tetraspanin-tetraspanin interactions (Stéphanie Charrin et al., 2002; Stéphanie 
Charrin, Manié, Thiele, et al., 2003).  The hypothesis that tetraspanins 
associate with lipids in the membrane is supported by the ability to precipitate 
tetraspanins with cholesterol in biochemical assays (Serru et al., 1999) and by 
the disruption of tetraspanin-tetraspanin interactions in palmitoylation mutants.  
Subsequent formation of large tetraspanin enriched microdomains from these 
small clusters is thought to be a highly dynamic process, which potentially 
occurs as a result of stimuli to induce formation of specialist structures within 
the membrane (Stéphanie Charrin et al., 2009).  These tetraspanin enriched 
microdomains have been shown to be highly dynamic in terms of tetraspanin 
movement into and out of the microdomain (Barreiro et al., 2008; Espenel et 
al., 2008).  Additionally, these microdomains are separate from lipid rafts in 
the membrane (Hemler, 2003).   
Together, this builds an image of tetraspanins as membrane organisers, 
which can interact directly with partner proteins and other tetraspanins.  
These dynamic interactions can drive formation of tetraspanin enriched 
microdomains, and thus regulate partner protein function. 
 
1.3.3 Tetraspanin function 
Tetraspanins have been identified across a range of different cell types and 
have been implicated in a wide variety of cellular processes.  Further 
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investigation into these proteins has revealed use of specific mechanisms in 
order to regulate partner protein function and thus have an impact on 
trafficking, signalling, adhesion and proteolysis within the cell. 
In some cases, tetraspanins have an important role in maturation and 
trafficking of partner proteins to the cell surface.  For example, the tetraspanin 
CD81 is required for cell surface expression of its partner, the B-lymphocyte 
antigen cluster of differentiation 19 (CD19).  in CD81 knockout mice, 
expression of CD19 on the surface of B cells was 50% reduced (Shoham et 
al., 2003) and in human patients lacking CD81 there was complete loss of cell 
surface CD19 (Zelm et al., 2010).  In both cases, this was due to impaired 
trafficking of CD19 from the ER to the golgi.  CD19 is an important co-receptor 
in B-cell receptor signalling and in enhancing B cell activation, therefore lack 
of CD81, which disrupts surface expression of CD19, leads to reduced B cell 
antibody responses in both mouse and human (Shoham et al., 2003; Zelm et 
al., 2010). 
Tetraspanins can also regulate particular signalling processes through 
regulation of their partner proteins.  One example of this is the tetraspanin 
Tspan12, which has been shown to interact with and regulate the Wnt 
receptor Frizzled 4 (Junge et al., 2009).  Following activation, Frizzled 4 
recruits co-receptors such as Lrp5 and downstream signalling activates the 
TCF/LEF family of transcription factors.  This process is particularly important 
in development of the retinal vasculature and mutations in Frizzled 4 or Lrp5 
cause familial exudative vitreoretinopathy (FEVR), in which under 
development of the retinal vasculature causes blindness (Ye, Wang, & 
Nathans, 2010).  Tspan12 does not directly activate or promote signalling of 
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Frizzled 4, but instead is thought to be responsible for promoting clustering of 
the receptor required for downstream signalling (Junge et al., 2009).  The 
importance of this interaction was highlighted when mutations in human 
Tspan12 were also found to cause FEVR and blindness (Nikopoulos et al., 
2010; Poulter et al., 2012). 
Another important function of some tetraspanins is to regulate adhesion, 
which is an important process for many cellular events.  An example of this is 
the role that the tetraspanins CD9 and CD151 play during leukocyte adhesion 
to endothelial cells and therefore subsequent extravasation from the blood 
flow at sites of inflammation.  The endothelial adhesion molecules ICAM-1 
and VCAM-1 are important for interaction with leukocyte integrins to reinforce 
firm adhesion of the leukocyte and to allow extravasation (Nourshargh, 
Hordijk, & Sixt, 2010).  It has been shown that ICAM-1 and VCAM-1 are co-
localised with CD9 and CD151 (Barreiro et al., 2005), and that the 
tetraspanins act to promote formation of nano-platforms on the endothelial cell 
surface which are enriched in ICAM-1 and VCAM-1 and therefore allow more 
efficient leukocyte adhesion (Barreiro et al., 2008).  Knockdown of either 
tetraspanin resulted in decrease surface expression of the adhesion 
molecules, reduce leukocyte adhesion and reduced leukocyte transmigration 
(Barreiro et al., 2005).  Additionally, the tetraspanin CD63 also has a role in 
facilitating leukocyte extravasation through regulation of P-selectin (Doyle et 
al., 2011).  Both CD63 and P-selectin are localised to intracellular organelles 
such as lysosomes and Weibel-Palade bodies and upon activation of the 
endothelium, is rapidly trafficked to the cell surface, when it interacts with P-
selectin glycoprotein ligand 1 (PSGL-1) on leukocytes and thus promotes 
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leukocyte recruitment (M Yáñez-Mó et al., 1998).  In the absence of CD63, P-
selectin expression at the cell surface was reduced, which caused a reduction 
in leukocyte recruitment and delayed extravasation, mimicking the 
phenotypes observed in P-selectin knockout mice (Doyle et al., 2011).  
Together, these studies demonstrate the important roles for tetraspanins in 
regulation of leukocyte recruitment and extravasation during the inflammatory 
response.  In addition to this, there have been multiple studies on the role of 
the tetraspanin CD151 in interaction with and regulation of the integrins α3β1, 
α6β1, and α6β4 (Sterk & Geuijen, 2002).  CD151 directly interacts with these 
laminin binding integrins via association with the α subunit of the integrin 
(Hemler, 2014).  Several modes of action have been documented for the 
mechanism by which CD151 regulates these partner proteins.  For example, 
CD151 limits the diffusion of the α6 subunit in the membrane, thus making the 
integrins more available for functions such as adhesion (X. H. Yang et al., 
2012).  CD151 has also been shown to regulate the distribution and recycling 
of α3 and α6 subunits, which is important during cell migration (Winterwood, 
Varzavand, Meland, Ashman, & Stipp, 2006; X. H. Yang et al., 2008).  The 
role that CD151 plays in regulation of these integrins has resulted in 
implication of CD151 in pathological angiogenesis and tumour cell growth, 
invasion and metastasis (Bailey et al., 2011; H.-X. Wang, Li, Sharma, 
Knoblich, & Hemler, 2011). 
Finally, tetraspanin proteins have also been implicated in regulation of 
proteolysis through interaction with partner proteins such as the ectodomain 
sheddase a disintegrin and metalloprotease domain-containing protein 10 
(ADAM10).  ADAM10 has a wide range of cleavage targets including Notch, 
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which has roles in development, amyloid precursor protein, which is the 
pathogenic peptide which causes Alzheimer’s disease and the endothelial 
junction molecule VE-cadherin amongst many others.  A subfamily of  six 
tetraspanins, termed the TspanC8s (highlighted in figure 1.6) were all shown 
to interact with ADAM10 (Dornier et al., 2012; Haining et al., 2012).  In 
addition to these tetraspanins regulating the maturation and cell surface 
expression of ADAM10, they were also shown to promote its proteolytic 
activity (Prox et al., 2012).  The authors predict that different tetraspanins 
within this subfamily may regulate targeting of ADAM10 to specific substrates 
in the cell and thus regulate proteolytic cleavage events in the cell (Haining et 
al., 2012). 
Tetraspanins are implicated in a wide variety of processes, though it can often 
be difficult to elucidate the exact mechanism for each specific tetraspanin as 
functional redundancy can occur across the family.  However, as 
demonstrated by the examples above, several specific interactions with 
partner proteins have been identified and the exact mechanism of tetraspanin 
regulation elucidated.  Knowledge of the precise mechanisms of tetraspanin 
function and the partner proteins they co-ordinate allows for a better 
understanding of the ‘fine-tuning’ involved in regulation of many different 
cellular events. 
 
1.3.4 Platelet tetraspanins 
Tetraspanins have been identified in platelets, though most of the platelet 
tetraspanins are understudied and their role in platelet activation poorly 
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understood.  Study of megakaryocyte mRNA has suggested that there could 
be as many as 18 tetraspanins in platelets (Macaulay et al., 2007; Protty et 
al., 2009), though only 10 have been identified using proteomics 
(Lewandrowski et al., 2009) and only five (CD9, CD63, CD151, Tspan9 and 
Tspan32) confirmed using specific antibodies (Haining, Yang, & Tomlinson, 
2011; Protty et al., 2009). 
Initial investigation into the role of the tetraspanins CD151 and Tspan32 on 
platelets identified defective thrombus formation in knockout mice for either 
tetraspanin (Goschnick et al., 2006; Lau et al., 2004; Orlowski et al., 2009).  
The CD151 knockouts displayed increased bleeding in vivo, and reduced 
platelet spreading and clot retraction during in vitro assays (Lau et al., 2004).  
Additionally, during in vivo models of thrombus formation through FeCl3 
induced, or laser induced injury, thrombi formed by the CD151 deficient mice 
were small and unstable (Orlowski et al., 2009).  Assessment of the Tspan32 
deficient mice produced very similar results; impaired spreading and clot 
retraction in vitro and reduced thrombus formation in vivo (Goschnick et al., 
2006).  In both cases, it was proposed that the phenotypes observed were 
due to defective signalling from the integrin αIIbβ3, though the exact 
mechanism by which these tetraspanins might control integrin function is not 
known.  It is possible that CD151 and Tspan32 could promote the active 
conformation of the integrin and thus increase activity, or that they might be 
involved in recruitment of other signalling proteins to promote downstream 
signalling.   
Conversely, characterisation of mice lacking either CD9 or CD63 yielded no 
major platelet phenotypes, though a mild increase in thrombus size in the 
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CD9 knockout mice suggested a potential negative regulatory role for this 
tetraspanin (Mangin, Kleitz, Boucheix, Gachet, & Lanza, 2009; Schröder et 
al., 2009).  Such a subtle phenotype seemed surprising considering CD9 is 
the second most highly expressed protein on the cell surface (Protty et al., 
2009), though similar observations have been made for this tetraspanin 
across other cell types in which it is expressed.  An exception to this was 
observed on oocytes, where CD9 appears to play a vital role in fertilisation.  
CD9 deficiency leads to female infertility due to defective sperm-egg fusion, 
an event which is critical for fertilisation (Kaji et al., 2000; Le Naour, 
Rubinstein, Jasmin, Prenant, & Boucheix, 2000; Miyado et al., 2014). 
Although the specific role of most other platelet tetraspanins is yet to be 
investigated, several platelet surface proteins have been identified as 
tetraspanin associated.  The integrin α6β1, the scavenger receptor CD36, the 
choline transporter CD92 and the ectodomain sheddase ADAM10 have all 
been identified as tetraspanin associated proteins on various cell types and, 
through a proteomics approach, have been observed as components of 
tetraspanin microdomains specifically on platelets (Haining et al., 2011).  
Additionally, the platelet collagen receptor GPVI has been identified as being 
tetraspanin associated, though there is no evidence for tetraspanin 
interactions with other important platelet surface proteins such as GPIb, 
αIIbβ3, α2β1 or α5β1 in co-immunoprecipitation experiments (Protty et al., 
2009).  These tetraspanin associated proteins, depicted in figure 1.8, provide 
hints to currently uncharacterised roles for tetraspanins on platelets.  For 
example, the ecto-domain sheddase ADAM10, which is known to interact with 
the TspanC8 subfamily of tetraspanins (discussed in section 1.3.3), is 
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important as a negative regulator of platelet activation, through cleavage of 
receptors such as GPVI and thus cessation of signalling.  The mechanism 
behind regulation of this process may be better understood if the exact role of 
tetraspanins in ADAM10 activation on platelets was known. 
The fine tuning of partner protein function by tetraspanins is important in many 
cell types, and it appears it is also important in platelet function.  The 
emerging roles of tetraspanins on platelets provide greater insight into the 
mechanisms behind platelet activation.  If the specific tetraspanin-partner 
protein interactions on platelets can be elucidated and the mechanisms of 
platelet activation better understood, then future development of more specific 
anti-platelet therapies is possible. 
 
 
Figure 1.8 – Tetraspanin associated proteins in platelets.  Tetraspanin proteins are 
represented in red; the five which have been identified on platelets using antibodies are 
labelled.  The proteins shown in the microdomain have been identified as tetraspanin 
associated in other cell types as well as in a proteomics screen in platelets.  Adapted from 
Haining et al, 2011. 
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1.3.5 Tspan18 
The tetraspanin Tspan18 was initially identified as a novel tetraspanin in an 
mRNA screen of embryonic chick spinal cord and was initially termed 
‘neurospanin’ (Perron & Bixby, 1999).  Northern blot analysis was used to 
monitor fold changes in expression, and up-regulation of Tspan18 was 
observed during development of the brain, especially during the period of 
axon growth, suggesting a potential role for Tspan18 in early development of 
the nervous system (Perron & Bixby, 1999).  Further to this initial study, 
Tspan18 has been implicated in the migration of chick neural crest cells; a 
process which is important during embryogenesis.  Tspan18 was shown to 
regulate cadherin-6B levels; down regulation of Tspan18 via a FoxD3-
dependant mechanism was required to allow down regulation of cadherin-6B 
expression and therefore crest cell migration (Fairchild & Gammill, 2013).  
Migration of neural crest cells is dependant on the process of epithelial-to-
mesenchymal transition (EMT), which allows tightly packed epithelial cells to 
depolarise and become mesenchymal cells capable of migration.  The novel 
role of Tspan18 in this process has implications not only in the mechanism of 
EMT, but also potentially in other migrating mechanisms such as cancer 
metastasis (Fairchild & Gammill, 2013).  
In addition to the role for Tspan18 in the developing nervous system, this 
tetraspanin has been identified as a susceptibility locus for mutations causing 
schizophrenia within the Han Chinese ethnic group (J. Yuan et al., 2013; Yue 
et al., 2011).  In a study using a genome-wide association approach, three 
single-nucleotide polymorphisms (SNPs) within the Tspan18 gene were 
identified to be linked with increased susceptibility for schizophrenia, though 
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the functional role for Tspan18 during pathogenesis of this disorder is not 
known (Yue et al., 2011).  A more recent study confirmed this link with one of 
the SNPs identified, in an independent population (J. Yuan et al., 2013). 
Aside from expression in the nervous system, Tspan18 has also been 
identified in cells of the vasculature, such as endothelial cells, platelets and 
CD4-positive T cells (Bailey et al., 2011; Colombo, 2010; Lewandrowski et al., 
2009; Macaulay et al., 2007; Protty et al., 2009).  The strong endothelial 
expression profile of Tspan18 was revealed during real time polymerase chain 
reaction (PCR) studies on human cells and mouse tissues.  Tspan18 
messenger ribonucleic acid (mRNA) was most highly expressed in human 
umbilical vein endothelial cells (HUVEC) and human microvascular 
endothelial cells (HMEC) in comparison to smooth muscle cells, fibroblasts, 
and in the cell lines PBL, DAMI, DG75, K562, HBP-AII, HEL, MDA-MB-231, 
RAJI, U937, HEK293T, or Jurkat cells (Colombo, 2010).  In mouse tissue, 
Tspan18 mRNA was found to be highest in lung tissue in comparison to brain, 
heart, kidney, liver, muscle, spleen and thymus, which is consistent with a 
preferential expression in endothelial cells (Colombo, 2010).  Additionally, 
analysis of transcriptomic data from serial analysis of gene expression 
experiments indicated that Tspan18 is most highly expressed in endothelial 
cell libraries (Bailey et al., 2011).  Together, these data strongly suggest that 
Tspan18 is expressed in endothelial cells.  Proteomics screens have also 
identified Tspan18 in human platelets (Lewandrowski et al., 2009), human 
and mouse megakaryocytes and CD4-positive T cells (Macaulay et al., 2007; 
Protty et al., 2009).  Also, Tspan18 mRNA has been identified in human and 
mouse platelets (Haining et al., 2012; Rowley et al., 2011).  Together, these 
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real time PCR and proteomics studies suggest that Tspan18 is expressed in 
both endothelial cells and platelets, though there are currently no publications 
which investigate the role of this tetraspanin within the vasculature. 
Interestingly, when assessed alongside a panel of other tetraspanins, only 
expression of Tspan18 was able to induce activity of a Ca2+ responsive 
nuclear factor activated T-cells (NFAT) luciferase reporter; expression of the 
tetraspanins CD9, CD63, CD151, Tspan32 and Tspan9 had no significant 
effect on the reporter (Colombo, 2010).  This work also demonstrated that 
Tspan18 induced NFAT activation independently of non-receptor tyrosine 
kinases of Src, Syk and Btk families, PLCγ, and IP3 receptors; over-
expression of Tspan18 still promoted NFAT activation in specific DT40 
knockout cell lines for these proteins (Colombo, 2010).  Additional functional 
studies demonstrated that the action of Tspan18 mimicked the action of the 
ionophore ionomycin, further implying a role for Tspan18 in regulation of Ca2+ 
mobilisation (Colombo, 2010).  
Although no partner protein has yet been identified for Tspan18, these 
findings suggest that Tspan18 could be interacting with and regulating a Ca2+ 
channel, or other protein involved in Ca2+ entry.  It is therefore possible that 
Tspan18 may have a role in regulation of Ca2+ signalling in cell types such as 
platelets, and thus a role in platelet signalling and activation. 
A useful tool for investigating the role of Tspan18 further is the Tspan18 
knockout mouse.  The Tspan18 knockout mouse was obtained from the 
Mutant Mouse Regional Resource Centre and was originally generated by 
Genentech Inc. and Lexicon Pharmaceuticals Inc.  They aimed to create an 
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extensive collection of knockouts, providing a resource to screen for new drug 
targets.  In total, a mouse knockout library of 472 secreted and 
transmembrane proteins was produced, including Tspan18 (Tang et al., 
2010).  The Tspan18 gene has a total of 10 exons and the start codon is 
found in exon 4 (NCBI accession NM_183180.1).  To knockout Tspan18, 
homologous recombination was used to target exons 4 and 5 in embryonic 
stem cells derived from strain 129/SvEvBrd (see figure 1.9 for targeting 
strategy).  The resulting chimeras were crossed with C57BL/6J albino mice to 
generate mice which were heterozygous for Tspan18.  These progeny were 
intercrossed to generate wildtype, heterozygous and homozygous mutant 
progeny.  Disruption of Tspan18 was confirmed by Southern hybridisation 
analysis (Tang et al., 2010). 
No notable phenotype was observed during a broad phenotypic screen 
completed by Genentech Inc. which included analysis of development, 
metabolism, and the immune and cardiovascular systems (Tang et al., 2010).  
No in-depth platelet function tests were completed.  A minor increase in 
anxiety response in female knockout mice was observed in an open field test 
when compared to wildtype gender matched littermates (Tang et al., 2010). 

















Figure 1.9 – Targeting strategy involved in generating the Tspan18 knockout mouse by 
homologous recombination.  Blue filled boxes represent coding exons and empty boxes 
represent untranslated regions.  The diagrams shown represent the wildtype Tspan18 gene 
structure (A), the target vector, pKOS-50 (B) and the resulting gene structure after 
homologous recombination (C) (Tang et al. 2010).  Wildtype, mutant and heterozygous 
progeny were identified by PCR of tissue taken from ear clips, using primers outlined in 
chapter 2, section 2.8.2 (D). 
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1.4 PROJECT OBJECTIVES 
The main aim of the work completed in this thesis was to characterise the 
function of the tetraspanin Tspan18 in platelets by using the Tspan18 
knockout mouse and cell line models.  The Tspan18 knockout mouse was 
available from the Mutant Mouse Regional Resource Centre, after being 
generated by Lexicon Pharmaceuticals and Genentech (Tang et al., 2010). 
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2.1 MICE, REAGENTS AND CELL CULTURE 
 
2.1.1 Mice  
Procedures using mice completed at the University of Birmingham, UK, were 
undertaken with the correct approval and licensing from the United Kingdom 
Home Office, under the project licence number 30/2721 and the personal 
licence number IE639FEE9.  Tspan18 deficient mice were generated during 
collaboration between Genentech Inc. and Lexicon Pharmaceuticals Inc. 
(Tang et al., 2010).  The mice were purchased from the Mutant Mouse 
Regional Resource Centre.  The Tspan18 mouse colony was sustained by 
breeding heterozygous pairs which produced Tspan18 wildtype, heterozygous 
and mutant progeny.  Therefore, wildtype littermates were used as controls 
alongside Tspan18 deficient mice in experiments.  C57Bl/6 wild type mice 
were purchased as required from Harlan Laboratories, UK, or Charles River, 
UK.   
 
2.1.2 Plasmids 
The NFAT/activator protein 1 (AP-1) luciferase transcriptional reporter 
construct has been described previously (Shapiro, Mollenauer, Greene, & 
Weiss, 1996; Michael G Tomlinson et al., 2004).  The pEF6 mock vector and 
pEF6-LacZ expression constructs were purchased from Invitrogen.  All N-
terminal FLAG-tagged tetraspanin expression constructs were made by 
cloning the tetraspanins into the pEF6-FLAG vector (Haining et al., 2012; 
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Protty et al., 2009).  The Myc-tagged pCDNA3.1 Orai1, Orai2 and Orai3 
expression constructs and the dominant negative FLAG-tagged MO70 Orai1 




Listed in table 2.1 below are details of antibodies used across all experiments 




Mouse α2 FITC Rat Emfret Analytics  
Mouse αIIb FITC Rat Emfret Analytics 
Mouse α6 FITC Rat Emfret Analytics 
Mouse ADAM10 FITC Rat R&D Systems 
Mouse CD9 FITC Rat Emfret Analytics 
Mouse GPIb FITC Rat Emfret Analytics 
Mouse GPVI FITC Rat Emfret Analytics 
Mouse CLEC-2 FITC Rat Prof. Steve Watson 
Rat IgG2a FITC Rat AbD Serotec  
Human/mouse tubulin 
(DM1A) 
Mouse Sigma  
Phosphotyrosine (4G10) Mouse Millipore 
Mouse IgG1 (MOPC) Mouse Sigma  
Human CD9 Mouse Prof Leonie Ashman 
Human GPIb Mouse Prof Leonie Ashman 
Human ADAM10 Mouse R&D Systems 







FLAG Rabbit Sigma 
FLAG (clone M2) Mouse Sigma 
MYC (9BII) Mouse Cell Signalling Technology 
 
Table 2.1 – Details of all antibodies used in western blotting, flow cytometry and 
immunoprecipitation experiments. 
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2.1.4 Cell culture 
All cells were kept in a humidified incubator at 37oC, 5% CO2.  The DT40 
chicken B cell line was obtained from laboratory stocks and was maintained in 
RPMI media with added supplements: 10% heat inactivated foetal bovine 
serum (FBS), 1% chicken serum, 4 mM glutamine,  100 units/ml penicillin, 
100 µg/ml streptomycin and 50 µM β2-mercaptoethanol (Michael G Tomlinson 
et al., 2004).  The HEK293T human embryonic kidney cell line was obtained 
from laboratory stocks and was maintained in DMEM media with added 
supplements: 10% heat inactivated FBS, 4 mM glutamine, 100 units/ml 
penicillin and 100 µg/ml streptomycin (Haining et al., 2012).  HUVEC were 
isolated by infusing the veins of umbilical cords with collagenase to dislodge 
the cells, or were obtained from Phil Stone (University of Birmingham, UK).  
HUVEC were grown on cell culture plates pre-treated with 0.1% (w/v) gelatine 
diluted in phosphate buffered saline (PBS) and were used up to passage six.  
They were maintained in M199 media with added supplements: 10% heat 
inactivated FBS, 4 mM glutamine, 0.3% bovine brain extract (Maciag, 
Cerundolo, Ilsley, Kelley, & Forand, 1979) (provided by Dr. Victoria Heath, 
University of Birmingham), 90 µg/ml heparin (Sigma), 100 units/ml penicillin 
and 100 µg/ml streptomycin (Kaur et al., 2011).  Human dermal fibroblasts 
were obtained from Dr. Victoria Heath and were maintained in DMEM media 
with added supplements: 10% heat inactivated FBS, 4 mM glutamine, 100 
units/ml penicillin and 100 µg/ml streptomycin (Kaur et al., 2011).   
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2.2 TRANSFECTION 
 
2.2.1 Transfection by electroporation 
DT40 B cells were transiently transfected by electroporation for use in the 
NFAT/AP-1 luciferase reporter assay, as previously described (Michael G 
Tomlinson et al., 2004).  Briefly, cells were suspended at 1.5x107 cells/400 µl 
in serum free media and were incubated with 20 µg NFAT/AP-1 luciferase 
transcriptional reporter (Shapiro et al., 1996; Michael G Tomlinson et al., 
2004), 2 µg pEF6-LacZ (Invitrogen) and 10 µg of either pEF6 mock vector 
(Invitrogen), or pEF6 FLAG-tagged tetraspanin (Haining et al., 2012; Protty et 
al., 2009) for 10 mins before electroporation at 350 V and 500 µF using a 
Gene-Pulser and capitance extender (Bio-Rad).  Cells were incubated for 10 
mins and then suspended in 8 ml complete serum-containing media. 
  
2.2.2 Transfection by polyethylenimine (PEI) 
HEK293T cells were transiently transfected using PEI (Sigma), for use in 
biochemical assays, as described (Ehrhardt et al., 2006; Haining et al., 2012).  
Briefly, cells were set up in complete media 24 hours before transfection.  
Opti-mem serum-free media (Gibco) was incubated with deoxyribonucleic 
acid (DNA) and PEI (1 mg/ml stock) for 10 mins to allow DNA/PEI complexes 
to form.  The mix was added to the cells, which were used for experiments 48 
hours after transfection.  Cell counts, and volume of reagents used are listed 
in table 2.2. 
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Plate Cells Media Opti-mem DNA PEI 
6-well 3 x 105 2 ml 100 µl 1 µg 4 µl 
6 cm 1 x 106 3 ml 300 µl 3 µg 12 µl 
10 cm 3 x 106 10 ml 1 ml 9 µg 36 ml 
15 cm 6 x 106 20 ml 2 ml 18 µg 72 ml 
 
Table 2.2 – Reagents and quantities required for PEI transfection of HEK293T cells. 
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2.3 PLATELET PREPARATION 
 
2.3.1 Mouse platelet preparation 
Both washed platelets and platelet rich plasma were prepared as previously 
described (Hughes et al., 2008).  Briefly, mice at 10-12 weeks old were 
terminally anaesthetised using isoflurane and blood was drawn from the 
exteriorised descending aorta directly into 150 µl acid citrate dextrose (ACD; 
120 mM sodium citrate, 110 mM glucose, 80 mM citric acid) when preparing 
washed platelets, or citrate concentrated solution (4%, Sigma) when 
preparing platelet rich plasma.  Withdrawn blood was then diluted in 200 µl of 
modified Tyrode’s buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 
mM NaHCO3, 20mM HEPES, 5 mM glucose, 1 mM MgCl2, pH 7.3).  Platelet 
rich plasma was extracted from the whole blood by centrifugation; 2 x 6 min at 
200 g to allow separation of platelet rich plasma from red blood cells.  
Washed platelets were prepared with an additional centrifugation step to 
pellet the platelets and separate them from the plasma; 6 min at 1000 g in the 
presence of 1 µg/ml PGI2 (Sigma). PGI2 was used to inhibit platelet activation 
and aggregation through increased cAMP and decreased intracellular Ca2+ 
concentration (Best, Martin, Russel, & Preston, 1977; Salvador Moncada, 
1982).  Platelets were then suspended in modified Tyrode’s buffer, counted 
and concentration adjusted as required. 
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2.3.2 Human platelet preparation 
Preparation of human platelets was approved by the University of Birmingham 
Ethics Committee and donors provided informed consent before donating 
blood, which was taken by a trained phlebotomist (Laura Cronin, Elizabeth 
Haining, or Farhat Khanim). Records of donors and volume of blood taken 
were completed in line with the ethical approval requirements. Washed 
human platelets were prepared as outlined previously (Pearce et al., 2004).  
Briefly, 50 ml of blood from healthy donors was drawn directly into 5 ml 
concentrated sodium citrate to act as an anticoagulant.  5 ml of pre-warmed 
ACD was added to the blood as further anti-coagulant and blood was 
centrifuged at 200 g for 20 min.  The supernatant (platelet rich plasma) was 
extracted and centrifuged at 1000 g for 10 min in the presence of PGI2 (1 
µg/ml).  The platelet pellet was suspended in modified Tyrode’s buffer, 
counted and the volume adjusted as required. 
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2.4 PLATELET FUNCTION ASSAYS 
 
2.4.1 Assessment of mouse blood cell counts 
Blood was drawn from the exteriorised descending aorta of terminally 
anaesthetised mice, as described in section 2.3.1.  A 60 µl sample of whole 
blood was analysed using Pentra 60 whole blood counting equipment (ABX 
Diagnostics).  All cell count readings were normalised for the added volume of 
the ACD and Tyrode’s buffer.  
 
2.4.2 Assessment of cell surface expression of platelet receptors 
Blood was drawn from the exteriorised descending aorta of terminally 
anaesthetised mice, as described in section 2.3.1.  5 µl of whole blood was 
stained for 30 min at room temperature with fluorescein isothiocyanate 
(FITC)-conjugated anti-mouse antibodies (Emfret), at a dilution of 1:10 in 
Tyrode’s buffer, as directed by the manufacturer’s guidelines.  Samples were 
analysed on a fluorescence activated cell sorting (FACS) Caliber (BD 
Biosciences) and platelets were gated by size on forward and side scatter and 
fluorescence was measured as geometric mean fluorescence intensity, which 
was normalised against an IgG control antibody using Cellquest Pro software.  
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2.4.3 Light transmission aggregometry 
Washed mouse platelets were prepared as described in section 2.3.1 and 
suspended at 2x108 platelets/ml ready for aggregation, as previously 
described (Hughes et al., 2008; Y. A. Senis et al., 2009).  Briefly, aggregation 
was measured in glass cuvettes, using a volume of 300 µl at 37°C with 
stirring.  Initial resting platelet readings were taken for 1 min, followed by 
stimulation by injection of 3 µl agonist (100 x concentrations).  Aggregation 
was measured by light transmission using aggregometer model 460VS 
(Chronolog, Lab Medics) and measurements recorded using a chart reader 
(Chronolog, Lab Medics). 
 
2.4.4 Measurement of platelet secretion  
Secretion of secondary mediators from platelet dense granules during 
aggregation was assessed via binding of platelet secreted ATP to an added 
firefly luciferin/luciferase premix (chromolume, Chrono-Log Corporation).  
Firefly luciferase is an enzyme which catalyses the chemical reaction which 
leads to the generation of light from luciferin.  The reaction, which is described 
by the equation below, requires ATP to produce lucifryl adenylate from 
luciferin.  In turn, oxyluciferin is formed in an excited state; as it returns to the 
ground level, a photon of light is emitted.  Therefore, the amount of ATP 
secreted from the platelets can be measured through the amount of light 
detected.  ATP concentration was calculated using an ATP standard to 
calibrate the measurements (Hughes et al., 2008; Y. A. Senis et al., 2009). 
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2.4.5 Platelet spreading 
Analysis of platelet spreading was undertaken as previously described 
(Hughes et al., 2008; Y. A. Senis et al., 2009).  Briefly, glass cover slips were 
coated with collagen related peptide (CRP) (10 µg/ml) or Fibrinogen (100 
µg/ml) overnight.  Cover-slips were blocked with 5mg/ml of denatured and 
filtered fatty acid free bovine serum albumin (Sigma) for 1 hour.  Washed 
mouse platelets were prepared as described in section 2.3.1, suspended at 
2x107 platelets/ml and incubated on the cover-slips for 45 min at 37°C in the 
presence of 10 µM indomethacin (Sigma) and 2 U/ml apyrase (Sigma) to 
inhibit platelet aggregation.  Platelets spread on fibrinogen coated cover-slips 
were also activated with 1 unit/ml thrombin.  Non-adherent platelets were 
washed away with phosphate buffered saline (PBS) and cover slips were 
fixed with 4% paraformaldehyde in PBS for 10 min.  Platelets were imaged 
using a 60X Plan APO 1.4NA oil immersion objective with a TE2000 (Nikon) 
microscope with Digital Sight DS-Qi1MC camera (Nikon) using NIS elements 
AR software (Nikon).  The area of single, in focus platelets was measured 
using thresholding in ImageJ Software for 150 platelets per condition. 
 
 
Luciferin + ATP Luciferyl adenylate + PPi 
Luciferyl adenylate + O2 Oxyluciferin + AMP + light 
Luciferase 
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2.4.6 Aggregate formation under flow 
Blood was drawn from the exteriorised descending aorta of terminally 
anaesthetised mice into 300 µl modified Tyrode’s buffer with heparin and 
PPACK (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 
20mM HEPES, 5 mM glucose, 1 mM MgCl2, pH 7.3, 15 u/ml heparin, 40 µM 
PPACK) to prevent thrombin generation (Hughes et al., 2010).  Flow cells in a 
24-well plate format (Fluxion) were coated with 30 µg/ml collagen for one hour 
and blocked with 5 mg/ml of denatured and filtered fatty acid free bovine 
serum albumin (Sigma) at 4°C overnight.  Blood was incubated with DiOC6 
membrane dye (0.2 µM) (Molecular Probes) at 37°C for 10 minutes and then 
perfused through the flow cell at shear rates of 300, 1000 or 3000 s-1 at 37°C 
using the Bioflux 200 microfluidic flow system (LabTech).  Images were 
continuously taken by fluorescence microscopy with a TE2000 (Nikon) 
microscope with Digital Sight DS-Qi1MC camera (Nikon) using NIS elements 
AR software (Nikon), using a 40x plan APO 1.4 NO oil immersion DIC 
objective. 
 
2.4.7 Platelet Ca2+ signalling measurements 
Washed mouse platelets prepared as outlined in section 2.3.1, were 
suspended at 1x108 platelets/ml in modified Tyrode’s buffer and incubated 
with Fura2-AM (Invitrogen) (10 µM) and pluronic F-127 (Molecular Probes) 
(0.2 µg/ml) for 30 min at 37 oC (Inoue et al., 2003).  Platelets were then 
washed in the presence of PGI2 (1 µg/ml) by centrifugation at 1000 g for 6 min 
to removed excess dye.  Platelets were suspended at 1x108 platelets/ml in 
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modified Tyrode’s buffer and 600 µl used for Ca2+ measurements, taken in a 
LS50B luminescence spectrometer (Perkin Elmer) in which excitation was 
alternated between 340 nm and 380 nm and measurements taken at 509 nm.  
Quantitative evaluation of Ca2+ concentration was calculated from the raw 
ratio values following calibration and use of the equation outlined below.  
Calibration of each value was achieved by obtaining the maximum and 
minimum ratio values.  The maximum value was measured after lysing the 
platelets with 0.1% Triton X-100 in the presence of 1.5 mM Ca2+.  The 
minimum value was measured after addition of 20mM ethylene glycol 
tetraacetic acid (EGTA) to chelate the Ca2+ in the media.   The Grynkiewicz 
equation was used to convert the raw data 340/380 nm ratio values into Ca2+ 
concentration values (Grynkiewicz, Poenie, & Tsienb, 1985).  The equation is 
defined below, where Kd = the dissociation constant of fura-2 (224 nM), R = 
measured fluorescence ratio value, Rmax = maximum ratio value, Rmin = 
minimum ratio value, Sf2/Sb2 = the ratio of fluorescence intensity at 380 nm in 
the absence of Ca2+ and at Ca2+-saturation. 
 
 
2.4.8 Platelet phosphotyrosine blotting 
Measurement of phosphorylation downstream of platelet surface receptor 
activation was completed as previously described (Hughes et al., 2008; Y. A. 
Senis et al., 2009).  Briefly, washed mouse platelets were prepared as 
[Ca2+] = Kd  x                     x 
(R – Rmin) 
(Rmax – R) 
(Sf2) 
(Sb2) 
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described in section 2.3.1 and suspended at 5x108 platelets/ml.  Lotrafiban 
(10 µm), indomethacin (10 µm), and apyrase (2 units/ml) were included in the 
suspension buffer to inhibit platelet aggregation.  Platelets were held at 37°C 
in a water bath without stirring, activated with CRP for 90 or 300 seconds and 
samples of 50 µl taken for resting and stimulated platelets.  Samples were 
lysed in an equal volume of 2x reducing sample buffer (0.1 M Tris pH 6.8, 4% 
sodium dodecyl sulphate (SDS), 20% glycerol, 5% 2 β-mercaptoethanol in 
dH20 containing bromophenol blue), separated by SDS- polyacrylamide gel 
electrophoresis (PAGE) using 4-12% gradient gels (Invitrogen) and visualised 
by western blotting as described in section 2.7.1, using an anti-
phosphotyrosine 4G10 antibody. 
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2.5 IN VIVO ASSAYS 
 
2.5.1 Tail bleeding 
The tail bleeding assay was used to assess haemostasis and was completed 
as described previously (Senis et al., 2009).  Litter-matched mice at 8-10 
weeks old were administered 0.05 mg/kg of the analgesic buprenorphine by 
subcutaneous injection prior to maintenance under continued isoflurane 
anaesthesia.  3 mm of the tail tip was removed using a razor blade and the tail 
left to hang freely without disruption.  Resulting blood drops were collected 
into pre-weighed 1.5 ml microfuge tubes.  The assay continued for 20 min, or 
until a maximum blood loss of 15% as estimated by weight (blood loss 
allowed = (mouse weight*0.15*70)/30, where a single drop of blood is 
estimated to be 30µl and total blood volume is assumed to be 70 µl/g.  For 
example, for a mouse weighing 20g: 20*0.15*70/30 = 7 drops allowed) was 
reached, or until bleeding ceased (judged as no blood fall for 5 min).  To end 
the procedure, the tail tip was cauterised. 
 
2.5.2 Thrombus formation following chemical injury 
This experiment was completed in Wurzburg, Germany, as previously 
described (Braun et al., 2009).  Briefly, platelets of mice were fluorescently 
labelled with Dylight-488 conjugated anti-GPIX Ig derivative.  Injury was 
induced to mesenteric arterioles by topical application of FeCl3 (20%) for 10 s.  
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Adhesion and aggregation of platelets was measured by fluorescence 
microscopy until complete occlusion of the vessel or a final time of 40 min. 
 
2.5.3 Thrombus formation following mechanical injury 
This experiment was completed in Wurzburg, Germany, as previously 
described (Braun et al., 2009).  Briefly, an ultrasonic flow probe was placed 
around the abdominal aorta of anaesthetised mice and thrombosis was 
induced by a single firm compression with forceps.  Blood flow was monitored 
until complete occlusion occurred; otherwise experiments were stopped 
manually after 30 minutes.   
 
2.5.4 Generating chimeric mice 
To generate chimeric mice with Tspan18 wildtype haematopoietic cells and 
knockout non-haematopoietic cells, and vice versa, an irradiation approach 
was used, as previously described (Hughes et al., 2010).  Briefly, the drinking 
water of 6-week old C57BL/6 wild type or Tspan18 deficient mice was treated 
with the antibiotic Baytrill for 1 week to reduce the risk of infection during the 
experiment.  The mice were then lethally irradiated with two separate doses at 
500 Gy, 3 hours apart.  One hour after the second dose of irradiation, the 
mice were injected via the tail vein with embryonic liver cells suspended in 
PBS, which had been harvested at embryonic day E16.5 and stored as a 
single cell suspension in freezing solution (90% FBS, 10% DMSO) at -80 oC.  
Mice were left to recover over a period of 6 weeks to allow reconstitution of 
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the haematopoietic system from the injected cells.  Genotyping of 
haematopoietic and non-haematopoietic cells was used to confirm success of 
the experiment, as outlined in sections 2.8.1 and 2.8.2.  Embryonic liver was 
selected for injecting in to the irradiated mice, as full and long term 
reconstitution of the multiple lineages within the haematopoietic system, 
including erythrocytes, T-cells, mast cells and macrophages, has been 
observed following transplant of foetal liver (Ema & Nakauchi, 2015; 
Forrester, Bernstein, Rossant, & Nagy, 1991).  The embryonic stem cells 
which are derived from foetal liver have been shown to have the ability to 
reconstitute the haematopoietic system, and are relatively easy to harvest in 
significant quantities in comparison to other sources of stem cells such as 
bone marrow.  As such, many studies within the field of platelet function 
testing have utilised this method of haematopoietic reconstitution (Hess et al., 
2014; Hughes et al., 2010; Suzuki-Inoue et al., 2010). 
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2.6 NFAT/AP-1 LUCIFERASE REPORTER ASSAY 
 
2.6.1 Measurement of luciferase signalling 
NFAT activity was monitored using a reporter assay, as described previously 
(Michael G Tomlinson et al., 2004).  DT40 cells were transfected as described 
in section 2.2.1 and after 16 hours, cells were counted, suspended at 2x106 
cells/ml and 50 µl aliquoted into triplicate wells in a 96-well plate.  An equal 
volume (50 µl) of media containing agonist was added to each well; cells were 
either left unstimulated, were stimulated with 50 ng/ml Phorbol 12-myristate 
13-acetate (PMA) (Merck Millipore) and 1 µM ionomycin (Merck Millipore), or 
were inhibited with 2 mM cyclosporin A (Merck Millipore) for 6 hours.  After 
incubation, cells were lysed in 11 µl harvest buffer (10% Triton X-100, 1 mM 
DTT, 200 mM potassium phosphate buffer; 450 mM K2HPO4, 46 mM KH2PO4) 
for 5 min.  100 µl from each well was transferred to an opaque 96-well plate 
and 100 µl assay buffer added (10 mM ATP, 20 mM MgCl2 in 0.2 M 
potassium phosphate buffer); luciferase activity was measured in a plate-
reading Mithras LB940 luminometer (Berthold Technologies) after injection of 
50 µl luciferin (1 mM) (Cambridge Bioscience).  
Luciferase activity data were normalised for transfection efficiency to β-
galactosidase activity using a kit (Applied Biosystems) as described 
previously (Michael G Tomlinson et al., 2004).  Briefly; cell pellets of 1x106 
cells were lysed in 80 µl lysis buffer for 5 mins.  Lysed cells were incubated 
with galacton reaction buffer in the dark for 1 hour and activity was measured 
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in a plate-reading Mithras LB940 luminometer (Berthold Technologies) after 
injection of light emission accelerator. 
Data was not normally distributed due to normalisation of the values to β-
galactosidase activity; therefore data were transformed into logarithmic values 
for analysis.  As a result, positive and negative error bars were calculated 
separately, to avoid presenting misleading quantities due to the logarithmic 
data.  For graphical representation, data were converted back into linear 
values. 
 
2.6.2 Analysis of protein expression following measurement of 
signalling 
For analysis of protein expression, whole cell lysate samples were separated 
by SDS-PAGE and analysed by western blot.  To prepare the samples, frozen 
DT40 whole cell pellets were lysed in 20µl lysis buffer (1% Triton X-100, 
10mM Tris pH 7.5, 150mM NaCl, 1mM EDTA, 0.02% sodium azide) 
containing 1% protease inhibitor cocktail (Sigma) per 1 x 106 cells for 30 
minutes on ice.  The supernatant was mixed with 2x non-reducing SDS-PAGE 
sample buffer (0.1 M Tris pH 6.8, 4% SDS, 20% glycerol in dH20 containing 
bromophenol blue), boiled for 5 min and 40µl of each sample was loaded into 
a 12% gel and separated by SDS-PAGE electrophoresis.  The gels were 
transferred onto an Immobilon FL PVDF membrane (Millipore), as described 
in section 2.7.1.   
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2.7 BIOCHEMICAL ASSAYS 
 
2.7.1 Western blotting 
For visualisation of protein expression, gels from SDS-PAGE electrophoresis 
were transferred onto either methanol activated Immobilon FL low 
fluorescence membranes (Millipore) for development using the Odyssey infra-
red scanner, or methanol activated Immobilon FL PVDF membranes for 
development on film.  Membranes were blocked in 5% milk or 3% bovine 
serum albumen (BSA) (First Link, UK) in TBST (20 mM Tris, 137 mM NaCl, 
0.1% Tween, pH 7.6) for at least 1 hour, incubated with primary antibody (1 
µg/ml) diluted in 3% BSA in TBST overnight, washed in TBST, and incubated 
with secondary antibody diluted in 3% BSA in TBST for 2 hours.  Immobilon 
FL membranes were blotted with secondary antibodies conjugated to infra-red 
dye (IR dye) 800 CW or 680 (LI-COR Biosciences) and were scanned using 
the Odyssey infra-red scanner (LI-COR Biosciences).  PVDF membranes 
were blotted with HRP-conjugated secondary antibodies (Pierce), developed 
using Pierce ECL western blot substrate (Thermo Scientific) and exposure to 
film. 
 
2.7.2 Immunoprecipitation in HEK293T cells 
Immunoprecipitation in HEK293T cells was completed as previously 
described (Haining et al., 2012).  Briefly, transfected HEK293T cells in 6-well 
plates were lysed in either 1% cold Triton X-100 (1% Triton X-100, 10 mM Tris 
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pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.02% sodium azide) or 1% digitonin (1% 
digitonin, dissolved in 100% methanol, diluted 1:10 in lysis buffer; 10 mM Tris 
pH 7.4, 150 mM NaCl, 0.02% NaN3) for 30 min on ice.  Insoluble material was 
removed by centrifugation at 20,000 g 10 min, and the supernatant incubated 
with rotation for 1.5 hours at 4oC with protein G sepharose 4B beads 
(Invitrogen), which had been coupled to an anti-FLAG M2 antibody; 20 µl 
beads and 1 µg antibody per sample, incubated with rotation at 4oC overnight.  
After incubation, the beads were washed 4 times with 1 ml lysis buffer, and 
mixed with 50 µl non-reducing SDS-PAGE sample buffer.  Samples were 
boiled for 5 min, 20 µl was loaded onto 12% gels and separated by SDS-
PAGE gel electrophoresis.  Gels were transferred onto an Immoblin FL 
membrane as outlined in section 2.7.1. 
 
2.7.3 Immunoprecipitation in human platelets 
Immunoprecipitation using human platelets was completed as previously 
described (Haining et al., 2012).  Briefly, platelets were prepared as described 
in section 2.3.2 at a density of 1 x 109 platelets/ml.  500 µl platelets were lysed 
in 500 µl 2x Brij97 lysis buffer (2% Brij97, 20 mM Tris pH 7.5, 150 mM NaCl, 2 
mM CaCl2, 2 mM MgCl2, 0.02% sodium azide) containing 20 µl protein 
sepharose G beads for pre-clearing, with rotation at 4oC for 1 hour.  Following 
lysis, the immunoprecipitation protocol and gel loading was completed as 
described in section 2.7.2. 
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2.7.4 Biotinylation  
Sulfo-NHS-LC-biotin reacts with amine groups and therefore labels lysine 
residues and the primary amine at the N-terminus of proteins.  The reagent is 
largely membrane impermeable, thus predominantly labels cell surface 
proteins.  Biotin was used to label HEK293T cells, as described previously 
(Haining et al., 2012; Y. A. Senis et al., 2009).  Briefly, transfected HEK293 T 
cells in a 6-well plate were first washed 3 times with PBS, then 1 ml of sulfo-
NHS-LC-biotin (Pierce) (1 mg/ml) was added and incubated on a rocker for 30 
min at room temperature.  The biotinylation reaction was quenched using 
glycine (100 mM), the cells were harvested and either lysed and treated as 
outlined in the immunoprecipitation protocol outlined in section 2.7.2, or were 
used as whole cell lysates, without immunoprecipitation. 
 
2.7.5 Cell surface cross-linking 
3, 3’-dithiobis[sulfosuccinimidylpropionate] (DTSSP) (Pierce) was used as a 
membrane impermeable chemical cross-linker, as previously described 
(Haining et al., 2012).  It consists of amine-reactive groups at either end, 
linked by a spacer of 1.2 nm in length.  Therefore, if two cell surface proteins 
are closely associated, with either their N-termini or lysine residues in close 
proximity, these proteins will be covalently cross-linked together by DTSSP.  
The spacer can subsequently be cleaved with reducing agents.  Transfected 
HEK293T cells were washed with PBS and treated with 2 mM DTSSP on a 
rocker at 4°C for 30 min.  0.1 M glycine solution was added to each well to 
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quench the cross-linking reaction.  Samples were lysed and 
immunoprecipitation completed as outlined in section 2.7.2. 
 
2.7.6 Enzyme linked immunosorbent assay (ELISA) 
Blood was drawn from the exteriorised descending aorta of terminally 
anaesthetised mice, as described in section 2.3.1, using only sodium citrate 
as an anticoagulant.  Plasma was separated from the whole blood by 
centrifugation at 1000 g for 10 min.  Following extraction, plasma samples 
were stored at -80oC until use.  Measurement of plasma concentration of vWF 
and FVIII was achieved using kits containing pre-coated micro-titre plates, 
following the manufacturer’s guidelines (Bioassay Technology Laboratory and 
My Biosource, respectively).  At completion of the assay, the plates were read 
at 450 nm using a microtitre plate reader (Anthos Zenyth 340rt).  
Concentration was calculated by extrapolation from a five-point standard 
curve generated with provided standard solutions of known concentration.   
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2.8 PCR 
 
2.8.1 Genotyping mouse tissue 
For identification of littermates and to provide tissue for genotyping, tissue 
was clipped from the ears of 1-2 week old mice and stored at -20oC until use.  
Tissue samples were incubated at 55oC overnight with 500 µl lysis buffer (100 
mM Tris-HCl, 5 mM EDTA, 0.2% SDS, 200 mM NaCl) with 5 µl proteinase K 
(Sigma).  After incubation, samples were centrifuged at 10,000 g for 2 min to 
pellet the insoluble material, and the supernatant was added to an equal 
volume of isopropanol to precipitate the DNA.  Samples were centrifuged at 
20,000 g for 20 min, the supernatant aspirated and the pellet suspended in 50 
µl DNAse free water.  DNA samples were incubated at 50 oC for 30 min and 
stored long term at 4 oC.  Each 20 µl PCR reaction contained 10 µl RedTaq 
master mix (Sigma), 7.4 µl water, 1.6 µl primers (Lexicon, primer sequences 
outlined in table 2.3), and 1 µl DNA.  The following PCR program was used: 5 
min at 95oC, followed by 35 cycles of 1 min at 95oC, 1 min at 58oC, 1 min at 
72oC, and a final 5 min at 72oC.  PCR products were run on 2% agarose gels 
and visualised using SYBR safe DNA gel stain (Life Technologies). 
 
2.8.2 Genotyping from mouse blood 
For assessment of chimeric mice, genotyping analysis of haematopoietic cells 
was necessary to confirm successful reconstitution of the haematopoietic cells 
from the transplanted cells.  Blood samples were taken from the mice 6 weeks 
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post irradiation and were incubated with 1 ml ACK red cell lysis buffer (150 
mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.2) for 5 min at room 
temperature before being centrifuged to pellet the intact white blood cells; the 
supernatant was discarded and the cell pellet saved.  This process was 
repeated three times to remove all traces of red blood cells from the sample.  
The lysis, DNA extraction and PCR protocol outlined in section 2.8.1 was then 
used. 
Wildtype specific (absent in targeted allele) 
5’ primer name DNA498-24 
3’ primer name DNA498-13 
Predicted band size 376 bp 
5’ primer sequence 5’ – AGGATGGGATAACTGTCTGG 
3’ – primer sequence 5’ – GCAGCGCATCGCCTTCTATC 
Mutation specific (absent in wildtype allele) 
5’ primer name Neo3A 
3’ primer name DNA498-13 
Predicted band size 227 bp 
5’ primer sequence 5’ – GCAGCGCATCGCCTTCTATC 
3’ – primer sequence 5’ – GCAGCGCATCGCCTTCTATC 
 
Table 2.3 – An outline of primer sequences of the primers used in PCR for genotyping of 
mouse tissue. 
 
2.8.3 Real time quantitative PCR 
Following siRNA knock down in HUVEC, 48 hours after transfection the cells 
were harvested and split to be used for experiments or for analysis by RT-
PCR.  RNA was extracted from HUVEC using a Total RNA Purification Kit 
(Norgen Biotek), according to the manufacturer’s guidelines, and the resulting 
yield of RNA was measured using a spectrophotometer (Nanodrop).  To 
generate the template required for the real-time PCR reaction, cDNA was 
generated from the extracted RNA using a High Capacity cDNA Reverse 
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Transcriptase kit (Invitrogen), which required the following PCR program to 
generate the cDNA: 25oC for 10 min, 37oC for 120 min, 85oC for 5 min.  The 
cDNA product was stored at -20oC short-term before use in the RT-PCR 
reaction, which utilised FAM-TAMRA TaqMan hydrolysis probes (Applied 
Biosciences) and GAPDH as the internal house keeping control gene.  RT-
PCR samples were analysed using an ABI Prism 700 Sequence Detection 
system (Applied Biosciences) and the following PCR program: 50oC for 2 min, 
95oC 10 min, followed by 44 cycles of 95oC for 15 sec, 60oC for 1 min.  MIQE 
guidelines were followed (Bustin et al., 2009); water controls were included to 
check for contamination and the efficiency of each experiment, which was 
required to be within 10% of the house keeping gene to be considered valid, 
was calculated from standard curves, generated from 2-fold serial dilutions of 
the cDNA in the PCR reaction mix. 
To calculate relative mRNA expression in each sample, the cycle threshold 
values (Ct) for Tspan18 were compared to the Ct of the housekeeping gene, 
GAPDH.  Ct marks the point of intersection between the amplification curve 
and the threshold line and was set at the exponential phase of amplification.  
To calculate the expression ratio of the gene of interest and to control for 
differences in efficiency of amplification across experiments, the Pfaffl method 
was used, for which the equation is outlined below (Pfaffl, 2001). 
 
 
Ratio =  
(E target)  
(E ref)  
∆Ct target  
∆Ct ref 
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Where E target is the real time PCR efficiency of the target gene (in this case, 
Tspan18) and E ref is the real time PCR efficiency of the housekeeping gene 
(in this case, GAPDH).  The ∆Ct target is the Ct of control – knockdown sample 
for the target gene (Tspan18) and the ∆Ct ref is the Ct of control – knockdown 
sample for the housekeeping gene (GAPDH) (Pfaffl, 2001). 
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2.9 ENDOTHELIAL FUNCTION ASSAYS 
 
2.9.1 siRNA Transfection of HUVEC 
HUVEC were transiently transfected using RNAiMAX (Invitrogen) and short 
interfering RNA (siRNAs) (Ambion) to knock-down proteins of interest during 
endothelial functional assays, as previously described (Kaur et al., 2011).  In 
brief, cells were set up in complete media 24 hours before transfection.  A 
duplex mix, containing siRNA duplex (20 µM stock) and Opti-mem serum-free 
media, and a lipofectamine mix, of lipofectamine (RNAiMAX) and Opti-mem, 
were incubated for 10 mins.  The two mixes were combined and incubated for 
a further 10 mins.  The cells were washed twice with PBS and the 
duplex/lipofectamine mix with additional Opti-mem media added to the plate.  
The cells were incubated at 37oC for 4 hours before the media was changed 
to complete HUVEC media without antibiotics.  Cells were used in endothelial 
functional assays 48 hours after transfection.  Cell counts, amount of DNA 






siRNA        Opti-mem 
Lipofectamine mix 
RNAiMAX    Optimem 
Final 
volume 
6-well 1.75 x 
105 
2.5 µl 167.5 µl 6-well 3 µl 1 ml 
6 cm 3.6 x 
105 
3.6 µl 241.4 µl 6 cm 4.3 µl 2 ml 
10 cm 1 x 106 10 µl 670 µl 10 cm 12 µl 4 ml 
 
Table 2.4 – Reagents and quantities required for siRNA knock down in HUVEC 
 
 
 - 86 - 
2.9.2 Scratch wound assay 
HUVEC were seeded at 3.5 x 105 cells per well of a gelatine-coated 6-well 
plate 24 hours before transfection, using siRNA, as described above.  48 
hours after transfection, HUVEC monolayers were wounded with a plastic 
pipette tip and cell migration was monitored using a 20X objective with a 
TE2000 (Nikon) microscope with Digital Sight DS-Qi1MC camera (Nikon) 
using NIS elements AR software (Nikon).  Images were taken every 15 
minutes for 12 hours and migration of the cells to close the wound was 
assessed using ImageJ software (Kaur et al., 2011).  Samples were taken to 
analyse knockdown efficiency by real time PCR, as described above. 
 
2.9.3 Co-culture tube formation assay of angiogenesis 
Fibroblasts were grown to confluence in a 12-well plate.  HUVEC which had 
been transfected with siRNA, as described above, 24 hours previously were 
plated on top of the fibroblast culture at 3 x 104 cells/ml, using 1 ml per well.  
For six days the cells were left to grow, being given fresh media every other 
day.  Following this incubation period, the tubes formed by the HUVEC were 
stained; cells were washed with PBS and fixed using 1 ml chilled ethanol 
(70%) for 30 min.  Fixed cells were then incubated with anti-human CD31 
antibody (1.29 µg/ml) in 400 µl buffer (1% BSA in PBS) at 37 oC for 40 min.  
Cells were washed with PBS, and incubated with anti-mouse IgG alkaline 
phosphatase (Sigma) (1:500) in 400 µl buffer (1% BSA in PBS) at 37 oC for 40 
min.  Cells were washed with PBS then dH2O before addition of 500 µl 
SigmaFast BCIP/NBT substrate (Sigma) dissolved in dH2O and were 
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incubated at room temperature for 25 min.  The reaction was stopped by 
washing with excess dH2O.  The plates were then imaged using a light 
microscope and tubule formation was assessed using AngioSys software 
(Kaur et al., 2011). 









TSPAN18 REGULATES GPVI INDUCED PLATELET 
ACTIVATION AND PLATELET Ca2+ SIGNALLING 
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3.1 INTRODUCTION 
 
3.1.1 Tspan18 is a platelet tetraspanin 
The expression of tetraspanins in platelets has been studied using several 
techniques including proteomics, mRNA analysis, and use of antibodies to 
confirm and quantitate protein expression (Haining et al., 2011).  One specific 
proteomics screen demonstrated that Tspan18 is one of the tetraspanins 
expressed on human platelets (Lewandrowski et al., 2009).  Additionally, 
Tspan18 has been identified at the mRNA level in human and mouse 
megakaryocytes (Macaulay et al., 2007; Protty et al., 2009) and human and 
mouse platelets (Haining et al., 2012; Rowley et al., 2011).  Aside from 
platelets, Tspan18 has also been identified in endothelial cells (Colombo, 
2010) and CD4+ T-cells (Protty et al., 2009), at the mRNA level, however a 
lack of antibodies has limited further investigation into its expression profile. 
Selected platelet tetraspanins have been investigated using knockout mouse 
models and some have been implicated in regulation of platelet activation.  
For example, mice lacking either CD151 or Tspan32 displayed impaired 
platelet function.  This was proposed to be caused by defective signalling from 
the major platelet integrin αIIbβ3 (Goschnick et al., 2006; Lau et al., 2004; 
Orlowski et al., 2009; Wright et al., 2004).  However, investigation into the 
CD9 and CD63 knockout mice yielded no major platelet phenotype except a 
mild increase in thrombus size in the CD9 knockouts (Mangin et al., 2009; 
Schröder et al., 2009).  The role of Tspan18 in platelet function has not yet 
been investigated.   
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When characterising platelet function, genetically modified mouse models are 
often used, as the effectiveness of in vitro assays is limited by the inability to 
culture or transfect these cells (B Nieswandt, Aktas, Moers, & Sachs, 2005).  
Therefore, to assess the role of Tspan18 in platelets, the Tspan18 knockout 
mouse was used.  The Tspan18 knockout mouse was obtained from the 
Mutant Mouse Regional Resource Centre and was originally generated by 
Genentech Inc. and Lexicon Pharmaceuticals Inc, as outlined in section 1.3.5 
(Tang et al., 2010). 
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3.2 AIMS 
The aim of this chapter was to assess the role of Tspan18 in platelet function 
and haemostasis by using Tspan18 deficient mice.  Both in vivo models and 
well defined in vitro assays were used to ascertain whether Tspan18 has a 
role in platelet activation or haemostasis. 
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3.3 RESULTS 
 
3.3.1 Normal blood cell numbers and expression of platelet surface 
receptors in Tspan18 deficient mice 
To evaluate blood cell counts in the Tspan18 deficient mice, blood was taken 
from anaesthetised mice and analysed using the Pentra 60 from ABX 
Diagnostics.  No significant difference was observed between Tspan18 
deficient and wildtype mice for platelet count, platelet volume, white blood cell 
count, or red blood cell count (figure 3.2, A-D).  Examination of the different 
white blood cell populations also distinguished no difference between 
Tspan18 deficient and wildtype mice (figure 3.2, E). 
To assess expression of the cell surface receptors which are important in 
platelet activation, flow cytometry was used.  Blood was taken from 
anaesthetised mice, stained with FITC-tagged antibodies for specific platelet 
surface proteins and mean fluorescence intensity values were corrected with 
an Ig control stain.  Tspan18 deficient platelets displayed normal expression 
of GPIb, the integrins α6 and αIIb, the metalloproteinase ADAM10, the 
tetraspanin CD9, and the signalling receptors, GPVI and CLEC-2 (figure 3.3). 
Taken together, these data suggest that Tspan18 does not have a role in 
blood cell production or regulation of surface expression of the platelet 
surface proteins tested. 




















































































































































































































































Figure 3.1 - Whole blood cell counts in Tspan18 deficient mice are normal.  Blood was 
collected from anaesthetised mice and analysed by whole blood counting on a Pentra 60 from 
ABX diagnostics.  Platelet count (A), platelet volume (B), white blood cell count (C), and red 
blood cell count (D) were assessed.  Data were analysed by T-test.  Error bars represent the 
standard error of the mean from 30 pairs of mice.  White blood cell populations were also 
measured (E), and these data were normalised by arcsin transformation and analysed by two-
way analysis of variance (ANOVA) with Bonferroni post-test.  Error bars represent the 
standard error of the mean from 30 pairs of mice. 
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Figure 3.2 – Platelets from Tspan18 deficient mice express normal levels of the major 
platelet surface receptors.  Blood was collected from anaesthetised mice, stained with FITC-
tagged antibodies for specific platelet surface proteins, and analysed by flow cytometry.  
Representative overlay traces are shown; green = wildtype platelets, pink = Tspan18 deficient 
platelets, and black = control Ig staining for wildtype platelets (control Ig staining for 
Tspan18 deficient platelets yielded the same results, data not shown) (A).  The mean 
fluorescence intensity values from 5 pairs of mice were collated and the mean +/- standard 
deviation values are displayed (B).  All data were analysed by T-test. 
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3.3.2 Tspan18 deficient platelets display disrupted aggregation 
downstream of GPVI 
To assess platelet activation and aggregation in Tspan18 deficient platelets, 
light transmission aggregometry (LTA) was used.  LTA, or Born 
aggregometry, is considered to be the gold standard in platelet function 
testing and relies on the principle that more light can transmit through a 
suspension of aggregated platelets, than a suspension of resting platelets 
(Born, 1962).  The percentage aggregation of platelets can therefore be 
assessed in terms of percentage light transmission.  Use of agonists which 
activate specific platelet surface receptors enabled assessment of specific 
signalling pathways important in platelet activation.  Analysis of both washed 
platelets and platelet rich plasma was completed.  Washed platelets provided 
a clean system in which to assess platelet function, without additional effects 
of plasma factors, as the platelets were washed out of the plasma and into 
buffer.  Platelet rich plasma allowed analysis of platelet activation by the 
agonist ADP, which activates P2Y receptors which become desensitised upon 
washing, and also provided more physiological conditions. 
Initially, platelets were washed out of whole blood into modified Tyrode’s 
buffer and stimulated with CRP (provided by Dr. R. Farndale), which is a 
synthetic peptide of GPO repeats cross-linked at N- and C- terminal cysteine 
or lysine residues.  This peptide specifically activates platelets via the platelet 
collagen receptor GPVI (Farndale, 2006).  In response to an intermediate 
dose of CRP, Tspan18 deficient platelets displayed defective aggregation.  In 
response to a high dose of CRP, Tspan18 deficient platelets were able to 
aggregate, but a delayed response in aggregation was observed (figure 3.4).  
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The reduction in aggregation was significant when compared to wildtype 
platelets at both intermediate and high doses of CRP, though the phenotype 
was not as severe at high doses of agonist (figure 3.4).  Washed platelet 
aggregation was also assessed downstream of signalling pathways other than 
GPVI, using agonists which activate other platelet surface proteins.  Thrombin 
(Sigma) is a potent platelet agonist, which stimulates platelet activation 
through cleavage of the PAR family of GPCRs (Brass, 2003; De Candia, 
2012).  CLEC-2 Ab (provided by Prof. S. Watson) activates the C-type lectin 
receptor CLEC-2 on platelets via a Src and Syk tyrosine kinase family 
dependant mechanism (Eble et al., 2006; May et al., 2009).  Collagen 
(HORM) (Nycomed Austria) can activate platelets indirectly, via vWF and the 
GPIb-V-IX complex, or directly via the integrin α2β1 and the platelet surface 
receptor GPVI (Farndale, 2006; Bernhard Nieswandt & Watson, 2003).   
When stimulated by thrombin, CLEC-2 antibody or collagen, washed Tspan18 
deficient platelets displayed normal aggregation; no difference was observed 
in comparison to wildtype platelets (figure 3.5).  Analysis of Tspan18 deficient 
platelet response to doses of collagen lower than 1 µg/ml were attempted, but 
the lack of response from wildtype platelets at such low doses prevented 
further investigation (data not shown). 
Following platelet activation, secretion of secondary mediators is an important 
step in driving thrombus formation, as it provides positive feedback to activate 
and recruit more platelets to the growing thrombus.  Secretion of ATP from 
dense granules was measured via addition of a luciferin/luciferase mix to the 
platelet solution and measurement of luminescence output.  Consistent with 
the aggregation data, secreted ATP was significantly reduced in Tspan18 
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deficient platelets in comparison to wildtype controls when activated with the 
GPVI-specific agonist, CRP, at either intermediate or high doses (figure 3.6, 
A).  However, when Tspan18 deficient platelets were stimulated with 
thrombin, CLEC-2 antibody or collagen, secretion was normal across multiple 
doses of agonist (figure 3.6, B-D). 
When aggregation was assessed in platelet rich plasma, the Tspan18 
deficient platelets again demonstrated defective aggregation downstream of 
CRP, at several different doses of agonist (figure 3.7).   Aggregation in 
platelet rich plasma was also assessed downstream of other platelet agonists.  
PAR4 peptide (AYPGKF) (provided by Dr. R. Farndale) was used as a 
thrombin substitute.  ADP (Sigma) induces platelet activation via two GPCRs; 
P2Y1 and P2Y12 activate phospholipase C and suppress cAMP formation 
respectively, thus leading to platelet activation (Jin et al., 1998; Zhang et al., 
2001).  In response these other agonists, Tspan18 deficient platelets 
aggregated completely normally (figure 3.8, A-B).  Interestingly, a minor 
defect in aggregation was observed in Tspan18 deficient platelets to a low 
dose of collagen, the physiological ligand of GPVI (figure 3.8 C).  This 
suggests that Tspan18 deficient platelets are more susceptible to defects in 
platelet rich plasma, than when they have been washed out of the plasma, as 
no defects were observed following collagen stimulation in washed platelets. 
Together, these data outline a defect during platelet aggregation and 
secretion, specifically downstream of the platelet collagen receptor, GPVI, 
which could be partially rescued through high doses of agonist.  This is 
evidence of a mild but specific fault in platelet activation within the GPVI 
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signalling pathway and suggests a role for Tspan18 in GPVI-induced platelet 
activation. 












































































































Figure 3.3 – Washed Tspan18 deficient platelets display reduced aggregation 
downstream of GPVI.  Blood was collected from anaesthetised mice; platelets were isolated 
from the whole blood and washed in modified Tyrode’s buffer.  Washed platelets were 
activated with two different doses of CRP and aggregation was measured via light 
transmission with stirring, a representative trace is shown in the upper panels.  Collated data 
of % aggregation at minute intervals were assessed and is shown in the lower panels.  All data 
were normalised by arcsin transformation and analysed by two-way ANOVA with Bonferroni 
post-test (* denotes P < 0.05, ** denotes P < 0.01 and *** denotes P < 0.001).  Error bars 
represent the standard error of the mean from 5-9 pairs of mice.  
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Figure 3.4 – Washed Tspan18 deficient platelets display normal aggregation to 
thrombin, CLEC-2 mAb and collagen.  Blood was collected from anaesthetised mice; 
platelets were isolated from whole blood and washed in modified Tyrode’s buffer.  Washed 
platelets were activated with thrombin (A), CLEC-2 antibody (B), or collagen (C).  
Aggregation was measured via light transmission with stirring, representative traces are 
shown in the upper panels.  Collated data of % aggregation at minute intervals were assessed 
and is shown in the lower panels.  All data were normalised by arcsin transformation and 
analysed by two-way ANOVA with Bonferroni post-test.  Error bars represent the standard 
error of the mean from 3-7 pairs of mice.  Note that no wildtype platelet response was 
observed at doses of collagen lower than 1 µg/ml (data not shown).  
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Figure 3.5 – Washed Tspan18 deficient platelets display reduced secretion downstream 
of GPVI.  Blood was collected from anaesthetised mice; platelets were isolated from whole 
blood and washed in modified Tyrode’s buffer.  Following activation with CRP (A), collagen 
(B), thrombin (C) or CLEC-2 antibody (D), secretion of ATP from platelet dense granules 
was measured using an added firefly luciferin/luciferase mix (chromolume, Chrono-Log 
Corporation).  All data were analysed by T-test (*** denotes P < 0.001, * denotes P < 0.05).  
Error bars represent the standard error of the mean from 3-9 pairs of mice.  
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Figure 3.6 – Tspan18 deficient platelets in platelet rich plasma display defective 
aggregation downstream of GPVI activation.  Blood was collected from anaesthetised 
mice; platelets were isolated from whole blood and collected as platelet rich plasma.  Platelets 
were activated with CRP.  Aggregation was measured via light transmission with stirring, 
representative traces are shown in the upper panels.  Collated data of % aggregation at minute 
intervals were assessed and is shown in the lower panels.  All data were normalised by arcsin 
transformation and analysed by two-way ANOVA with Bonferroni post-test (* denotes P< 
0.05).  Error bars represent the standard error of the mean from 3-4 pairs of mice.  
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Figure 3.7 – Tspan18 deficient platelets in platelet rich plasma display normal 
aggregation to PAR4 peptide and ADP, but mildly defective aggregation to collagen.  
Blood was collected from anaesthetised mice; platelets were isolated from whole blood and 
collected as platelet rich plasma.  Platelets were activated with PAR4 peptide (A), ADP (B), 
or collagen (C).  Aggregation was measured via light transmission with stirring, 
representative traces are shown in the upper panels.  Collated data of % aggregation at minute 
intervals were assessed and is shown in the lower panels.  All data were normalised by arcsin 
transformation and analysed by two-way ANOVA with Bonferroni post-test (** denotes P < 
0.01).  Error bars represent the standard error of the mean from 4-5 pairs of mice.  
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3.3.3 Tspan18 deficient platelets display disrupted spreading 
downstream of GPVI 
To further investigate the role of Tspan18 in platelet function, a platelet 
spreading assay was used, in which the ability of platelets to spread on 
immobilised agonist was assessed.  As previously, blood was taken from 
anaesthetised mice and the platelets washed out from the whole blood into 
modified Tyrode’s buffer.  Platelets were then spread on glass cover slips pre-
treated with immobilised agonist before being fixed, imaged and analysed for 
surface area using ImageJ software. 
When Tspan18 deficient platelets were exposed to cover slips coated in CRP, 
a significant reduction in the area spread was observed when compared to 
wildtype control platelets (figure 3.9, A).  However, when Tspan18 deficient 
platelets were exposed to cover slips coated with fibrinogen, no difference in 
the area spread was observed (figure 3.9, B). 
Taken together with the data from the aggregation experiments, this outlines a 
clear disruption to platelet function specifically downstream of CRP 
stimulation, suggesting defective signalling within the GPVI signalling 
pathway. 






































































Figure 3.8 – Washed Tspan18 deficient platelets display reduced spreading downstream 
of GPVI.  Blood was collected from anaesthetised mice; platelets were isolated from whole 
blood and washed in modified Tyrode’s buffer.  Washed platelets were exposed to cover slips 
coated with CRP (A) or fibrinogen (B) and the area of the adhered platelets was measured.  
Representative images are shown.  All data were analysed by T-test (*** denotes P < 0.001). 
Error bars represent the standard error of the mean from 4 pairs of mice (150 platelets were 
analysed per mouse). 
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3.3.4 Protein tyrosine phosphorylation induced by GPVI is normal in 
Tspan18 deficient platelets 
Following the observations from the platelet function tests that outlined a 
potential role for Tspan18 in regulation of platelet activation via GPVI, it was 
important to assess whether Tspan18 had a role in regulation of signalling 
from the GPVI receptor itself.  Once activated, GPVI signals via an ITAM motif 
within the associated FcRγ chain, which leads to a complex phosphorylation 
cascade (Bernhard Nieswandt & Watson, 2003; Watson et al., 2005).  
Therefore, functionality of GPVI can be assessed by measuring downstream 
phosphorylation.  Blood was taken from anaesthetised mice; platelets were 
isolated from the blood, washed in modified Tyrode’s buffer and stimulated 
with CRP.  Samples were taken into reducing sample buffer, separated by 
SDS-PAGE and western blotted with an anti-4G10 antibody to show 
phosphorylated tyrosine residues.  To quantitate phosphorylation, band 
intensity was measured using the Odyssey infra red imaging system (LICOR). 
No observable difference was noted in the pattern of tyrosine phosphorylation 
following GPVI stimulation between Tspan18 deficient and wildtype platelets.  
This was true for basal levels of phosphorylation and at two time points post-
stimulation (figure 3.10, A).  No difference was observed after measurement 
of band intensity of the band observed at approximately 72 kDa, which 
corresponds to phosphorylated Syk, at any of the time points across three 
different doses of agonist (figure 3.10, B).  Similarly, no significant difference 
was observed after measurement of the band at 135 kDa, which corresponds 
to phosphorylated PLCγ (figure 3.10, C).  However, close inspection of the 
intensity of the pp135 band after stimulation with 3 µg/ml CRP may suggest 
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an increase in phosphorylation in Tspan18 deficient platelets in comparison to 
wildtype. This may warrant further investigation, though does not appear to 
suggest a major phenotype. 
These data demonstrate normal signalling from GPVI, which implies that 
Tspan18 may be having an effect further downstream in this signalling 
pathway. 
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Figure 3.9 – Protein tyrosine phosphorylation induced by GPVI is normal in Tspan18 
deficient platelets.  Blood was collected from anaesthetised mice; platelets were isolated 
from whole blood and washed in modified Tyrode’s buffer.  Platelets were activated with 
three different doses of CRP.  Samples were taken at several time-points, separated by SDS-
PAGE and blotted with an anti-phosphotyrosine antibody, 4G10.  A representative blot from 
5 separate experiments is shown (A).  The band at pp72, corresponding to phosphorylated 
Syk (B) and pp 135 corresponding to phosphorylated PLCγ (C), were quantitated using the 
Odyssey infra-red (LICOR) imaging system.  All data were normalised by logarithmic 
transformation and analysed by two-way ANOVA with Bonferroni post-test.  Error bars 
represent the standard error of the mean from 5 separate experiments. 
 - 111 - 
3.3.5 Tspan18 deficient platelets have reduced SOCE and reduced global 
Ca2+ signalling 
It has been shown previously that platelet activation, and specifically the GPVI 
signalling pathway, is reliant on SOCE (Braun et al., 2009; David Varga-
Szabo, Braun, et al., 2008).  Additionally, previous studies, using cell line over 
expression models had suggested a role for Tspan18 in Ca2+ signalling 
(Colombo, 2010).  Therefore, it is possible that the defects observed in 
platelet activation in Tspan18 deficient platelets were caused by defective 
Ca2+ signalling.  To investigate the potential role for platelet Tspan18 in 
SOCE, Ca2+ signalling was measured in Tspan18 deficient platelets.  Blood 
was taken from anaesthetised mice and platelets were isolated and washed in 
modified Tyrode’s buffer.  Platelets were then loaded with the Ca2+ sensitive 
fluorescent dye, Fura2-AM and Ca2+ measurements were taken using a 
luminescence spectrophotometer.   
Initial investigation into the role of Tspan18 in Ca2+ signalling in platelets 
focussed on platelet response following agonist stimulation.  Platelets were 
suspended in Tyrode’s buffer containing 1.5 mM Ca2+ and were stimulated 
with different platelet agonists.  Ca2+ measurements were taken to measure 
Ca2+ influx following platelet stimulation.  After stimulation with CRP or 
collagen, a significant reduction in the rate of Ca2+ mobilisation was observed 
in Tspan18 deficient platelets (figure 3.11, A).  Additionally, the maximal Ca2+ 
concentration observed was significantly reduced in Tspan18 deficient 
platelets in comparison to wildtype platelets (figure 3.11, B).  However, both 
the rate of Ca2+ influx and the maximal Ca2+ concentration achieved in 
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Tspan18 deficient platelets was normal after stimulation with thrombin (figure 
3.11).   
This suggests that Ca2+ mobilisation and influx of Ca2+ from the extracellular 
environment appears to be reduced in Tspan18 deficient platelets 
downstream of GPVI activation. 
To more specifically investigate the potential role of Tspan18 in SOCE, the 
platelets were treated with thapsigargin (Sigma) which acts to induce 
emptying of the intracellular Ca2+ stores via inhibition of sarco/endoplasmic 
reticulum Ca2+-ATPase (SERCA) Ca2+ ion pumps in the endoplasmic and 
sarcoplasmic reticulum, thus preventing Ca2+ flux back into the stores (Lytton, 
Westlin, & Hanley, 1991).   
Initially, the platelets were suspended in Ca2+-free media and were stimulated 
the thapsigargin to measure release of Ca2+ from intracellular stores.  
Following stimulation with thapsigargin, 1.5 mM Ca2+ was added back to the 
extracellular buffer to allow SOCE to occur.  Throughout the experiment, the 
cytosolic Ca2+ concentration was measured to monitor release of Ca2+ from 
the intracellular stores and influx from the extracellular environment .  The rate 
of entry of Ca2+ from the extracellular environment was reduced to 0.0026 s-1 
in Tspan18 deficient platelets, in comparison to 0.0038 s-1 in the wildtype 
control platelets (figure 3.12, A).  However, the final, maximal change in Ca2+ 
concentration was not significantly different between Tspan18 deficient and 
wildtype platelets (figure 3.12, B).   
The reduction in Ca2+ entry from the extracellular environment was preceded 
by a reduction in the release of Ca2+ from the intracellular stores.  This was 
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observed following thapsigargin treatment in the presence of Ca2+ free media, 
prior to Ca2+ being added back to the extracellular buffer.  The rate of release 
of Ca2+ from the stores was reduced to 0.010 s-1 in Tspan18 deficient platelets 
when compared to a rate of 0.022 s-1 in wildtype control platelets (figure 3.13, 
A).  Although a reduction in the rate of Ca2+ release from the stores was 
observed, there was no significant difference in maximal concentration of Ca2+ 
achieved in Tspan18 deficient platelets (figure 3.13, B).  This suggests that 
Tspan18 deficient platelets have mildly defective release of Ca2+ from 
intracellular stores, resulting in slower accumulation of Ca2+ in the cytosol 
following thapsigargin stimulation. 
Together, these data suggest defective release of Ca2+ from the intracellular 
store and defective SOCE in Tspan18 deficient platelets.  However, this Ca2+ 
signalling defect appears to only limit platelet activation and Ca2+ signalling 
downstream of GPVI.  It is therefore not surprising that no major difference in 
maximal Ca2+ concentration was observed after such a strong stimulus as 
thapsigargin. 
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Figure 3.10 – Global Ca
2+
 signalling is reduced in Tspan18 deficient platelets 
downstream of GPVI.  Blood was collected from anaesthetised mice; platelets were isolated 
from whole blood and washed in modified Tyrode’s buffer.  The platelets were loaded with 
the Ca
2+
 sensitive dye Fura-2 AM and Ca
2+
 measurements taken using a luminescence 
spectrophotometer.  Platelets were stimulated with CRP, collagen or thrombin as indicated, in 
the presence of 1.5 mM extracellular Ca
2+
. Average data from 4 separate experiments were 
fitted to a non-linear regression using an exponential one-phase association equation (A).  
Rate constants (K) were compared using an F-test (*** denotes P < 0.01).  The maximal 
change in [Ca
2+
] was also calculated (B). Data were analysed by T-Test (* denotes P < 0.05).  
Error bars represent the standard error of the mean from 4 separate experiments.   
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Figure 3.11 – Store operated Ca
2+
 entry is reduced in Tspan18 deficient platelets.  Blood 
was collected from anaesthetised mice; platelets were isolated from whole blood and washed 
in modified Tyrode’s buffer.  The platelets were loaded with the Ca
2+
 sensitive dye Fura-2 
AM and Ca
2+
 measurements taken using a luminescence spectrophotometer.  Platelets were 
stimulated with thapsigargin (TG) to induce emptying of the intracellular Ca
2+
 stores and Ca
2+ 
was then added back to the extracellular media at 1.5 mM to allow SOCE to occur. Average 
data from 5 separate experiments were fitted to a non-linear regression using an exponential 
one-phase association equation (A).  Rate constants (K) were compared using an F-test (*** 
denotes P < 0.001).  The maximal change in [Ca
2+
] was calculated (B).  Data were analysed 
by T-Test.  Error bars represent the standard error of the mean from 5 separate experiments.   
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Figure 3.12 - Release of Ca
2+
 from intracellular stores is reduced in Tspan18 deficient 
platelets within Ca
2+
 free media. Blood was collected from anaesthetised mice; platelets 
were isolated from whole blood and washed in modified Tyrode’s buffer.  The platelets were 
loaded with the Ca
2+
 sensitive dye Fura-2 AM and Ca
2+
 measurements taken using a 
luminescence spectrophotometer.  Platelets were treated with thapsigargin (TG) to induce 
emptying of the intracellular Ca
2+
 stores. Average data from 5 separate experiments were 
fitted to a non-linear regression using an exponential one-phase association equation (A).  
Rate constants were compared using an F-test (*** denotes P < 0.001).  The maximal change 
in [Ca
2+
] was also calculated (B). Data were analysed by T-Test.  Error bars represent the 
standard error of the mean from 5 separate experiments.   
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3.3.6 Aggregate formation under flow is normal for Tspan18 deficient 
platelets 
While in vitro platelet function tests which utilise washed platelets or platelet 
rich plasma are well characterised and provide a detailed view of specific 
signalling pathways involved in platelet activation, other assays can be 
employed to provide a more physiological view of platelet function.  One 
assay which better mimics in vivo conditions of platelet aggregation is the flow 
adhesion assay, which was completed using the Bioflux system from Fluxion.  
Platelets were fluorescently stained in whole blood, which was perfused 
through collagen-coated capillaries and aggregate formation was monitored 
using fluorescence microscopy.  The blood was perfused through the 
capillaries at rates of 300 s-1 (to represent venous shear) or 1000 s-1 (to 
represent arterial shear). 
No difference was observed in the dynamics of aggregate formation between 
blood from Tspan18 deficient mice and wildtype mice for either the high or low 
shear rates tested (figure 3.14, A and figure 3.15, A).  Additionally, there was 
no difference in the final area of the flow cell covered by platelet aggregates 
when quantified using ImageJ software (figure 3.14, B and figure 3.15, B). 
The lack of phenotype observed in this in vitro flow adhesion assay is 
consistent with the largely normal aggregation to collagen which was 
observed (figure 3.5). 
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Figure 3.13 – Aggregate formation under arterial shear conditions in the Tspan18 
knockout platelets is normal.  Whole blood from wildtype and Tspan18 deficient mice was 
perfused over a collagen-coated flow cell (30 µg/ml) using the Fluxion Bioflux system at a 
shear rate of 1000s-1.  Representative fluorescence images at minute-interval time points 
show normal aggregate formation by the Tspan18 deficient platelets (A).  Coverage of the 
flow cell by aggregates was measured at minute intervals, using thresholding in ImageJ (B).  
Data were normalised by arcsin transformation and analysed by two-way ANOVA with 
Bonferroni post-test.  Error bars represent standard error of the mean from 3 pairs of mice.  













































































Figure 3.14 – Aggregate formation under venous shear conditions in the Tspan18 
knockout platelets is normal.  Whole blood from wildtype and Tspan18 deficient mice was 
perfused over a collagen-coated flow cell (30 µg/ml) using the Fluxion Bioflux system at a 
shear rate of 300s-1.  Representative fluorescence images at minute-interval time points show 
normal aggregate formation by the Tspan18 deficient platelets (A).  Coverage of the flow cell 
by aggregates was measured at minute intervals, using thresholding in ImageJ (B).  Data were 
normalised by arcsin transformation and analysed by two-way ANOVA with Bonferroni post 
test.  Error bars represent standard error of the mean from 3 pairs of mice.  
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3.3.7 Thrombus formation in vivo is normal in Tspan18 deficient mice  
To provide further physiological assessment of the role of Tspan18 in vivo, 
two different models of thrombus formation were used to provide assessment 
of thrombus formation and the dynamics of thrombus growth.  These were 
carried out by Ina Theilmann in the lab of Bernard Nieswandt, Wurzburg, 
Germany. 
The first model used was mechanical injury of the abdominal aorta, during 
which the exposed vessel was injured using forceps and blood flow was 
monitored with a Doppler flow-meter.  Previous studies have demonstrated 
that thrombus formation in this model is mainly triggered by collagen (Braun et 
al., 2009; Grüner et al., 2005).  No significant difference in vessel occlusion 
was observed in Tspan18 deficient mice in comparison to wildtype control 
mice (figure 3.16). 
The second model used was the FeCl3 injury model, in which exteriorised 
mesentery arterioles were exposed to chemical injury by topical application of 
FeCl3.  The platelets were labelled with a fluorescent stain and thrombus 
formation monitored via fluorescence microscopy.  This model of thrombus 
formation has previously been shown to be a highly thrombin dependant 
process, as loss of GPVI is only partially protective against thrombus 
formation (Braun et al., 2009; Renné et al., 2005).  There was no difference 
observed in the onset of thrombus formation, as the first thrombi appeared in 
Tspan18 deficient mice at a similar time as in wildtype mice (figure 3.17, A).  
Additionally, there was no difference in the time to complete occlusion of the 
vessel (figure 3.17, B). 
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These in vivo models provided an insight into the physiological affects of 
Tspan18 deficiency on thrombus formation, showing that Tspan18 does not 
play a role in thrombus formation in these particular in vivo models.    










































Figure 3.15 – Thrombus formation in vivo is normal in Tspan18 deficient mice following 
mechanical injury.  Mice were anaesthetised, the abdominal aorta was exposed and the 
vessel was mechanically injured through a single firm compression with forceps.  Blood flow 
was monitored with a Doppler flow meter and time until complete occlusion of the vessel 
measured.  Each symbol represents one individual.  Data were analysed by T-test.  Data 
collated by Ina Theilmann from the Nieswandt laboratory, Wurzburg, Germany, as part of a 
collaboration. 









































































































































































Figure 3.16 – Thrombus formation in vivo is normal in Tspan18 deficient mice following 
chemical injury.  Mice were anaesthetised and the mesentery was exteriorised through an 
abdominal incision.  Platelets were fluorescently labelled (Dylight 488 conjugated anti-GPIX 
Ig derivative).  Small mesenteric arterioles were exposed to FeCl3 induced chemical injury via 
topical application.  The time for appearance of the first thrombi (A) and the time until 
complete occlusion of the vessel (B) were measured using fluorescence intravital microscopy.  
Representative fluorescence images before and after injury are shown (C).  Each symbol 
represents one individual.  Data were analysed by T-test.  Data collated by Ina Theilmann 
from the Nieswandt laboratory, Wurzburg, Germany, as part of a collaboration. 
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3.3.8 Haemostasis is disrupted in Tspan18 deficient mice 
To provide a broad analysis of haemostasis in the Tspan18 deficient mice, a 
tail bleeding assay was used.  Given the observation of normal thrombus 
formation in Tspan18 deficient mice and the relatively mild platelet phenotype 
observed, a major disruption to haemostasis was not predicted.  Mice were 
anaesthetised, 3 mm was amputated from the tip of the tail and blood loss 
was monitored over a maximum period of 20 minutes.  Due to restrictions on 
the Home Office licence permitting this work, the mice were limited to a 
maximum loss of 15% of total blood, calculated by bodyweight. 
The Tspan18 deficient mice bled significantly more than wildtype littermates 
(figure 3.18).  Additionally, several of the Tspan18 deficient mice bled 
severely enough to cause premature termination of the assay by cauterisation 
of the wound, to prevent blood loss excessive to that permitted by the licence.  
The phenotype observed could therefore have been more severe if the assay 
had been permitted to continue.  The Tspan18 deficient mice appear to show 
a heterogeneous population, in which some individuals bleed but other 
individuals did not bleed, whereas the wildtype mice demonstrate a 
homogenous population in which the variance is small, and none of the mice 
bleed.  The variable phenotype observed is discussed in more detail in 
section 3.4 (discussion of this chapter) and in chapter 5. 
These data demonstrate a clear disruption to haemostasis in Tspan18 
deficient mice, despite only a mild platelet functional defect and normal 
thrombus formation in vivo. 
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Figure 3.17 – Impaired haemostasis in the tail bleeding assay in Tspan18 deficient mice.  
The tail tip of anaesthetised mice was amputated and amount of blood lost was measured.  
Each symbol represents an individual.  Data were analysed by Fisher’s exact test; individuals 
were ranked as ‘bleeding’ or ‘not bleeding’ where ‘bleeding’ was defined as one or more drop 
of blood, equivalent to 30 µl lost (*** denotes P < 0.001).  Data displayed is either the % of 
total permitted blood loss (A); each mouse was permitted to lose a maximum of 15% of total 
blood determined by body weight, due to restrictions on the Home Office animal licence, or 
as total volume of blood lost with a bracket to indicate termination of the assay for individuals 
which lost 100% of permitted blood (B). 
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3.4 DISCUSSION 
 
The main aim of the work in this chapter was to characterise the role of 
Tspan18 in platelets by using the Tspan18 knockout mouse.  When platelet 
function was assessed, defective aggregation, secretion and spreading was 
observed, specifically downstream of the platelet collagen receptor GPVI, 
though induction of tyrosine phosphorylation from GPVI itself was normal.  
Additionally, Ca2+ signalling following CRP stimulation and SOCE were 
reduced in Tspan18 deficient platelets.  Together, these data suggested a role 
for Tspan18 in platelet activation, potentially via regulation of Ca2+ signalling, 
specifically downstream of GPVI.  In addition to the specific, yet mild, defect in 
platelet activation, the Tspan18 deficient mice displayed a severe disruption to 
haemostasis, as they bled significantly more than wildtype controls.  
Additionally, thrombus formation was shown to be normal in two different in 
vivo models.  
Although the precise role of Tspan18 on platelets is not known, the data 
presented in this chapter suggest a specific function for this tetraspanin in 
regulation of the GPVI signalling pathway.  As the GPVI signalling pathway is 
reliant on Ca2+ signalling, and specifically SOCE (Braun et al., 2009; David 
Varga-Szabo, Braun, et al., 2008), it is possible that Tspan18 could regulate 
Ca2+ signalling, or more specifically, SOCE in platelets.  This hypothesis is 
supported by previous studies on Tspan18 which reported a potential role for 
Tspan18 in Ca2+ signalling in a cell line over-expression system (Colombo, 
2010).   
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Interestingly, some of the functional defects observed in Tspan18 deficient 
platelets replicated similar observations made in platelets deficient for the 
SOCE channel Orai1.  The mice used to study Orai1 in platelets were 
generated as chimeras; lethally irradiated wildtype mice, which received a 
transplant of Orai1-/- or control cells to reconstitute the haematopoietic system, 
as the whole body knockouts displayed early lethality and growth retardation, 
making study of platelets difficult (Braun et al., 2009).  Similar to the results 
described in this chapter, Orai1 deficient platelets displayed defective 
aggregation specifically downstream of GPVI, and also a reduction in SOCE 
and Ca2+ signalling following activation by platelet agonists (Braun et al., 
2009).  These similarities suggest that Tspan18 and Orai1 could share a 
common signalling pathway, and that Tspan18 could have a role in interaction 
with and regulation of Orai1 or another member of the SOCE pathway.   
However, the phenotypes observed in Orai1 deficient platelets were more 
severe than those observed for Tspan18 deficient platelets; a reduction in 
Ca2+ signalling was observed downstream of all platelet agonists, not just 
CRP, and there was a disruption to thrombus formation in vivo, as assessed 
by the mechanical injury method (Braun et al., 2009).  The cause for this 
difference in severity of phenotypes may be due to the level of regulation that 
Tspan18 might provide within the SOCE pathway.  It could be possible that 
Tspan18 is important in fine-tuning the process of SOCE, rather than entirely 
regulating its function.  In which case, removal of Tspan18 could disrupt the 
efficiency of Ca2+ entry, but might not inhibit it completely, leading to less 
severe phenotypes.  This could also explain the subtle phenotype observed in 
reduced SOCE following stimulation by thapsigargin in Tspan18 deficient 
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platelets.  In comparison to Orai1 deficient platelets, the alteration in SOCE is 
markedly reduced (Bergmeier et al., 2009; Braun et al., 2009).  Again, if 
Tspan18 has a role in fine-tuning the mechanism of extracellular Ca2+ entry 
via Orai1, then it’s removal may well disrupt Ca2+ entry without blocking it 
completely.  Removal of Orai1 removes the ability of Ca2+ to enter the cell 
from the extracellular environment, whereas removal of Tspan18 may just 
disrupt this process resulting in a lower rate of Ca2+ flux rather than complete 
inhibition of this process.  Differences observed across different studies are 
not an uncommon occurrence; previous studies on the role of Orai1 in 
platelets have not always produced similar results.  A model utilising a loss of 
function mutant for Orai1 (Orai1R93W) demonstrated a reduction in Ca2+ 
mobilisation in Orai1R93W platelets, but did not report the same platelet 
functional defects observed in Orai1-/- deficient platelets (Bergmeier et al., 
2009).  This demonstrates how variations in experimental design and 
differences across different mouse models can lead to differences in severity 
and appearance of specific phenotypes. 
The potential role of Tspan18 in platelet Ca2+ signalling needs further 
investigation, as although the Ca2+ signalling experiments undertaken in this 
chapter highlighted a disruption to Ca2+ mobilisation in the absence of 
Tspan18, the exact role of this tetraspanin could not be determined.  In the 
presence of physiological levels of extracellular Ca2+ (1.5 mM), Tspan18 
deficient platelets had a reduced SOCE capacity when stimulated with the 
GPVI agonists CRP and collagen.  When Ca2+ measurements were taken 
following stimulation with platelet agonists in Ca2+-free media, the signal could 
not be detected above the background noise, therefore no conclusions could 
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be drawn on the release of Ca2+ from intracellular stores following agonist 
stimulation (data not shown).  However, in experiments utilising thapsigargin 
in Ca2+-free media and then in the presence of 1.5 mM Ca2+, a reduction in 
both intracellular store release and influx of Ca2+ from the extracellular 
environment was observed.  This may suggest that Tspan18 has a role at 
several different levels of Ca2+ signalling in platelets, and future experiments 
to provide a more in depth analysis of the Ca2+ signalling in Tspan18 deficient 
platelets would be useful. 
Additionally, following the observations made during measurement of Ca2+ 
signalling in the platelets, it may be useful to repeat the aggregation 
experiments and the measurement of protein phosphotyrosine induction 
experiment in the presence of physiological levels of Ca2+.  These 
experiments were completed in Tyrode’s buffer without added Ca2+, and as 
such more severe phenotypes could potentially be masked.  If Tspan18 has a 
role in SOCE, as suggested by the changes in Ca2+ signalling following 
thapsigargin stimulation, then completing aggregation analysis in the 
presence of extracellular Ca2+ might demonstrate a more severe difference in 
the aggregation capability of Tspan18 deficient and wildtype platelets due to 
the lack of Ca2+ influx from the extracellular environment.  This might also 
explain the slight difference in phosphotyrosine signalling observed for band 
pp135.  The importance of taking extracellular Ca2+ into consideration in 
future experiments is further supported by the results observed during the 
aggregation experiments conducted in PRP.  Defective aggregation was 
observed at higher does of CRP and at low doses of collagen in PRP, 
whereas defective aggregation in washed platelets was less severe.  PRP 
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contains more extracellular Ca2+, as the platelets have not been washed out 
of the plasma.  It is therefore possible that the additional extracellular Ca2+ in 
PRP demonstrates a more marked phenotype within the Tspan18 deficient 
platelets, suggesting a SOCE defect. 
Perhaps the most surprising result within this chapter was that despite normal 
thrombus formation and only a mild platelet functional phenotype in Tspan18 
deficient mice, these animals had a severe disruption to haemostasis.  It is 
unlikely that the increase in bleeding was caused by platelet functional 
defects, as the platelet phenotypes were so mild in the Tspan18 deficient 
mice, and mice lacking GPVI display only moderate bleeding (B Nieswandt, 
Schulte, et al., 2001).  Additionally, the tail bleeding data clearly represents 
the Tspan18 deficient mice as a heterogeneous population, in which some 
individuals bleed and some do not, as the variance in the population was 
large.  This is despite the fact that the disruption to platelet activation was 
consistently observed across all individuals, showing a clearly homogenous 
response.  This suggests that another cell or tissue might be the driving force 
behind disrupted haemostasis.  Other cells such as the endothelium, which is 
responsible for release of clotting factors such as vWF (Kanaji, Fahs, Shi, 
Haberichter, & Montgomery, 2012) and FVIII (Everett, Cleuren, Khoriaty, & 
Ginsburg, 2014), and vascular smooth muscle cells, which regulate 
vasoconstriction (Wilson et al., 2005), play vital roles in haemostasis.  This 
suggests that Tspan18 could be important in one or more of these cell types 
in regulation of haemostasis, in addition to its role in the GPVI signalling 
pathway.   
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Key questions still need to be addressed in order to better understand the role 
of Tspan18 within the vasculature.  Firstly, the potential role for Tspan18 in 
Ca2+ signalling and SOCE needs further investigation in order to better 
understand the role of Tspan18 in the GPVI signalling pathway.  Secondly, 
the role of this tetraspanin in non-haematopoietic cells needs to be evaluated 
in order to assess the potential affect that Tspan18 could be having on 
haemostasis.  The work in the following chapters aimed to investigate both of 
these areas further. 
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4.1 INTRODUCTION 
 
4.1.1 Store operated Ca2+ entry 
Following receptor activation at the cell surface, the primary phase of Ca2+ 
mobilisation occurs via release of Ca2+ from intracellular stores, often the ER, 
via IP3 receptors (Berridge & Irvine, 1984; Smyth et al., 2010).  Reduced Ca
2+ 
concentration within the ER induces influx of Ca2+ from the extracellular 
environment during the secondary phase of Ca2+ mobilisation, known as 
SOCE.  SOCE is important in maintaining sustained levels of Ca2+ in the cell 
and for replenishing depleted intracellular Ca2+ stores (Smyth et al., 2010).  
SOCE relies on STIM1 which acts as a Ca2+ sensor in the ER, and the Orai 
family of proteins (Orai1, 2 and 3), which are vital as the pore-forming 
subunits of channels at the plasma membrane (Smyth et al., 2010).  Upon 
depletion of Ca2+ in the ER, a conformational change and oligomerization of 
STIM1 occurs, followed by rearrangement of STIM1 in the ER to punctate 
structures close to the plasma membrane (Liou, Fivaz, Inoue, & Meyer, 2007).  
An interaction between STIM1 and Orai at the plasma membrane induces 
multimerisation of Orai allowing formation of functional channels and flux of 
Ca2+ from the extracellular environment into the cell (Hou et al., 2012).  As the 
basic outline of Ca2+ signalling and SOCE in figure 4.1 demonstrates, 
increases in intracellular Ca2+ concentration can then activate downstream 
targets such as calcineurin, leading to NFAT activation and transcription. 
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4.1.2 The NFAT/AP-1 luciferase reporter assay 
The NFAT/AP-1 luciferase reporter assay is a useful tool for providing highly 
sensitive measurements of Ca2+ signalling.  This transcriptional reporter 
utilises promoters for both NFAT and AP-1, and is therefore maximally 
activated by combined Ca2+ and mitogen-activated protein kinase (MAPK) 
signalling pathways (M G Tomlinson et al., 2007).  The NFAT promoter of this 
reporter is activated by increased intracellular Ca2+, which induces activation 
of the protein phosphatase calcineurin via the Ca2+ binding protein 
calmodulin.  When activated, calcineurin dephosphorylates cytosolic NFAT 
within the serine rich region in the C-terminal tail, exposing a nuclear 
transduction signal.  NFAT then translocates to the nucleus, where it interacts 
with other transcription factors and regulates gene transcription (Crabtree & 
Olson, 2002).  The AP-1 promoter is activated downstream of the MAPK 
signalling cascade.  Formation of AP-1 occurs via heterodimerisation of the 
transcription factors c-Jun and c-Fos, after upstream phosphorylation by the 
JNK and ERK pathways respectively (Karin, 1995).  In cells transfected with 
the NFAT/AP-1 luciferase reporter, culmination of the MAPK and Ca2+ 
signalling pathways leads to AP-1 and NFAT activation; transcription of 
luciferase occurs and the magnitude of signalling assessed through addition 
of luciferin and measurement of luminescence (figure 4.1).  The use of PMA 
to activate the MAPK pathway via PKC and RasGRP (Landau, 1982; Tognon 
et al., 1998) and ionomycin to raise free intracellular Ca2+ levels (Liu & 
Hermann TE, 1978) can activate the reporter (figure 4.1).  The use of 
cyclosporin A, an immunosuppressant drug used after transplantation, to 
inhibit calcineurin and prevent phosphorylation and nuclear translocation of 
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NFAT (Handschumacher, Harding, Rice, Drugge, & Speicher, 1984; Mattila et 






































Figure 4.1 – Model of NFAT/AP-1 reporter activation.  Measurement of Ca
2+
 and MAPK 
signalling pathways within cells is possible using the NFAT/AP-1 luciferase reporter assay.  
Use of PMA and ionomycin can induce activation of MAPK and Ca
2+
 pathways respectively, 
leading to luciferase transcription.  The calcineurin inhibitor, cyclosporin A, inhibits 
downstream NFAT activation and therefore also luciferase transcription. 
 
4.1.3 Tspan18 in NFAT activation and Ca2+ signalling 
In previous studies using the NFAT/AP-1 luciferase reporter assay, Tspan18 
was shown to be unique across a panel of six different tetraspanins, including 
CD9, CD63, CD151, Tspan32 and Tspan9, in its ability to activate NFAT 
signalling in DT40 B-cell and Jurkat T-cell lines (Colombo, 2010).  It was 
confirmed that Tspan18 activated the luciferase reporter via the NFAT 
promoter, rather than the AP-1 promoter, which suggested a role for Tspan18 
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in upstream Ca2+ signalling (Colombo, 2010).  This work also demonstrated 
that Tspan18 induced NFAT activation independently of non-receptor tyrosine 
kinases of Src, Syk and BtK families, PLCγ, and IP3 receptors; over-
expression of Tspan18 still promoted NFAT activation in specific DT40 
knockout cell lines for these proteins (Colombo, 2010).  The activation of 
NFAT by Tspan18 was also observed, using fluorescence microscopy, in 
HeLa cells containing green fluorescent protein (GFP)-tagged NFAT; 
translocation of activated NFAT-GFP to the nucleus was increased in cells 
transfected with Tspan18 in comparison to mock transfected cells (Tomlinson, 
unpublished data).  Together, these data suggested a role for Tspan18 in 
regulation of Ca2+ signalling downstream of Ca2+ release from intracellular 
stores. 
The work in the previous chapter outlined a role for Tspan18 within the GPVI 
signalling pathway and therefore in platelet activation, and although the 
precise mechanism was not elucidated, the data again suggested a role for 
this tetraspanin within the Ca2+ signalling pathway.  Although previous studies 
have implicated Tspan18 in regulation of Ca2+ signalling, the precise 
mechanism of action and the potential partner protein(s) of this tetraspanin 
are still not known. 
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4.2 AIMS 
There were three key aims driving the work in this chapter.  Firstly, to identify 
whether a specific domain within the extracellular region of Tspan18 is 
important for activation of a Ca2+-responsive NFAT reporter.  Secondly, to 
determine whether Orai1 is important for Tspan18 induced activation of the 
NFAT reporter, and finally to determine whether Tspan18 interacts with the 
SOCE proteins STIM1 or Orai.  The NFAT/AP-1 luciferase reporter assay was 
used to identify the domains of Tspan18 which are important in NFAT 
activation and to determine whether Tspan18 requires Orai1 in this process.  
An immunoprecipitation approach was used to identify potential Tspan18 
interacting proteins within the SOCE signalling pathway. 
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4.3 RESULTS 
 
4.3.1 Importance of the Tspan18 variable region in Tspan18 induced 
activation of a Ca2+ sensitive reporter in DT40 B cells 
Findings from previous studies (Colombo, 2010), demonstrated that Tspan18 
was specific across a panel of tetraspanins in its ability to activate an 
NFAT/AP-1 transcriptional reporter.  This work also suggested that Tspan18 
activated the reporter through regulation of Ca2+ mobilisation.  To investigate 
this further, and to confirm these findings, the NFAT/AP-1 reporter was used. 
Tspan18 was expressed alongside the Ca2+ responsive NFAT/AP-1 luciferase 
reporter in DT40 B cells.  Cells were left unstimulated, inhibited with the 
calcineurin inhibitor cyclosporin A, or were treated with PMA and ionomycin 
as a positive control; PMA activates the MAPK signalling pathway and thus 
the AP-1 promoter and ionomycin activates Ca2+ signalling which leads to 
downstream NFAT activation, culminating in maximal activation of the 
reporter.  In agreement with the preceding data, expression of Tspan18 
induced a substantial increase in NFAT activation in unstimulated cells (figure 
4.2, A).  This increase was significant in comparison to both a mock 
transfection, which contained only an empty vector (pEF6) as a negative 
control, and to expression of another tetraspanin, CD9.  When cells were 
treated with cyclosporin A, NFAT activation was inhibited, even when 
Tspan18 was expressed, demonstrating that Tspan18 is dependant on 
calcineurin (figure 4.2, A).  Maximal activation of the reporter was observed in 
all transfections after treatment with PMA and ionomycin (figure 4.2, B).  To 
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confirm protein expression of the FLAG-tagged tetraspanin constructs, 
samples were separated by SDS-PAGE electrophoresis and western blotted 
with an anti-FLAG antibody (figure 4.2, C).   
In agreement with previous findings, these data demonstrate the ability of 
Tspan18 to activate NFAT and also highlights the dependence of this process 
on calcineurin, suggesting a role for Tspan18 in Ca2+ signalling. 
Previous studies attempted to investigate which domains of Tspan18 were 
important in activating NFAT by using a chimeric construct.  In the chimera, 
the transmembrane and intracellular regions of human Tspan18 were 
replaced with those of CD9.  This chimera was able to activate NFAT 
(Colombo, 2010), demonstrating the importance of the extracellular region of 
Tspan18 in NFAT activation. 
In order to locate more specifically which domain of Tspan18 is important for 
NFAT activation, a new chimera was made, in which only the variable region 
within the large extracellular loop of Tspan18 was present and the rest of the 
protein was CD9 (figure 4.3, A).  The chimera, Tspan18 or CD9 were 
expressed alongside the NFAT/AP-1 luciferase reporter in DT40 B-cells and 
cells were left unstimulated, or treated with PMA and ionomycin as previously 
described.  Expression of the chimera induced an increase in NFAT activation 
similar to that observed when Tspan18 was expressed, and which was 
significant in comparison to both mock transfected control and CD9 (figure 
4.3, B).  Maximal activation of the reporter was observed in all conditions after 
treatment with PMA and ionomycin (figure 4.3, C).  As previously, similar 
protein expression of the FLAG-tagged tetraspanin constructs was confirmed 
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by SDS-PAGE electrophoresis and western blotting (figure 4.3, D).  An 
opposite chimeric construct was also made, in which the variable region of 
CD9 was swapped into the structure of Tspan18.  However, this construct 
could not be successfully expressed in the DT40 B cells (data not shown); 
therefore the ability of this construct to activate the NFAT luciferase reporter 
could not be assessed. 
These data demonstrate the importance of the variable region of Tspan18 in 
activation of Ca2+ signalling, and suggest that only this region is required to 
induce NFAT activation, in the context of an intact tetraspanin.   

























































































































































Figure 4.2 – Tspan18 activates a Ca
2+
 responsive NFAT luciferase reporter in DT40 B 
cells.  DT40 B cells were transfected via electroporation with an NFAT-luciferase reporter, β-
galactosidase expression construct, and either empty vector control, FLAG-tagged CD9, or 
FLAG-tagged Tspan18.  Cells were left unstimulated or treated with the calcineurin inhibitor 
cyclosporin A (A), or were stimulated with PMA and ionomycin (B).  Luciferase activity was 
measured in a luminescence plate reader after addition of luciferin.  All data were corrected 
for β-galactosidase values, normalised by logarithmic transformation, and analysed by one-
way ANOVA and Tukey’s multiple comparison test (** denotes P < 0.01, *** denotes P < 
0.001).  Error bars represent the standard error of the mean from 3 separate experiments and 
were calculated asymmetrically due to logarithmic manipulation of the data; all values were 
converted back to linear values for presentation.  Whole cell lysates from all experiments 
were separated by SDS-PAGE and western blotted with an anti-FLAG antibody; a 
representative blot is shown (C).  

















































































































































Figure 4.3 - The variable region of Tspan18 is sufficient to activate NFAT, in the context 
of an intact tetraspanin.  A chimeric construct was made from CD9 and Tspan18, which 
included the variable region from the large extracellular loop of Tspan18 (A).  DT40 B cells 
were transfected via electroporation with NFAT-luciferase reporter, β-galactosidase 
expression construct, and either empty vector control, FLAG-tagged CD9, FLAG-tagged 
Tspan18, or FLAG-tagged chimera.  Cells were left unstimulated (B), or were stimulated with 
PMA and ionomycin (C).  Luciferase activity was measured in a luminescence plate reader 
after addition of luciferin.  All data were corrected for β-galactosidase values, normalised by 
logarithmic transformation, and analysed by one-way ANOVA and Tukey’s multiple 
comparison test (*** denotes P < 0.001).  Error bars represent the standard error of the mean 
from 6 separate experiments and were calculated asymmetrically due to logarithmic 
manipulation of the data; all values were converted back to linear values for presentation.  
Whole cell lysates from all experiments were separated by SDS-PAGE and western blotted 
with an anti-FLAG antibody; a representative blot is shown (D).  This work was completed in 
collaboration with an undergraduate student, Adam Peall. 
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4.3.2 Dominant negative Orai1 inhibits Tspan18 induced NFAT activation 
Data from previous studies had outlined a role for Tspan18 in Ca2+ signalling 
downstream of release of Ca2+ from intracellular stores, but upstream of 
calcineurin activation (Colombo, 2010).  The resulting hypothesis therefore, 
was that Tspan18 might have a role in regulation of SOCE.  To investigate the 
potential role of Tspan18 in SOCE, a dominant negative form of the SOCE 
channel Orai1, which has a mutation in the mouth of the channel causing loss 
of specificity for Ca2+, was used (Gwack et al., 2007).  In order to form 
functional pore-forming channels, Orai1 proteins cluster into multimer units 
(Hou et al., 2012; Mignen et al., 2008).  Therefore expression of dominant 
negative Orai1 disrupts functional channel formation and reduces SOCE. 
DT40 B-cells were transfected with the NFAT/AP-1 luciferase reporter and 
either Tspan18, dominant negative Orai1, Tspan18 and dominant negative 
Orai1, or dominant negative Orai1 and active calcineurin as a positive control.  
As previously, cells were left unstimulated, or were treated with PMA and 
ionomycin.  Expression of Tspan18 alone induced a significant increase in 
NFAT activation above mock transfected control, as shown previously.  
However, when dominant negative Orai1 was co-expressed, a complete 
inhibition of Tspan18 induced NFAT activation was observed (figure 4.4, A).  
Dominant negative Orai1 also inhibited PMA and ionomycin signalling (figure 
4.4, B); the predicted reduction of Ca2+ influx into the cell, caused by the 
mutated channel, would lead to reduced downstream calcineurin activation 
and therefore failure to activate the NFAT promoter of the reporter.  When 
active calcineurin was expressed, an increase in NFAT activation was 
observed in both unstimulated (figure 4.4, A), and PMA/ionomycin treated 
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cells (figure 4.4, B), even though dominant negative Orai1 was present.  The 
active calcineurin provided a positive control by bypassing the need for 
functioning Orai1 channels and increased Ca2+ concentration, therefore 
directly inducing NFAT activation.  As previously, protein expression of FLAG-
tagged Tspan18 and Myc-tagged dominant negative Orai1 was confirmed by 
SDS-PAGE electrophoresis and western blotting (figure 4.4, C). 
This finding demonstrates the dependence of Tspan18 on functioning Orai1 
channels in order to induce Ca2+ signalling and NFAT activation.  This lends 
further evidence to the hypothesis that Tspan18 may regulate SOCE. 





































































































































































































Figure 4.4 - Dominant-negative Orai1 inhibits Tspan18-induced NFAT activation.  DT40 
B cells were transfected via electroporation with NFAT-luciferase reporter, β-galactosidase 
expression construct, and either empty vector control, FLAG-tagged Tspan18, or Myc-tagged 
dominant negative (DN) Orai1.  As a positive control, active calcineurin was used.  Cells 
were left unstimulated (A) or stimulated with PMA and ionomycin (B).  Luciferase activity 
was measured in a luminescence plate reader after addition of luciferin.  All data were 
corrected for β-galactosidase values, normalised by logarithmic transformation, and analysed 
by ANOVA and Tukey’s multiple comparison test (** denotes P < 0.01, *** denotes P < 
0.001).  Error bars represent the standard error of the mean from 6 separate experiments and 
were calculated asymmetrically due to logarithmic manipulation of the data; all values were 
converted back to linear values for presentation.  Whole cell lysates from all experiments 
were separated by SDS-PAGE and western blotted with an anti-FLAG antibody and an anti-
Myc antibody; a representative blot is shown (C).  This work was completed in collaboration 
with a Masters student, Tammy Lloyd. 
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4.3.3 Tspan18 interacts with the Orai family of Ca2+ channels 
To identify Tspan18-interacting proteins, focussing on potential partners from 
within the SOCE pathway, an immunoprecipitation approach was used.  
HEK293T cells were transfected with Myc-tagged Orai1, Orai2, Orai3, or 
STIM1 and either an empty vector negative control (pEF6), or FLAG-tagged 
Tspan18.  Two different Orai1 constructs were used; Orai1 (a) and Orai1 (b).  
The cells were lysed in 1% digitonin lysis buffer, which is well established for 
identification of tetraspanin partner proteins (Haining et al., 2012).  Following 
immunoprecipitation for the FLAG tag of Tspan18, samples were separated 
by SDS-PAGE and western blotted for the Myc tag of the proteins of interest.  
Band intensity was quantitated using the Odyssey infra-red imaging system 
(LI-COR).  An interaction was detected between Tspan18 and Orai1, Orai2 
and Orai3 when blotting immunoprecipitation samples with an anti-Myc 
antibody (figure 4.5, A).  The relative band intensities demonstrated a 
significant increase above mock transfected control when Tspan18 was co-
expressed with either of the Orai1 constructs, Orai2, or Orai3 (figure 4.5, 
panel B).  The relative band intensity relating to the interaction between 
Tspan18 and Orai1 was much higher than that observed with Orai2 or Orai3 
(figure 4.5, panel B).  However, Orai2 and Orai3 were not expressed as highly 
as Orai1 in this system, as shown by the whole cell lysate anti-Myc western 
blot (figure 4.5, A).  No interaction was observed between Tspan18 and the 
SOCE sensory molecule STIM1.  Whole cell lysate samples blotted for the 
Myc tag confirmed expression of Orai1, Orai2, Orai3, and STIM1 and a FLAG 
blot confirmed expression of Tspan18 (figure 4.5, A).   
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The data presented here reveals an interaction between Tspan18 and the 
Orai channel family of SOCE proteins, which reinforces the hypothesis that 
Tspan18 may have a role in regulation of the SOCE pathway. 
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Figure 4.5 – Tspan18 interacts with the Orai family of Ca
2+
 channels.  HEK293T cells 
were transfected using PEI with Myc-tagged Orai1, Orai2, Orai3 or STIM1 and either an 
empty vector control or FLAG-tagged Tspan18.  Cells were lysed in 1% digitonin and 
immunoprecipitated with an anti-FLAG antibody.  Samples were separated by SDS-PAGE 
and both immunoprecipitated and whole cell lysate samples blotted with anti-FLAG and anti-
Myc antibodies, representative blots are shown (A).  The blots were visualised using the 
Odyssey infra-red imaging system (LI-COR) and band intensity quantitatively measured (B).  
All data were normalised by logarithmic transformation and analysed by T-test (* denotes P < 
0.05, ** denotes P < 0.01).  Error bars represent standard error of the mean from 3 separate 
experiments. 
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 4.3.4 Tspan18 forms a robust interaction with Orai1 
Further study into the interaction between Tspan18 and Orai proteins was 
limited to Orai1.  Orai1, rather than Orai2 or Orai3 has been previously shown 
to maintain the role of SOCE channel in platelets (Braun et al., 2009).  As 
such, it was considered the most relevant potential partner protein in this 
project, and the most suitable to take forward into further studies. 
To assess whether Tspan18 was unique in forming an interaction with the 
SOCE channel Orai1, an immunoprecipitation experiment in HEK293T cells 
was employed across a panel of different tetraspanins.  The tetraspanins 
tested were CD9, CD63, CD151, Tspan32, Tspan9, Tspan18 and the 
Tspan18-CD9 chimera.  After the HEK293T cells were transfected with Myc-
tagged Orai1 and a FLAG-tagged tetraspanin, samples were lysed and 
blotted and band intensity quantitated, as described previously.  The 
previously identified interaction between Tspan18 and Orai1 was observed 
and an interaction was also detected between the chimera and Orai1 when 
immunoprecipitation samples were blotted with an anti-Myc antibody (figure 
4.6, A).  When either Tspan18 or the chimera was expressed, the band 
intensity was significantly increased above mock transfected control 
containing empty vector (pEF6) (figure 4.6, B).  However, the relative band 
intensity for the interaction between the chimera and Orai1 was reduced from 
the interaction between Tspan18 and Orai1, by approximately 75%.  
Additionally, a weak band was observed when Tspan32 was co-expressed 
alongside Orai1; relative band intensity was low, but still demonstrated a 
significant increase above control, suggesting that Orai1 may also be 
interacting with Tspan32.  However, CD9, CD63, CD151 and Tspan9 did not 
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interact with Orai1 in this experiment.  To act as a positive control, the well 
characterised tetraspanin-partner protein interaction between CD9 and CD9P-
1 was used (S Charrin et al., 2001; Serru et al., 1999).  CD9P-1 was 
successfully co-immunoprecipitated with CD9 (figure 4.6 A) and this was 
significant in comparison to mock transfected control (figure 4.6 B). 
To assess how robust these interactions were, the experiment was repeated 
under more stringent lysis conditions.  As previously, the panel of tetraspanins 
were expressed in HEK293T cells alongside Orai1.  Samples were then lysed 
in 1% triton X-100 lysis buffer with 0.1% SDS, which disrupts tetraspanin 
microdomains and most weak interactions, including some tetraspanin-partner 
protein interactions (Stéphanie Charrin et al., 2009; Haining et al., 2012).  
Following immunoprecipitation and western blotting, band intensity was 
quantitated as described previously.  Only the interaction between Orai1 and 
Tspan18 was maintained under stringent lysis conditions as the interactions 
with Tspan32 and the chimera were disrupted (figure 4.7, A) and this was 
significant when quantitated (figure 4.7, B).  The interaction between CD9 and 
CD9P-1 was also lost in these stringent lysis conditions. 
To further characterise the nature of the interaction between Tspan18 and 
Orai1 a cross-linking experiment was used.  This allowed for comparison of 
this interaction with the well characterised interaction between Tspan14 and 
ADAM10 (Dornier et al., 2012; Haining et al., 2012), which was used as a 
positive control.  It also allowed for further analysis of the interaction between 
the chimera and Orai1.  Prior to lysis in 1% triton X-100 with 0.1% SDS and 
immunoprecipitation, the cells were treated with either the cell surface cross-
linker DTSSP, or PBS control.  DTSSP is a membrane impermeable chemical 
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cross-linker, linked by a spacer of 1.2 nm in length; if two cell surface proteins 
are closely associated, these proteins will be covalently cross-linked together 
by DTSSP, which can subsequently be cleaved with reducing agents.  
Samples were western blotted and band intensity measured as previously 
described.  Following pre-treatment with DTSSP, the maximal level of 
interaction between Tspan18 and Orai1 was observed, whereas with pre-
treatment with only PBS, there was a 50% decrease in band intensity which 
represented the interaction between Tspan18 and Orai1 (figure 4.8, A).  
Despite the reduction in band strength, the relative band intensity was still 
significantly increased from the control (figure 4.8, panel B).  The interaction 
with the chimera and Orai1 was almost entirely lost in the stringent lysis 
conditions without the presence of the chemical cross-linker.  Similarly, the 
interaction between ADAM10 and Tspan14 was almost entirely lost under 
stringent lysis without cross-linking. 
Taken together, these data show that both Tspan18 and the chimera interact 
with the SOCE channel Orai1 and that this interaction is relatively specific 
across a panel of different tetraspanins.  Additionally, the data demonstrates 
that the interaction between Tspan18 and Orai1 is very robust, being able to 
withstand stringent lysis conditions beyond that of the well characterised 
interactions between CD9 and CD9P-1 and Tspan14 and ADAM10.  The 
cross-linking experiment also highlights the cell surface localisation of this 
interaction, as DTSSP, which is membrane impermeable, enhances the 
interaction.  Finally, the data also demonstrates that the chimera has a 
reduced affinity for Orai1, as stabilisation of the interaction via cross-linking is 
required under stringent lysis conditions. 
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Figure 4.6 – Tspan18 interacts with Orai1.  HEK293T cells were transfected using PEI 
with Myc-tagged Orai1 or CD9P-1 and either an empty vector control, or a FLAG-tagged 
tetraspanin.  Cells were lysed in 1% digitonin and immunoprecipitated with an anti-FLAG 
antibody.  Samples were separated by SDS-PAGE and both immunoprecipitated and whole 
call lysate samples blotted with anti-FLAG and anti-Myc antibodies, a representative blot is 
shown (A).  The blots were visualised using the Odyssey infra-red imaging system (LI-COR) 
and band intensity quantitatively measured (B).  All data were normalised by logarithmic 
transformation, and data for Orai1 immunoprecipitation were analysed by one-way ANOVA 
and Dunnet’s post test and data for CD9P-1 immunoprecipitation were analysed by T-test (** 
denotes P < 0.01, ***denotes P < 0.001).  Error bars represent standard error of the mean 
from 3 separate experiments. 
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Figure 4.7 – Tspan18 interacts with Orai1 under stringent lysis conditions.  HEK293T 
cells were transfected using PEI with Myc-tagged Orai1 or CD9P-1 and either an empty 
vector control, or a FLAG-tagged tetraspanin.  Cells were lysed in 1% triton with 0.1% SDS 
and immunoprecipitated with an anti-FLAG antibody.  Samples were separated by SDS-
PAGE and both immunoprecipitated and whole call lysate samples blotted with anti-FLAG 
and anti-Myc antibodies, a representative blot is shown (A).  The blots were visualised using 
the Odyssey infra-red imaging system (LI-COR) and band intensity quantitatively measured 
(B).  All data were normalised by logarithmic transformation, data for Orai1 
immunoprecipitation were analysed by one-way ANOVA and Dunnet’s post test and data for 
CD9P-1 immunoprecipitation were analysed by T-test (** denotes P < 0.01).  Error bars 
represent standard error of the mean from 3 separate experiments.  
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Figure 4.8 – A comparison of the Tspan18-Orai1 interaction under weak and stringent 
lysis conditions.  HEK293T cells were transfected using PEI with Myc-tagged Orai1 or 
ADAM10 and either an empty vector control or a FLAG-tagged tetraspanin.  Cells were 
incubated with either the chemical cross-linker DTSSP or PBS, then lysed in 1% Triton X-
100 lysis buffer containing 0.1% SDS and immunoprecipitated with an anti-FLAG antibody.  
Samples were separated by SDS-PAGE and both immunoprecipitated and whole call lysate 
samples blotted with anti-FLAG and anti-Myc antibodies, a representative western blot is 
shown (A).  The blots were visualised using the Odyssey infra-red imaging system (LI-COR) 
and band intensity quantitatively measured (B).  All data were normalised by logarithmic 
transformation and analysed by one-way ANOVA and Tukey’s multiple comparison test (** 
denotes P < 0.01, *** denotes P < 0.001).  Error bars represent standard error of the mean 
from 4 separate experiments.  
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4.3.5 Tspan18 preferentially interacts with de-glycosylated Orai1 
Orai1 has an N-linked glycosylation site at N223 in the extracellular loop 
between the third and fourth transmembrane domains (Prakriya et al., 2006).  
The glycosylated form of Orai1 was identified due to the appearance of a 
band at a higher molecular weight than predicted from the amino acid 
sequence when western blotting for Orai1; deglycosylated Orai1 is observed 
at approximately 35 kDa and the glycosylated form at 45 kDa (Gwack et al., 
2007; Prakriya et al., 2006).  The interaction observed between Tspan18 and 
Orai1 in the immunoprecipitation experiments conducted in this chapter 
occurred only with a form of Orai1 at approximately 35 kDa (see figures 4.5 – 
4.8). 
To test whether Tspan18 preferentially interacts with de-glycosylated Orai1, 
Tspan18 or empty vector control (pEF6) were expressed in HEK293T cells 
alongside Orai1.  Samples were then lysed in 1% digitonin, treated with 
PNGase F (Sigma); an endoglycosidase, which cleaves N-linked 
glycoproteins at the link between asparagine and N-acetylglucosamines 
(Maley, Trimble, Tarentino, & Plummer, 1989) or PBS control, 
immunoprecipitated and western blotted as described previously.  Following 
treatment with PNGase and immunoprecipitation for the Myc tag of Orai1 to 
enrich for this protein, only one band of approximately 35 kDa was observed 
(figure 4.9), representing de-glycosylated Orai1.  However, without treatment 
with PNGase, two bands were observed at approximately 35 and 45 kDa 
(figure 4.9), representing glycosylated and de-glycosylated Orai1 respectively.  
When samples were immunoprecipitated for the FLAG tag of Tspan18 rather 
than the Myc tag of Orai1, only the lower molecular weight band at 
 - 156 - 
approximately 35 kDa, representing de-glycosylated Orai1 was observed, with 
or without pre-treatment with PNGase (figure 4.9).   
This clearly shows the two forms of Orai1; glycosylated and de-glycosylated 
and also demonstrates that Tspan18 only interacts with de-glycosylated 
Orai1. 
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Figure 4.9 – Tspan18 interacts with the de-glycosylated form of Orai1.  HEK293T cells 
were transfected using PEI with Myc-tagged Orai1 and either an empty vector control or 
FLAG-tagged Tspan18.  Cells were lysed in 1% digitonin and immunoprecipitated with an 
anti-FLAG antibody.  Samples were split and half treated with PNGase to cleave all N-linked 
glycosylations.  Samples were separated by SDS-PAGE and both immunoprecipitated and 
whole cell lysate samples blotted with anti-FLAG and anti-Myc antibodies.  A representative 
western blot is shown from two separate experiments. 
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4.4 DISCUSSION 
 
The research completed in this chapter was focussed around three key aims; 
to investigate which region of Tspan18 was important for activation of the 
Ca2+-responsive NFAT reporter, which has been previously investigated 
(Colombo, 2010), to assess the role of Orai1 in Tspan18-induced NFAT 
reporter activation, and to identify whether Tspan18 interacted with Orai or 
STIM proteins. The data presented in this chapter demonstrated that the 
variable region within the large extracellular loop of Tspan18 is sufficient to 
activate the NFAT reporter.  Also, that Tspan18 is dependant on functioning 
Orai1 to induce Ca2+ signalling.  Additionally, an interaction between Tspan18 
and the Orai family of Ca2+ entry channels was observed; this interaction 
appeared to occur preferentially with only the de-glycosylated form of Orai1 
and does appear to occur at the cell surface, within the HEK293T cell over-
expression system.  Together, these data strongly suggest a role for Tspan18 
in regulation of SOCE via interaction with the Ca2+ channel Orai1. 
The observation that the Tspan18-CD9 chimera was able to activate the 
NFAT reporter, confirmed that the variable region alone is sufficient to 
replicate the function of Tspan18 in the context of an intact tetraspanin.  This 
could suggest that an interaction forms between Tspan18 and its partner 
protein via this variable region and that this interaction could be responsible 
for downstream Ca2+ signalling and NFAT activation.  This would not be a 
novel idea within the tetraspanin field, as the variable region within the large 
extracellular loop across the tetraspanin family has often been suggested as 
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the most likely region for protein-protein interactions (Stipp, Kolesnikova, & 
Hemler, 2003).  Several examples have been shown where the variable 
region of a tetraspanin is vital for normal function of the partner protein; 
association of CD151 with specific integrins occurs via a region within the 
large extracellular loop (Kazarov, Yang, Stipp, Sehgal, & Hemler, 2002), the 
high affinity interaction of CD81 with the E2 envelope protein of HCV requires 
the variable region (Higginbottom et al., 2000), and the variable region within 
the large extracellular loop of CD9 is important for normal adhesive function of 
ICAM-1 and VCAM-1 on endothelial cells during leukocyte extravasation 
(Barreiro et al., 2005). 
Despite the functional ability of the chimera to activate the NFAT reporter, the 
interaction between Orai1 and the chimera was not maintained under 
stringent lysis, suggesting that this interaction was not as robust as that 
between Tspan18 and Orai1.  This implies that domains other than the 
variable region of Tspan18 may be important in either maintaining a strong 
interaction with Orai1, or regulating the localisation of the tetraspanin to allow 
maximal interaction with Orai1.  Domains other than the variable region within 
the large extracellular loop of tetraspanins have been shown to be important 
in interaction with partner proteins.  For example, the transmembrane region 3 
of the tetraspanin uroplakins is important for partner protein interaction (Min et 
al., 2006) and the EWI-2 interaction with the tetraspanin CD81 is reliant on 
transmembrane regions 3 and 4 (Montpellier et al., 2011).  Therefore, 
domains from CD9 within the chimera could be partially disrupting the 
interaction. 
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The interaction between Tspan18 and Orai1 appeared to occur at the cell 
surface, as demonstrated by the cross-linking experiment.  The cell surface 
cross-linker used, DTSSP, is membrane impermeable, therefore the increase 
in band intensity representing the Tspan18-Orai1 interaction under cross-
linked conditions must represent cell surface interaction only.  Tspan18 has 
previously been observed at the cell surface in stably transfected Jurkat T 
cells, using a surface biotinylation approach (Tomlinson, unpublished data).  
Together this suggests that Tspan18 may be interacting with and regulating 
Orai1 at the cell surface, though further investigation is required to 
characterise the nature of the interaction and the effect it has on Orai1 
function. 
The observation that Tspan18 interacts with the SOCE channel Orai1 
supports the hypothesis that Tspan18 is involved in regulation of Ca2+ 
signalling; however the precise mechanism is still not known.  Typically, 
tetraspanins regulate the function of their partner proteins in one of several 
key mechanisms.  The TspanC8 sub family of tetraspanins, which all interact 
with the metalloproteinase ADAM10, regulate the biosynthesis and maturation 
of this protein (Dornier et al., 2012; Haining et al., 2012; Prox et al., 2012).  It 
has also been speculated that these tetraspanins could be taking ADAM10 to 
specific locations in the cell.  The tetraspanins CD9 and CD151 interact with 
and regulate the endothelial adhesion molecules ICAM-1 and VCAM-1 by 
clustering these proteins to form adhesive platforms for optimal leukocyte 
capture and extravasation at points of inflammation (Barreiro et al., 2008, 
2005).  Also, analysis of the lateral mobility of tetraspanins within the plasma 
membrane has shown highly dynamic interactions within tetraspanin enriched 
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microdomains, which could therefore impact on the lateral mobility of partner 
proteins (Espenel et al., 2008).  The mechanism by which Tspan18 may 
regulate Orai1 could involve any of these processes.  It is possible that the 
interaction observed between the chimera and Orai1 is due to a clustering 
mechanism.  For example, the formation of complexes between Tspan18 and 
Orai1 as well as interactions formed between the chimera and Tspan18 could 
allow association of the chimera with Orai1 through incorporation into the 
tetraspanin microdomain.  Therefore, the less direct interaction between the 
chimera and Orai1 may result in a less robust interaction which cannot 
withstand stringent lysis conditions.  
It is interesting that Tspan18 only interacts with de-glycosylated Orai1, and 
this observation could provide clues to the mechanism by which Tspan18 
regulates this Ca2+ channel.  One hypothesis is that the interaction between 
these proteins occurs early in the biosynthesis of Orai1, prior to addition of 
post-translational modifications.  However, the interaction between Tspan18 
and Orai1 might not be limited to a role in early-stage biosynthesis.  It has 
been shown that the de-glycosylated form of Orai1 is fully functional in its 
localisation and in its ability to allow flux of Ca2+ into the cell (Gwack et al., 
2007).  It could be possible that interaction with Tspan18 protects Orai1 from 
glycosylation and that de-glycosylated Orai1 has a specific and separate 
function in the cell.  As the role of glycosylation on Orai1 and the affects that 
glycosylation has on its function have not yet been elucidated, it is difficult to 
predict why Tspan18 preferentially interacts with only the de-glycosylated 
form of this Ca2+ channel. 
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Further work is required to fully elucidate the mechanism by which Tspan18 
may be regulating its partner protein, Orai1. 









THE HAEMOSTASIS DEFECT IN TSPAN18 KNOCKOUT MICE 
IS DUE TO TSPAN18 DEFICIENCY IN NON- HAEMATOPOIETIC 
CELLS  
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5. 1 INTRODUCTION 
 
5.1.1 Tspan18 is an endothelial tetraspanin 
Investigating the expression profile of Tspan18 is difficult due to the lack of 
antibodies; however Tspan18 expression can be monitored at the mRNA 
level.  One study, which utilised publicly available large scale transcriptomic 
data from serial analysis of gene expression experiments, revealed that 
Tspan18 is more highly expressed in endothelial versus non-endothelial 
libraries (Bailey et al., 2011).  Other studies using quantitative real time PCR 
identified Tspan18 at higher levels in human endothelial cells such as HUVEC 
and HMEC than other cell types such as smooth muscle cells, fibroblasts, 
hepatocytes, and cell lines of haematopoietic and non-haematopoietic origin 
(Colombo, 2010).  Additionally, real time PCR on a range of mouse tissues 
including brain, heart, kidney, liver, lung, muscle, spleen and thymus, found 
Tspan18 mRNA levels to be highest in lung, suggesting an endothelial 
expression profile (Colombo, 2010).  However, the role of Tspan18 on 
endothelial and other non-haematopoietic cells has not been studied. 
 
5.1.2 The role of non-haematopoietic cells in haemostasis 
The process of haemostasis is regulated not only by platelet activation and 
thrombus formation, but also by contributions of non-haematopoietic cells, 
including endothelial cells and smooth muscle cells.  Vasoconstriction occurs 
at sites of injury to narrow the vessel and reduce blood flow, thus reducing 
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blood loss (van Hinsbergh, 2012).  This process requires the contraction of 
vascular smooth muscle cells, which is regulated by vasoconstrictive agents 
and through activation of the nervous system (van Hinsbergh, 2012).  Just 
one example of the multiple stimuli which acts as a vasoconstrictor is TxA2.  
TxA2 is released by platelets and induces contraction of vascular smooth 
muscle via activation of a G protein coupled pathway leading to increased 
intracellular Ca2+ concentrations, activation of myosin light chain kinase and 
muscle cell contraction (Wilson et al., 2005).  The nervous system can also 
induce vasoconstriction, through production and release of norepinephrine 
from stimulated neurons of the sympathetic nervous system (Thomas, 2011).  
Norepinephrine can then go on to stimulate smooth muscle cell contraction, 
through increasing intracellular Ca2+ concentration, thus driving 
vasoconstriction (Thomas, 2011).  
The endothelium can provide both negative signals to regulate haemostasis in 
normal vessels, and positive signals to promote thrombus formation at sites of 
vascular injury.  The endothelium can inhibit platelet activation through 
release of inhibitory molecules such as PGI2 and NO, and through expression 
of cell surface receptors, such CD39, which hydrolyses platelet-released ADP 
to prevent platelet activation (Becker, Heindl, Kupatt, & Zahler, 2000; Marcus 
et al., 1997; van Hinsbergh, 2012).  When necessary, the endothelium can 
stimulate platelet activation and the clotting cascade via release of clotting 
factors such as vWF and FVIII.  vWF mediates the adhesion of platelets to the 
exposed sub-endothelial matrix at sites of vascular injury.  A small amount of 
vWF is produced in megakaryocytes and is stored in α-granules in platelets, 
to be released upon platelet activation (Blann, 2006).  However, the majority 
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of vWF is stored in, and released from Weibel-Palade bodies within 
endothelial cells (Blann, 2006).  Endothelial vWF alone has been shown to be 
sufficient to support haemostasis (Kanaji et al., 2012), and interestingly, 
exocytosis of the contents of Weibel-Palade bodies, following vessel injury, is 
regulated by increased intracellular Ca2+ signalling (Rondaij, Bierings, Kragt, 
van Mourik, & Voorberg, 2006).  The clotting factor, FVIII is closely associated 
with vWF via a direct interaction which acts to stabilise FVIII in the blood 
stream (Everett et al., 2014).  Upon activation initiated by a response to injury, 
FVIII dissociates from vWF and promotes the clotting cascade via interaction 
with other clotting factors.   
 
5.1.3 Use of chimeric mice to investigate the role of Tspan18 in 
haemostasis  
As described in the first results chapter, Tspan18 deficient mice displayed a 
severe disruption to haemostasis, as they bleed significantly more than 
wildtype mice in a tail bleeding assay.  This is despite normal thrombus 
formation in vivo and only a mild platelet functional defect.  Additionally, the 
bleeding observed appears more severe than that documented for either 
GPVI deficient mice (B Nieswandt, Schulte, et al., 2001), or mice with Orai1 
deficient platelets (Braun et al., 2009), which suggests that the platelet defects 
alone can not explain the haemostasis phenotype observed.  To investigate 
the role of non-haematopoietic cells in haemostasis, it is possible to use 
chimeric mice with different haematopoietic and non-haematopoietic 
compartments.  To generate chimeric mice, whole embryonic livers were 
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harvested from the embryos of pregnant Tspan18 wildtype or Tspan18 
deficient mice.  A single cell suspension was generated from the whole liver 
and transplanted into lethally irradiated C57BL/6 wildtype or Tspan18 deficient 
mice to reconstitute the haematopoietic system.  Therefore, mice with 
Tspan18 deficient platelets and wildtype endothelium (and other non-
haematopoietic cells) as well as mice with Tspan18 deficient endothelium 
(and other non-haematopoietic cells) and wildtype platelets were generated. 
 - 168 - 
5.2 AIMS 
The aim of this chapter was to investigate the mechanism behind the bleeding 
phenotype observed in the Tspan18 deficient mice.  By generating chimeric 
animals with wildtype haematopoietic cells and Tspan18 knockout non-
haematopoietic cells, and vice versa, the role of haematopoietic and non-
haematopoietic Tspan18 in haemostasis could be assessed. 
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5.3 RESULTS 
 
5.3.1 Non-haematopoietic cells appear to drive the disruption to 
haemostasis in Tspan18 deficient mice 
To investigate the role of Tspan18 in haemostasis and to elucidate the effects 
of platelet Tspan18 as opposed to non-haematopoietic Tspan18, chimeric 
mice were generated from both C57BL/6 wildtype mice and Tspan18 deficient 
mice, using lethal irradiation and injection of embryonic liver cells to 
reconstitute the haematopoietic system, as outlined in section 5.1.3.  The tail 
bleeding assay was then repeated. 
When assessed using the tail bleeding assay described in chapter 3, the 
C57BL/6 recipient mice did not bleed, whether they had Tspan18 wildtype or 
Tspan18 deficient platelets and other haematopoietic cells (figure 5.1).  When 
Tspan18 deficient chimeras with either knockout or wildtype haematopoietic 
cells were tested, a significant increase in bleeding was observed.  The 
bleeding mimicked the pattern observed for the Tspan18 whole body 
knockout mice, in which a heterogeneous population was observed, as some 
of the mice bled and some did not (figure 5.1).  The chimeric mice were bled 
alongside 8 litter matched pairs of whole body Tspan18 wildtype or knockout 
animals as controls and, as previously, the Tspan18 deficient mice displayed 
an increase in bleeding and a highly heterogeneous population was observed 
whereas the wildtype mice did not bleed (figure 5.1).   
These data demonstrate that mice with Tspan18 wildtype non-haematopoietic 
cells do not have a disruption to haemostasis, whereas mice with Tspan18 
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knockout non-haematopoietic cells display a disruption to haemostasis, 
regardless of the genotype of the haematopoietic cells.  This suggests that the 
platelets in the Tspan18 deficient mice do not drive the bleeding phenotype, 
therefore suggesting a non-haematopoietic driving force behind the bleeding 
observed.  
Genotyping analysis of post-transplant blood samples was carried out to 
assess success of the reconstitution of the haematopoietic system from the 
transplanted cells.  Genomic DNA was isolated from white blood cells and 
used for PCR using primers specifically for wildtype Tspan18 (visualised at 
376 bp) and gene targeted Tspan18 (visualised at 227 bp).  In recipients of 
wildtype embryonic liver cells, only a band at 376 bp was visualised, 
representing wildtype Tspan18.  In recipients of knockout embryonic liver 
cells, only a band at 227 bp was visualised, representing disrupted Tspan18 
(figure 5.2).  This demonstrated successful reconstitution of the 
haematopoietic system from the transplanted cells, and that generation of the 
chimeric animals had been achieved.  Bands at both 376 bp and 227 bp were 
observed for tail tip tissue harvested from the mice post-transplant (figure 
5.2).  The appearance of both bands suggests both Tspan18 wildtype and 
deficient cells were present, which would be expected, as some blood 
contamination could have occurred during harvesting of this tissue which 
would mean that both haematopoietic and non-haematopoietic cells may have 
been present. 
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Figure 5.1 – Normal haemostasis in the tail bleeding assay in C57BL/6 chimeric mice, 
but impaired haemostasis in Tspan18-/- chimeric mice.  The tail tip of anaesthetised mice 
was amputated and amount of blood lost was measured.  Each symbol represents an 
individual.  Data were analysed by Fisher’s exact test; individuals were ranked as ‘bleeding’ 
or ‘not bleeding’ where ‘bleeding’ was defined as one or more drop of blood, equivalent to 30 
µl lost (* denotes P < 0.05, *** denotes P < 0.001).  Data displayed is either the % of total 
permitted blood loss (A); each mouse was permitted to lose a maximum of 15% of total blood 
determined by body weight, due to restrictions on the Home Office animal licence, or as total 
volume of blood lost with a bracket to indicate termination of the assay for individuals which 
lost 100% of permitted blood (B).  Non-chimeric mouse data is a reproduction of all collated 
data for Tspan18 wildtype and knockout individuals, including 8 pairs which were bled in 
parallel to the chimeric mice. 
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Figure 5.2 – Validation of Tspan18 chimeric mice by genotyping.  6-week old wildtype 
C57BL/6 (A) or Tspan18-/- (B) recipient mice were lethally irradiated prior to injection with 
embryonic liver cells from either Tspan18 deficient or wildtype mice.  The mice recovered 
over 6 weeks to enable reconstitution of the haematopoietic system from the transplanted 
cells.  Tissue samples were taken before transplantation and blood and tissue samples were 
taken after reconstitution of the haematopoietic system.  Genomic DNA was isolated from the 
samples and the PCR products run on a gel to visualise Tspan18 wildtype and gene targeted 
bands (wildtype Tspan18 PCR product is visualised at 376 bp and disrupted Tspan18 PCR 
product visualised at 227 bp).  A representative gel is shown. 
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5.3.2 Plasma levels of endothelial-derived clotting factors vWF and FVIII 
are normal in Tspan18 deficient mice 
One known impact that the endothelium has on haemostasis is biosynthesis 
and release of specific clotting factors which, as described earlier, can act to 
promote platelet activation and the clotting cascade.  As demonstrated by the 
data presented earlier in this chapter, non-haematopoietic cells appear to be 
driving the bleeding observed in Tspan18 deficient mice.  Tspan18 is 
expressed in endothelial cells; therefore it is possible that an endothelial-
derived defect is driving the bleeding. 
To investigate the cause of the potentially endothelial-driven bleeding in the 
Tspan18 deficient mice, plasma concentrations of specific clotting factors 
were measured by ELISA.  Blood was taken from anaesthetised mice and the 
plasma was separated by centrifugation.  Mouse plasma concentration of 
vWF was measured using pre-coated micro-titre ELISA plates from BT-
Laboratory and mouse plasma concentration of FVIII was measured using 
pre-coated micro-titre ELISA plates from My Biosource.  The plasma 
concentration of both vWF and FVIII was found to be normal in plasma from 
Tspan18 deficient mice when compared to plasma from wildtype mice (figure 
5.3 A and B). 
Therefore endothelial Tspan18 does not appear to have a role in regulation of 
the basal levels of plasma vWF or FVIII.  This suggests that either another 
mechanism, involving endothelial, or other non-haematopoietic cells, could be 
causing the bleeding in the Tspan18 deficient mice, or that Tspan18 might 
have a more complex role in regulating the function of these clotting factors; 
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the latter could be regulation of their release upon injury by Tspan18, which, 
in the case of vWF, has been previously shown to be a Ca2+ dependant 
mechanism (Rondaij et al., 2006).  
















































































































































































Figure 5.3 – Tspan18 deficient mice have normal levels of plasma vWF and FVIII.  
Blood was taken from anaesthetised mice and the plasma was isolated from whole blood by 
centrifugation.  Concentration of vWF and FVIII was assessed by ELISA, using pre-coated 
micro-titre plates from BT-Laboratory for vWF (A) or My Biosource for FVIII (B).  Error 
bars represent the standard error of the mean from 4 pairs of mice.  All data were analysed by 
T-test. 
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5.3.3 Knockdown of Tspan18 in HUVEC appears to disrupt endothelial 
cell function 
As a preliminary investigation into the potential role of Tspan18 on endothelial 
cells, in vitro assays using HUVEC were employed.  Expression of Tspan18 
was disrupted using two different siRNA duplexes in comparison to a control 
siRNA duplex. Optimisation of knockdown is outlined in appendix 2. 
The first method of assessing endothelial cell function was the scratch wound 
assay; a confluent monolayer of HUVEC was wounded using a pipette tip and 
the migration of the cells to close the wound was monitored using time-lapse 
microscopy.  In HUVEC which had been treated with the Tspan18 siRNA.1 
duplex, a significant reduction in wound closure was observed at 6 and 12 
hours post-wounding, in comparison to cells treated with the control siRNA 
(figure 5.4 A-C).  Tspan18 knock down for both duplexes was assessed by 
real-time PCR, in comparison to the control siRNA (figure 5.4, D). 
The second endothelial function assay was a co-culture tube-formation assay, 
in which HUVEC were cultured alongside fibroblasts and the formation of 
tube-like structures was assessed (figure 5.5, A).  The number of junctions 
formed appeared to be reduced in HUVEC treated with either Tspan18 siRNA 
duplex (figure 5.5, C), though the length of the tubules and the number of 
tubules formed appeared mainly undisrupted (figure 5.5, A and D).  Tspan18 
knock down for both duplexes was assessed by real-time PCR, in comparison 
to the control siRNA (figure 5.5, E).  











































































































































Figure 5.4 – Tspan18 knockdown disrupts endothelial function in a scratch wound 
assay.  Tspan18 expression was disrupted in HUVEC using siRNA.  The HUVEC were 
grown to be confluent before scratching a wound through the monolayer of cells with a 
pipette tip.  Time-lapse microscopy was used to monitor the migration of the cells to close the 
wound; representative images are shown (A).  Images were analysed using ImageJ software at 
6 (B) and 12 (C) hours post-wounding, to quantitatively measure wound closure.  All data 
were normalised by arcsin transformation and analysed by one-way ANOVA with Dunnet’s 
multiple comparison (* denotes P < 0.05, ** denotes P < 0.01).  Relative Tspan18 mRNA 
levels were assessed by real time PCR (D).  Error bars represent the standard error of the 
mean from 3 separate experiments. 
 










































































































































































































Figure 5.5 – Tspan18 knockdown disrupts endothelial function in a tube formation 
assay.  Tspan18 expression was disrupted in HUVEC using siRNA and the HUVEC were 
seeded onto fibroblasts in a co-culture environment and cultured for 6 days to allow tube-like 
structures to form.  The HUVEC were then fixed and stained for CD31, using an alkaline 
phosphatase conjugated secondary antibody for visualisation under a light microscope.  
Representative images are shown (A).  The images were analysed by thresholding; the length 
of tubules (B), number of junctions (C) and number of tubules (D) were measured.  Relative 
mRNA levels were assessed by real time PCR (E).  Error bars represent the standard error of 
the mean from 2 separate experiments. 
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5.4 DISCUSSION 
 
The main aim of the work in this chapter was to investigate the role of 
Tspan18 in haemostasis and to investigate whether non-haematopoietic 
derived dysfunction was the cause of disrupted haemostasis in the Tspan18 
deficient mice.  Chimeric mice derived from C57BL/6 wildtype animals 
displayed no bleeding phenotype, whether they had wildtype or Tspan18 
deficient haematopoietic cells.  However, chimeric mice derived from Tspan18 
deficient animals displayed an increase in bleeding, whether they had 
wildtype or Tspan18 deficient haematopoietic cells, suggesting that the 
disrupted haemostasis in Tspan18 deficient mice is driven by defects in non-
haematopoietic cells.  Interestingly, Tspan18 is known to be expressed in 
endothelial cells; a cell type which plays multiple roles in haemostasis.  It is 
therefore possible that endothelial Tspan18 has a role in regulation of 
haemostasis.  However, the bleeding was not caused by disruption to basal 
plasma concentration of endothelial released vWF or FVIII.  Preliminary 
investigation into the role of Tspan18 on endothelial cells appeared to 
highlight a role for Tspan18 in endothelial cell migration and tube formation, 
though further experiments are required to confirm these results. 
The generation of chimeric mice, using embryonic foetal liver cells to 
reconstitute the haematopoietic system enabled the roles of Tspan18 in 
haematopoietic and non-haematopoietic cells within the process of 
haemostasis to be investigated. Use of foetal liver to reconstitute the 
haematopoietic system in mice is a widely used method, as embryonic stem 
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cells from the liver are able to provide long term reconstitution across the 
range of haematopoietic cell lineages (Ema & Nakauchi, 2015; Forrester et 
al., 1991).  Use of PCR to genotype the chimeric mice demonstrated that the 
reconstitution method was successful and that only a minimal, if any, 
population of original haematopoietic cells remained after irradiation.  Use of 
this method to drawn conclusions on the role of Tspan18 in haemostasis 
relies on the assumption that the platelets derived from the embryonic liver 
stem cell lineages have the same biology and function as those which were 
derived from the original adult mouse stem cells, prior to irradiation.  In order 
to better understand this, platelet function tests such as those completed in 
chapter 3, could be completed on the reconstituted platelets from the chimeric 
mice, to assess whether they function in the same way as normal adult 
platelets. 
Interestingly, the severity of bleeding observed in either Tspan18 deficient 
mice or the chimeric mice derived from Tspan18 deficient mice appears to 
vary widely across the population.  This is in contrast to the largely consistent 
results observed for Tspan18 wildtype mice, which do not bleed.  The unequal 
variance between these populations represents the heterogeneity within the 
Tspan18 knockout mice.  Why there would be such a high levels of variance 
within this population is not known, but it suggests that certain individuals are 
more susceptible to bleeding than others.  Similar results have been observed 
for the tail bleeding assay previously, as mice deficient in the tyrosine 
phosphatase CD148 demonstrated a bimodal distribution of bleeding (Y. A. 
Senis et al., 2009).  Additionally, a similar distribution was also observed for 
GPVI deficient mice which had been generated on a mixed 129 x1 / SvJ x 
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C57Bl/6J background (Cheli et al., 2008).  Through use of a genome wide 
single-nucleotide polymorphism screen, a modifier locus was identified, which 
was shown to affect the extent of disruption to haemostasis following GPVI 
deficiency (Cheli et al., 2008).  Interestingly, the Tspan18 knockout mice were 
also generated on a mixed background (Tang et al., 2010).  Therefore, the 
bimodal distribution of bleeding observed in the Tspan18 knockout mice could 
be the result of contribution of a modifier locus.  Alternatively, the bimodal 
population could be the result of another factor, for example affects of the 
environment.  If the bleeding phenotype is weak, but is exacerbated by stress, 
for example, then the increase in bleeding could be observed only in some 
individuals, when stress becomes a secondary factor. 
As Orai1 has been identified as a novel partner protein for Tspan18 (see 
chapter 4), it is possible that Tspan18 is regulating Orai1 and Ca2+ signalling 
in endothelial cells.  A disruption to endothelial Ca2+ signalling due to Tspan18 
deficiency could impact on endothelial function and may drive the bleeding 
phenotype observed.  However, it is also possible that Tspan18 could be 
interacting with a different partner protein and altering endothelial cell function 
in a different way.  It would be interesting to assess the Orai1 endothelial cell 
specific knockout mouse for disruptions to haemostasis and to see whether 
these mice might phenocopy the results observed for Tspan18 knockout mice. 
Although the basal plasma concentration of vWF and FVIII appear to be 
normal in Tspan18 deficient mice, it is still possible that Tspan18 has a role in 
regulation of one or both of these clotting factors.  Deficiency or defective 
function of vWF is the cause of the bleeding disorder von Willebrand disease 
(vWD) and it might be possible that although the basal concentrations of vWF 
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are normal in Tspan18 deficient mice, there might be another defect which 
has not yet been investigated.  For example, the release of this clotting factor 
following injury could be impaired, therefore studying basal plasma 
concentration alone cannot provide definitive evidence that these factors are 
functioning normally in the blood.  It has been previously shown that release 
of vWF from Weibel-Palade bodies following injury, occurs via a Ca2+ 
regulated process (Rondaij et al., 2006).  It is therefore feasible that although 
basal plasma levels of vWF are normal in the Tspan18 deficient mice, release 
of vWF from the endothelium following injury may well be disrupted, due to 
disrupted Ca2+ signalling, and could be causing the bleeding phenotype 
observed.  An investigation into the injury-induced release of these clotting 
factors in Tspan18 deficient mice is required before a role for Tspan18 in 
regulation of vWF or FVIII function can be dismissed completely.  
The role for Tspan18 in endothelial cells may not involve regulation of vWF or 
FVIII, but may include regulation of another aspect of endothelial function in 
haemostasis. For example, the endothelium can act to reduce thrombus and 
clot formation via inhibition of platelet adhesion and activation (van Hinsbergh, 
2012).  Release of PGI2 by endothelial cells promotes anti-thrombotic effects 
by inhibiting platelet activation (Becker et al., 2000; Salvador Moncada, 1982; 
van Hinsbergh, 2012).  Endothelial cells can also release NO, which aids in 
the platelet-inhibitory actions of PGI2 (van Hinsbergh, 2012).  In order to 
assess whether the levels of NO or PGI2 are disrupted and are causing 
defective haemostasis, plasma concentrations could be measured.  For 
example, to investigate plasma NO levels, a spectrophotometric approach 
could be used, in which plasma NO can be reduced to NO2 for detection by 
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Griess reagent, which induces a colour change in response to high NO2 and 
is therefore used for colorimetric detection of nitrite in samples (Giustarini, 
Rossi, Milzani, & Dalle-Donne, 2008). 
Both the scratch wound assay and the tube formation assay were used to 
assess the effect on endothelial cell function following knockdown of Tspan18. 
In both cases, knockdown of Tspan18 appeared to disrupt endothelial cell 
function, as a reduction in wound closure and a reduction in tube formation 
was observed following disruption of Tspan18.  This suggests that Tspan18 
has a role in regulating normal endothelial cell function, but further work is 
required to confirm these results and to investigate whether endothelial 
Tspan18 has a role in haemostasis, or whether it is involved in another 
endothelial cell process. 
It is possible that the mechanism by which Tspan18 regulates haemostasis 
could be separate from the endothelium, and may involve regulation of other 
cell types, such as vascular smooth muscle.  The fine balance of positive and 
negative regulation of haemostasis is clearly disrupted in Tspan18 deficient 
mice; however to fully understand the mechanism by which Tspan18 may be 
regulating haemostasis, further investigation is required.  Ideally, generation 
of an antibody for Tspan18 is required to be able to confirm the expression 
profile of this tetraspanin and therefore better hypothesise in which cell types 
it may be having an effect.  An antibody against this tetraspanin would also 
enable investigation of endogenous protein and allow assessment of the 
Tspan18-Orai1 interaction at the endogenous level, rather than within an 
over-expression system.  It would be interesting to investigate whether 
Tspan18 interacts with partner proteins other than Orai1, and whether the 
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disruption to haemostasis observed is due to defective Ca2+ signalling and 
SOCE, or whether there is another mechanism.  Ca2+ signalling experiments 
in endothelial cells and other Tspan18 expressing cells would be useful to 
investigate this question. 
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6.1 Summary of key findings 
The main aim of this thesis was to characterise the role of the tetraspanin 
Tspan18 in platelet function.  Generation of the Tspan18 knockout mouse in a 
large scale mouse knockout project (Tang et al., 2010) provided the means to 
characterise the role of Tspan18 in platelets, and use of cell line models 
enabled investigation into the mechanism of Tspan18 action and identification 
of potential binding partners.  Characterisation of Tspan18 deficient platelets 
highlighted a very specific role for Tspan18 in regulation of platelet activation 
downstream of collagen receptor GPVI signalling, as Tspan18 deficient 
platelets displayed defective aggregation, secretion and spreading 
downstream of the GPVI-specific agonist CRP.   Additionally, Tspan18 
deficient platelets had a reduced ability to mobilise Ca2+ following stimulation 
with CRP or collagen and following emptying of intracellular Ca2+ stores, the 
latter suggesting a SOCE defect.  The Tspan18 deficient mice did not display 
any defect in thrombus formation in the two in vivo models tested, but a large 
increase in bleeding was observed in Tspan18 deficient mice compared to 
wildtype controls.  This bleeding defect was concluded to most probably be 
caused by defective non-haematopoietic function, leading to a disruption to 
coagulation, rather than as a direct result of the mild platelet defects.  During 
in vitro analyses, the variable region within the large extracellular loop of 
Tspan18 was shown to be important for Tspan18 to induce an increase in 
activation of a Ca2+ responsive reporter.  Additionally, through use of a 
dominant negative form of the SOCE channel Orai1, the ability of Tspan18 to 
induce increased intracellular Ca2+ was shown to be dependant on functioning 
Orai1 channels.  Finally, through an immunoprecipitation approach, a novel 
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partner protein was identified for Tspan18, as a robust interaction formed 
between Tspan18 and Orai1, for which the variable region was important.  
Taken together, these data highlight a novel tetraspanin-partner protein 
interaction that may outline a role for Tspan18 in regulation of Ca2+ entry by 
regulation of Orai1.  In terms of platelet activation, Tspan18 appears to be 
particularly important in Ca2+ signalling downstream of GPVI activation.  The 
ability of Tspan18 to activate Ca2+ is unique across a panel of different 
tetraspanins (Colombo, 2010) and the interaction between Tspan18 and Orai1 
was specific.  It is unlikely that other tetraspanins would be able to 
compensate for the role of Tspan18, as there are no close relatives to 
Tspan18 with similar sequence and there is no evidence for the closest 
relative, Tspan1, expression on platelets.  The findings in this thesis therefore 
potentially represent a highly specific and unique mechanism. 
 
6.2 The interaction between Tspan18 and Orai1 
The interaction that was observed between Tspan18 and Orai1 is a novel 
tetraspanin-partner protein interaction which has not been observed 
previously.  Although the interaction appeared to be highly robust, as it was 
able to withstand stringent lysis conditions, the interaction consistently only 
occurred with the low molecular weight form of Orai1, corresponding to de-
glycosylated Orai1 (Gwack et al., 2007; Prakriya et al., 2006).  The reason 
behind the specificity of Tspan18 interacting with only de-glycosylated Orai1 is 
unknown, though it is not the first time that Orai1 interacting proteins have 
been shown to preferentially interact with the de-glycosylated form.  During 
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immunoprecipitation experiments using over-expressed Orai1 and STIM1 in 
HEK293T cells, STIM1 was shown to interact with the lower molecular weight 
form of Orai1 (Vig et al., 2006).  Additionally, in experiments using soluble 
STIM1 fragment peptides to identify the regions of STIM1 which are important 
for activation of Orai1, it was shown that a region within the C-terminal of 
STIM1, named the CRAC activation domain (CAD), was sufficient to interact 
with Orai1 and induce channel opening (Park et al., 2009).  When the CAD 
peptide was over-expressed in HEK293T cells alongside Orai1 and 
immunoprecipitation employed, the interaction was observed between CAD 
and the low molecular weight form of Orai1 (Park et al., 2009).  Interestingly, it 
is not only the interaction between Orai1 and STIM1 which has demonstrated 
a preference for the lower molecular weight of the Ca2+ channel.  In a study 
which outlined a role for secretory pathway Ca2+-ATPase (SPCA2) in store-
independent activation of Orai1, immunoprecipitation experiments for both 
endogenous and over-expressed protein demonstrated that the interaction 
which formed was between SPCA2 and the low molecular weight form of 
Orai1 (Feng et al., 2010).  As of yet, there has been no explanation for the 
specific interaction between only the low molecular weight form of Orai1 and 
it’s binding partners.  However, the occurrence of this interaction across 
multiple binding partners and within experiments studying both over-
expressed and endogenous protein, suggests that the interaction of Tspan18 
with only de-glycosylated Orai1 is unlikely to be a co-immunoprecipitation 
artefact. 
Further evidence for the interaction of Tspan18 with Orai1 was outlined 
through use of a cross-linking assay in chapter 4.  The use of a membrane 
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impermeable surface cross-linker increased the signal observed for the 
interaction between Tspan18 and Orai1 and stabilised the interaction between 
the Tspan18/CD9 chimeric construct and Orai1.  This suggests that the 
interaction between Tspan18 and Orai1 is preserved at the cell surface. 
It is interesting that Tspan18 also appeared to interact with the other members 
of the Orai family; Orai2 and Orai3.  However, the extent of these interactions 
were not investigated as far as the interaction with Tspan18 and Orai1, 
therefore it is not possible to discern the importance or relevance of these 
interactions.  It is possible that Tspan18 only interacts with Orai2 and Orai3 
indirectly, mediated by a common interaction with Orai1.  It would be possible 
to test to robustness of these interactions using more stringent lysis 
conditions. 
 
6.3 The mechanism of Tspan18 action 
Despite the functional studies completed in both cell line models and the 
Tspan18 deficient platelets which suggested a role for Tspan18 in Ca2+ 
mobilisation, the mechanism of action of this tetraspanin is still unknown.  As 
Tspan18 has been shown to interact with Orai1, it is reasonable to 
hypothesise that the interaction between Tspan18 and this Ca2+ channel 
could be regulating its function and thus effecting Ca2+ flux into the cell, as 
outlined in figure 6.1 A.  However, exactly how Tspan18 is regulating Orai1 is 
more difficult to predict, as there are several viable mechanisms which may 
occur. 
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Firstly, as outlined in figure 6.1 B, Tspan18 could be regulating the 
biosynthesis, trafficking and therefore expression of Orai1.  Tetraspanins have 
previously been observed regulating the expression and biosynthesis of their 
partner proteins.  For example, the tetraspanin CD81 is required for trafficking 
of its partner, CD19, from the ER to the golgi and thus regulates the cell 
surface expression of CD19 (Shoham et al., 2003; Zelm et al., 2010).  
Additionally, the TspanC8 subfamily of tetraspanins have all been shown to 
interact with ADAM10, regulating its maturation, cell surface expression and 
proteolytic activity (Dornier et al., 2012; Haining et al., 2012; Prox et al., 
2012).  As other tetraspanins have been shown to interact with their partner 
proteins early during their biosynthesis, it is possible that Tspan18 interacts 
with Orai1 early in biosynthesis, within the ER or the golgi, and thus has a role 
in regulating its expression at the cell surface.  SOCE is known to be highly 
sensitive to expression levels of both STIM and Orai proteins.  Over-
expression studies have shown that an imbalance of these proteins can 
disrupt SOCE, as over-expression of Orai without STIM, or visa versa, 
disrupts SOCE and reduces Ca2+ influx into the cell (Mercer et al., 2006; 
Soboloff et al., 2006).  This clearly demonstrates the need for balance of both 
STIM and Orai expression for SOCE to occur optimally.  Tspan18 could have 
a role in maintaining the correct levels of Orai1 in the cell for optimal SOCE.  
In order to begin to assess the potential role of Tspan18 in regulation of Orai1 
expression, Orai1 antibodies were characterised for use in western blotting 
and immunoprecipitation experiments, as outlined in appendix 3.  Two 
commercially available Orai1 antibodies were shown to western blot over-
expressed human Orai1 protein in transfected HEK293T cells, but the level of 
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endogenous Orai1 in mouse platelets was either too low to detect, or the 
antibodies might not detect mouse Orai1 as well as human Orai1 (appendix 
figure 3a).  Initial characterisation of the antibodies for immunoprecipitation 
was completed in human platelets (appendix figure 3b).  To test the 
hypothesis that Tspan18 regulates the expression levels of Orai1, these 
antibodies could now be used for immunoprecipitation of Orai1 from wildtype 
and Tspan18 deficient platelets, followed by western blotting to detect 
endogenous expression levels in the presence and absence of Tspan18.  
Additional techniques, such as flow cytometry could also be utilised to assess 
the cell surface expression of Orai1 in Tspan18 knockout vs wildtype 
platelets, to assess the correct surface localisation of the protein as well as 
overall expression.  However, this would rely on the use of good antibodies to 
the extracellular region of Orai1, which are not currently available. 
Another feasible hypothesis, depicted in figure 6.1 C, is that Tspan18 may be 
regulating and facilitating the clustering of Orai1.  One key example of 
tetraspanin proteins which facilitate clustering of their partner protein is the 
role that CD9 and CD151 play in regulation of ICAM-1 and VCAM-1, which 
are vital during leukocyte extravasation during inflammation.  These 
tetraspanins promote formation of nano-platforms of these endothelial 
adhesion molecules, by clustering ICAM-1 and VCAM-1 to allow more 
efficient adhesion and transmigration of leukocytes (Barreiro et al., 2008, 
2005; Nourshargh et al., 2010).  Tspan18 could potentially be facilitating 
formation of functional Orai1 channels through clustering of Orai1 monomers 
in the membrane.  As discussed in detail in chapter 1, the formation of Orai1 
channels is not well characterised.  Some groups have suggested that Orai1 
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channels are formed of 4 separate subunits (Ji et al., 2008; Maruyama et al., 
2009; Mignen et al., 2008) and some have proposed 6 subunits are required 
(Hou et al., 2012).  Some studies have outlined the presence of preformed 
channels in the membrane, which only require activation to allow Ca2+ influx 
into the cell (Madl et al., 2010), whereas other groups suggest that resting 
Orai1 is found as a dimer and that dimerisation of these dimers must occur for 
channel activation (Penna et al., 2008).  It is possible that Tspan18 could be 
associated with Orai1 monomers and have a role in the regulation of 
clustering these monomers into higher order complexes to promote formation 
of Orai1 channels.  Alternatively, Tspan18 could be involved in channel 
activation rather than channel formation, by providing a platform for preformed 
Orai1 channels to cluster, therefore inducing formation of Orai1-rich puncta to 
allow maximal Ca2+ influx.  When activated, STIM1 proteins form puncta in 
areas of the ER which are adjacent to the plasma membrane (Smyth et al., 
2010).  This creates a platform for optimal interaction with Orai1 channels to 
induce Ca2+ influx.  It is possible therefore that Tspan18 enables formation of 
similar Orai1 puncta in the plasma membrane to further enhance and drive 
channel activation and Ca2+ mobilisation.  To test these hypotheses, 
fluorescence microscopy could be employed in cells transfected with tagged 
Orai1 to monitor puncta formation.  This method has been used widely to 
study Orai1 clustering events and to elucidate the role of several different 
regulatory proteins in SOCE (Giurisato et al., 2014).  Use of cells deficient in 
Tspan18 through siRNA knockdown would enable measurement of Orai1 
puncta formation in the absence of Tspan18. 
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Alternatively, Tspan18 could be regulating Orai1 through an entirely distinct 
mechanism.  The dynamic interactions formed within tetraspanin enriched 
microdomains within the membrane not only regulate compartmentalisation of 
the membrane, but can also affect the lateral mobility of specific membrane 
proteins (Espenel et al., 2008).  If interaction with Tspan18 alters the lateral 
mobility of Orai1, this might alter potential interaction events between Orai1 
monomers and thus affect the efficiency of functional channel formation.  The 
ability to measure the minute details of membrane dynamics has been 
developed through use of single particle tracking analysis (Sako, Minoghchi, & 
Yanagida, 2000; Schütz, Kada, Pastushenko, & Schindler, 2000).  This 
method utilises fluorescence microscopy to monitor the dynamics of single 
molecules within the membrane and enables measurement of diffusion 
coefficients, modes of motion and special and temporal behaviour of those 
molecules (Sako et al., 2000; Schütz et al., 2000).  This technique has been 
utilised to demonstrate the highly dynamic nature of tetraspanin microdomains 
through monitoring the membrane dynamics of the abundantly expressed 
tetraspanin CD9 (Espenel et al., 2008).  This technique could be utilised to 
monitor Orai1 lateral mobility and behaviour within the membrane in the 
presence or absence of Tspan18, to investigate whether Tspan18 has a role 
in regulation of the membrane dynamics of this Ca2+ channel. 
Finally, it is possible that Tspan18 plays a role in incorporation of Orai1 into 
tetraspanin enriched microdomains which also contain GPVI.  The platelet 
collagen receptor GPVI has been shown to be tetraspanin associated, so it is 
reasonable to assume it may be enriched in some tetraspanin microdomains 
(Protty et al., 2009).  The importance of SOCE and especially the proteins 
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Orai1 and STIM1 have been highlighted in platelet activation downstream of 
GPVI signalling, though platelet activation via G-protein coupled processes 
does not appear to be so dependant on SOCE (Braun et al., 2009; David 
Varga-Szabo, Braun, et al., 2008).  Therefore, there might be a currently 
uncharacterised mechanism which would explain the requirement for Orai1 
specifically in GPVI induced platelet activation.  If Tspan18 is responsible for 
bringing Orai1 into the microdomain with GPVI, this may allow for a platform 
for optimal signalling to occur, where downstream phosphorylation cascades 
function efficiently and in close proximity, allowing for maximal Ca2+ influx and 
platelet activation.  However, platelet responses such as integrin activation 
and P-selectin exposure have also been previously shown to be Orai1-
dependant processes, but not specific to GPVI pathways (Bergmeier et al., 
2009).  This suggests that Orai1 might be important across multiple platelet 
pathways, not just the GPVI pathway, though how exactly Tspan18 fits into 
this mechanism is as yet unknown. 




















Figure 6.1 – Potential mechanisms of Tspan18 regulation of Orai1.  Tspan18 interacts 
with the CRAC channel Orai1, though the mechanism by which Tspan18 regulates Orai1 is 
unknown.  The interaction between Tspan18 and Orai1 suggests that Tspan18 may have a role 
in regulation of channel formation or channel activation and therefore effect intracellular Ca
2+
 
concentrations (A).  Tspan18 could be acting to regulate the biosynthesis and trafficking of 
Orai1 and therefore might be important for the correct cell surface expression of Orai1 (B).  
The Tspan18-Orai1 interaction may facilitate clustering of Orai1 within the plasma membrane 
and therefore enhance and assist in the formation of functional Orai1 channels to allow flux of 
Ca
2+
 into the cell (C). 
 
6.4 The role of Tspan18 on non-haematopoietic cells 
Although the main aim of this thesis was to characterise the role of Tspan18 
in platelets, some of the results observed implicated Tspan18 in other, non-
haematopoietic cell types.  The work using chimeric mice, outlined in detail in 
chapter 5, demonstrated that the bleeding phenotype observed in the 
Tspan18 deficient mice was due to defects in non-haematopoietic cells rather 
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than the platelets.  However, it still not known which cell types might be 
implicated in this disruption to haemostasis and the mechanism has not been 
elucidated. 
It is possible that the bleeding defects observed in the Tspan18 deficient mice 
are caused by defective endothelial or smooth muscle cell function.  
Endothelial cells play multiple roles in haemostasis, not least through release 
of pro- and anti-thrombotic agents and coagulation factors, and smooth 
muscle cells are important during the process of vasoconstriction to reduce 
blood flow and limit blood loss (Thomas, 2011; van Hinsbergh, 2012).  
Tspan18 has been previously identified in endothelial cells through both 
SAGE analysis and by real time PCR of mouse tissues and human cells 
(Bailey et al., 2011; Colombo, 2010).  Therefore it is possible to hypothesise 
that endothelial Tspan18 could have role in regulation of haemostasis.  During 
preliminary investigation into the potential roles of Tspan18 in endothelial cells 
(outlined in chapter 5), knockdown of Tspan18 in HUVEC caused defective 
migration in a wound closure assay and defective tube formation in a co-
culture assay.  These data suggest that Tspan18 does have a role in 
maintaining normal endothelial cell function, but exactly what that role is and 
what effects this might have on endothelial function in vivo is still to be 
investigated. 
One known impact that endothelial cells have on haemostasis is the release 
of the clotting factors vWF and FVIII from Weibel-Palade bodies in response 
to vascular injury (Blann, 2006).  The response of endothelial cells to injury to 
release these clotting factors is believed to be a Ca2+ dependant process 
(Rondaij et al., 2006).  Therefore it is possible that injury-induced release of 
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vWF and FVIII from Weibel-Palade bodies in endothelial cells is regulated by 
Tspan18 and might be defective in the Tspan18 deficient mice, causing the 
increase in bleeding.  It is not necessarily the case that basal levels of these 
clotting factors would be affected, which could explain why normal basal 
plasma levels of vWF and FVIII were observed in the Tspan18 deficient mice. 
An interesting recent investigation also highlighted the importance of the 
endothelium in driving the coagulation cascade by providing a surface for the 
prothrombinase complex to form (Ivanciu, Krishnaswamy, & Camire, 2014).  
The multiple steps within the coagulation cascade ultimately lead to formation 
of thrombin, which cleaves fibrinogen to form fibrin, which acts to stabilise the 
forming clot against disruption by the blood flow (Stegner & Nieswandt, 2011).  
Two important factors involved in this process are factor Xa (FXa) and factor 
Va (FVa), which drive thrombin formation.  A recent study demonstrated that 
formation of prothrombinase from these factors is supported by the damaged 
endothelium rather than being entirely driven by the activated platelet cell 
surface as previously assumed (Heemskerk, Mattheij, & Cosemans, 2013; 
Ivanciu et al., 2014).  This description of coagulation on the endothelial cell 
surface, distinct from the platelet thrombus, provides another mechanism by 
which endothelial cells regulate haemostasis.  This process involves exposure 
of phosphatidylserine by the activated endothelium to provide the surface for 
prothrombinase activation (Ivanciu et al., 2014).  Exposure of 
phosphatidylserine is a Ca2+ dependant process, which could therefore 
potentially be regulated by endothelial Tspan18. 
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6.5 Future directions 
Having identified a novel tetraspanin-partner protein interaction, the most 
immediate investigation following this thesis should focus on elucidating the 
mechanism of regulation of Orai1 by Tspan18.  As discussed in section 6.3, 
the potential role of Tspan18 in regulation of Orai1 expression is already 
being investigated through immunoprecipitation and western blotting methods 
using the Tspan18 deficient platelets.  There are also experiments using 
fluorescence microscopy which could be used to investigate other potential 
mechanisms of action such as cellular localisation and clustering.  Future 
experiments to further investigate the complex interplay of Tspan18 in Ca2+ 
signalling are also required, to elucidate whether this tetraspanin has roles in 
both release of Ca2+ from intracellular stores and SOCE, or whether it’s 
function is limited to just one area of this signalling pathway.  The additional 
experiments outlined in section 3.4, such as completion of platelet function 
testing in the presence of extracellular Ca2+ would help to clarify these 
questions. 
Having described a comprehensive characterisation of the role of Tspan18 in 
platelet function in this thesis, it would also be interesting to investigate the 
roles of Tspan18 in other cell types.  Perhaps the most obvious direction to 
move the project next would be to complete a full characterisation of the role 
of Tspan18 in endothelial cells.  Previous studies have demonstrated 
Tspan18 expression in endothelial cells, and as shown by the preliminary 
work at the end of chapter 5, Tspan18 may have a role in normal endothelial 
cell function.  It would be interesting to further investigate the potential role of 
endothelial Tspan18 in the bleeding phenotype observed in the Tspan18 
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knockout mouse, but would also be useful to analyse other aspects of 
endothelial cell function.  For example, the role of Tspan18 in vascular 
development, vascular integrity and angiogenesis could be investigated.  
Interestingly, Tspan18 has been implicated in migration of chick neural crest 
cells due to regulation of cadherin 6B expression (Fairchild & Gammill, 2013).  
The potential role for Tspan18 in regulation of endothelial cell migration and 
thus angiogenesis should therefore be investigated.  Interestingly, cadherin 6 
is expressed on platelets, and has a potential role in platelet activation as a 
possible ligand for the integrin αIIbβ3 (Dunne et al., 2012).  Preliminary 
investigation into cadherin 6 expression on Tspan18 deficient platelets using a 
commercially available antibody to measure surface expression by flow 
cytometry was unsuccessful (data not shown).  It would be interesting to 
follow this up with an antibody that works to investigate the potential role for 
Tspan18 in regulation of cadherin 6 expression in platelets. 
It is possible that Tspan18 has a wider expression profile and that it also plays 
roles in other cell types.  In order to better investigate the expression profile of 
Tspan18 and to elucidate in which cell types it might be important, the 
expression profile of Tspan18 must be better characterised.  In order to 
achieve this, ideally generation of a Tspan18 antibody is required.  This would 
allow assessment of endogenous protein expression levels.  Additionally, the 
Tspan18 knockout mouse is a useful tool in further characterising the 
expression profile of Tspan18.  Due to the lactose operon (Lacz) which is 
included in the target vector used to generate the knockout mouse, 5-bromo-
4-chloro-3-indolyl-β-D-galactopyranoside (Xgal) staining could be employed to 
measure in which tissues Tspan18 would have been expressed.  Lacz 
 - 200 - 
encodes for the β-galactosidase enzyme, therefore wherever Tspan18 would 
have been expressed in the mouse tissues, β-galactosidase will be expressed 
instead.  This enzyme hydrolyses X-gal to form a blue compound; therefore X-
gal staining produces blue staining in tissues which would have expressed 
Tspan18.   
As outlined in section 1.3.5, Tspan18 has already been studied in the 
development of the nervous system and has also been identified as a 
susceptibility locus for schizophrenia (J. Yuan et al., 2013; Yue et al., 2011).  
It could be interesting to further investigate the role of Tspan18 in the 
developing brain and to elucidate whether Tspan18 mutations which lead to 
schizophrenia lead to defective Orai1 and reduced Ca2+ signalling. 
In order to complete the Tspan18 story, the mechanism of Tspan18 action 
must be elucidated and the extent that it regulates other cell types must also 
be investigated.  At first hand, it appears that Tspan18 may not provide a 
potential new drug target for thrombosis for treatment of heart attack and 
stroke, due to the haemostatic defects observed.  However, not all of the 
Tspan18 deficient mice bled which, as discussed in chapter 5, may be due to 
a potential genetic modifier effect.  If this can be better understood, then 
perhaps Tspan18 would offer an attractive target, to be able to specifically 
target Orai1 and Ca2+ signalling downstream of GPVI during platelet 
activation, without disruption to multiple other cell types. 
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APPENDIX 1 
 
Tspan18 knockout mice have normal body weight and normal heart 
weight. 
As a basic assessment of overall health and development of the Tspan18 
deficient mice, litter matched pairs at 8-9 weeks old were weighed.  There 
was no difference in the bodyweight of Tspan18 deficient mice and wildtype 
mice (appendix figure 1a).  Additionally, as a basic assessment of cardiac 
health, the hearts of litter matched pairs at 10-12 weeks old were weighed.  
There was no difference in the weight of hearts of Tspan18 deficient mice and 
wildtype mice (appendix figure 1b). 





















Appendix figure 1a – Bodyweight of the Tspan18 deficient mice is normal.  Litter 
matched pairs of wildtype and Tspan18 deficient mice were weighed at 8-9 weeks old.  Data 

































































Appendix figure 1b –Tspan18 deficient mice have normal heart weight.  Hearts were 
harvested from litter matched pairs of wildtype and Tspan18 deficient mice at 10-12 weeks 
old.  Tissue was blotted to remove excess blood and hearts weighed.  Data were normalised to 
total bodyweight for each individual, and analysed by T-test.  Each symbol represents an 
individual. 
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APPENDIX 2  
 
Optimisation of siRNA knockdown of Tspan18 in HUVEC 
As a preliminary investigation into the potential role of Tspan18 on endothelial 
cells, in vitro assays using HUVEC were employed.  Expression of Tspan18 
was disrupted using two different siRNA duplexes in comparison to a control 
siRNA duplex. 
To optimise knockdown of Tspan18, HUVEC were harvested either 48, 72, or 
96 hours post-transfection, Tspan18 mRNA was assessed via real time 
quantitative PCR.  Both duplexes induced the highest level of knockdown 48 
hours post transfection, and no difference was observed in Tspan18 
expression between non-transfected cells and a control siRNA duplex 
(appendix figure 2). 
















































Appendix figure 2 – Optimisation of Tspan18 knockdown in HUVEC using siRNA.  
Expression of Tspan18 was disrupted using two different siRNA duplexes, compared with 
non-transfected cells and a control siRNA duplex.  HUVEC were transfected with siRNA 
duplexes using RNAiMAX and were harvested 48, 72, or 96 hours post-transfection.  
Tspan18 expression was assessed via real time PCR.  Relative mRNA levels of Tspan18 in 
each sample are shown.  Error bars represent the standard error of the mean from 3 separate 
experiments. 
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APPENDIX 3 
 
Characterising Orai1 antibodies 
To better investigate the impact of Tspan18 on Orai1 and to be able to 
monitor endogenous levels of Orai1, rather than rely on over-expression 
systems, a suitable Orai1 antibody was required. 
To characterise Orai1 antibodies for use in western blotting, HEK293T cells 
were transfected with two different Myc-tagged human Orai1 constructs.  
Cells were then lysed, samples separated by SDS-PAGE electrophoresis and 
protein expressed assessed by western blotting.  Two different Orai1 
antibodies were tested; ProSci 4281 (Orai1-CT), raised against a 16 amino 
acid region at the carboxyl terminus of Orai1, and ProSci 4041 (Orai1-NT), 
raised against an 18 amino acid region at the amino terminus of Orai1.  
Expression of Orai1 in the HEK293T cells was confirmed by blotting with an 
anti-Myc antibody.  Blotting with either of the Orai1 antibodies detected bands 
corresponding to the correct molecular weight for Orai1 when HEK293T cells 
were transfected with either Orai1 construct, whereas no corresponding 
bands were observed in the non-transfected control sample (appendix figure 
3a).  To assess whether endogenous levels of Orai1 could be detected by 
western blotting, washed mouse platelets were prepared, lysed, separated by 
SDS-PAGE electrophoresis and blotted with the Orai1-CT antibody.  Several 
non-specific bands were observed and no clear band corresponding to the 
molecular weight of Orai1 could be distinguished (appendix figure 3a, B).  The 
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inability to distinguish the endogenous levels of Orai1 was probably due to the 
low levels of endogenous Orai1 present in mouse platelets. 
To attempt to detect endogenous levels of Orai1, an immunoprecipitation 
approach was used.  To characterise the Orai1 antibodies for 
immunoprecipitation, human platelets were used rather than mouse platelets, 
as they are abundant and readily available. 
Human platelets were isolated from the blood and washed into modified 
Tyrode’s buffer.  The platelets were lysed, immunoprecipitated, and samples 
were separated by SDS-PAGE and western blotted.  Immunoprecipitation for 
CD9 was completed alongside those for Orai1, as a positive control, and both 
MOPC and Rab IgG were used as negative controls.  A band of 
approximately the correct molecular weight for Orai1 was observed after 
blotting with the Orai1-CT antibody following immunoprecipitation with either 
Orai1 antibody, and was also observed when blotting the platelet whole cell 
lysate (appendix figure 3b).  Immunoprecipitation for CD9 resulted in 
enrichment of this tetraspanin. 






























































































Appendix figure 3a - Characterising Orai1 antibodies for use in western blotting.  
HEK293T cells were transfected using PEI with Myc-tagged Orai1.  Whole cell lysate 
samples were separated by SDS-PAGE and western blotted with either an Orai1 antibody, an 
anti-Myc antibody to check expression, or a tubulin antibody to control for loading (A).  
Mouse platelets were isolated from the whole blood and lysed in sample buffer.  Samples 
were separated by SDS-PAGE and western blotted with an Orai1 antibody (B).  
Representative blots are shown from 3 separate experiments.  





































































































Appendix figure 3b – Characterising Orai1 antibodies for immunoprecipitation.  Human 
platelets were isolated from the blood and lysed in Brij97 lysis buffer.  Samples were 
immunoprecipitated as labelled above, separated by SDS-PAGE and western blotted as 
labelled above.  A representative blot from 2 separate experiments is shown. 
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